<doc>
<label>BVAIT 2009</label>
<inclusion> 1. Men and postmenopausal women 40 years old 2. Fasting tHcy 8.5 mol/L 3. No clinical signs/symptoms of cardiovascular disease (CVD). . </inclusion>
<exclusion> 1. Fasting triglycerides > 5.64 mmol/L (500 mg/dL). 2. Diabetes mellitus or fasting serum glucose > 6.99 mmol/L (126 mg/dL). 3. Systolic blood pressure ≥ 160 mm Hg and/or diastolic blood pressure ≥ 100 mm Hg. 4. Untreated thyroid disease. 5. Creatinine clearance < 70 mL/min. 6. Life-threatening illness with prognosis 5 years. 7. Five alcoholic drinks daily.</exclusion>
</doc>
<doc>
<label>CHAOS 2002</label>
</doc>
<doc>
<label>FOLARDA 2004</label>
</doc>
<doc>
<label>GOES 2003</label>
<inclusion> 1. Myocardial infarction, 2. Coronary artery lesions (> 60%) on coronary angiography, 3. Percutaneous coronary intervention (PCI), 4. Coronary artery bypass graft surgery (CABG), 5. Patients had to be stable, with no invasive vascular procedures scheduled, 6. Statin therapy for at least three months, 7. Taking any form of vitamin B-containing medication, regularly or sporadic . </inclusion>
<exclusion> 1. Age < 18 years, 2. History of low vitamin B12 levels, 3. Therapy for hyperhomocysteinemia, 4. Severe renal failure, or any other treatment for renal disease, 5. Hepatic disease, 6. Severe heart failure (New York Heart Association functional class IV), 7. Serious illness that would exclude follow-up time of at least three years.</exclusion>
</doc>
<doc>
<label>HOPE-2 2006</label>
<inclusion> Men and women aged > 55 years, Hstory of vascular disease (coronary, cerebrovascular, or peripheral vascular) or diabetes and additional risk factors for atherosclerosis, Irrespective of their homocysteine levels, from countries with mandatory folate fortifi- cation of food (Canada and the United States) and countries without mandatory folate fortification (Brazil, western Europe, and Slovakia) </inclusion>
<exclusion> Patients taking vitamin supplements containing more than 0.2 mg of folic acid per day</exclusion>
</doc>
<doc>
<label>NORVIT 2006</label>
<inclusion> Men and women aged 30 to 85 years, History of acute MI within seven days before randomisation. </inclusion>
<exclusion> Coexisting disease associated with a life expectancy < 4 years, Prescribed treatment with B vitamins or untreated vitamin B deficiency, Inability to follow the protocol, as judged by the investigator</exclusion>
</doc>
<doc>
<label>SEARCH 2010</label>
<inclusion> 1. Men and women. 2. Aged 18 to 80 years. 3. History of MI. 4. Had no clear indication for folic acid. 5. Blood cholesterol levels of at least 135 mg/dL if already taking a statin medication or 174 mg/dL if not (to convert cholesterol to mmol/L, multiply by 0.0259). . </inclusion>
<exclusion> 1. Chronic liver, renal, or muscle disease. 2. History of any cancer (except non-melanoma skin cancer). 3. Use of potentially interacting medications.</exclusion>
</doc>
<doc>
<label>SU.FOL.OM3 2010</label>
<inclusion> 1. Men and women. 2. Aged 45 to 80 years. 3. History of acute coronary or cerebral Ischaemic event within the 12 months before randomisation. . </inclusion>
<exclusion> 1. Age (< 45 years or > 80 years) 2. Ill defined diagnosis of cardiovascular disease. 3. Inability or unwillingness to comply with study treatment. 4. Disease or treatment that might interfere with metabolism of homocysteine or omega 3 fatty acids, in particular methotrexate for treating cancer or rheumatoid arthritis and chronic renal failure (plasma creatinine concentration > 200 mol/L or creatinine clearance < 40 mL/min). 5. Individuals with transient Ischaemic attacks.</exclusion>
</doc>
<doc>
<label>VISP 2004</label>
<inclusion> Non-disabling Ischaemic stroke(Modified Rankin Stroke Scale 3): Onset 120 days before randomisation. Focal neurological deficit of likely atherothrombotic origin, classified as ischaemic stroke by questionnaire/algorithm or confirmed as new cerebral infarction consistent with symptoms by cranial computed tomography or brain magnetic resonance imaging, Total homocysteine level 25th percentile for North American stroke population, Age: ≥ 35 years, Accessibility for follow-up, Agreement to take study medication and not take other multivitamins or pills containing folic acid or vitamin B6, Written informed consent. </inclusion>
<exclusion> Potential sources of emboli (atrial fibrillation within 30 days of stroke, prosthetic cardiac valve, intracardiac thrombus or neoplasm, or valvular vegetation), Other major neurological illness that would obscure evaluation of recurrent stroke, Life expectancy 2 years, Renal failure requiring dialysis, Untreated anaemia or untreated vitamin B12 deficiency, Systolic blood pressure 185 mm Hg or diastolic blood pressure 105 mm Hg on 2 readings 5 minutes apart at time of eligibility determination, Refractory depression, severe cognitive impairment, or alcoholism or other substance abuse, Use within the last 30 days of medications that affect total homocysteine level (methotrex- ate, tamoxifen, levodopa, niacin, or phenytoin) or bile acid sequestrants that can decrease folate levels, Childbearing potential, Participation in another trial with active intervention, General anaesthesia or hospital stay of 3 days, any type of invasive cardiac instrumen- tation, or endarterectomy, stent placement, thrombectomy, or any other endovascular treatment of carotid artery within 30 days prior to randomisation or scheduled to be performed within 30 days after randomisation</exclusion>
</doc>
<doc>
<label>VITATOPS 2010</label>
<inclusion> 1. Stroke (ischaemic or haemorrhagic) or transient ischaemic attack (eye or brain), as defined by standard criteria, within the past 7 months. 2. Patients with haemorrhagic stroke. . </inclusion>
<exclusion> 1. Taking folic acid, vitamin B6 , vitamin B12 , or a folate antagonist (e.g., methotrexate). 2. Pregnant or women of childbearing potential. 3. Patients with limited life expectancy (e.g., because of ill health).</exclusion>
</doc>
<doc>
<label>WAFACS 2008</label>
</doc>
<doc>
<label>WENBIT 2008</label>
<inclusion> Age: 18 years or older, Undergoing coronary angiography for suspected CAD and/or aortic valve stenosis at the 2 university hospitals in western Norway . </inclusion>
<exclusion> Unavailability for follow-up, Participation in other trials, Hisytory of alcohol abuse, serious mental illness, or cancer</exclusion>
</doc>
<doc>
<label>Carson 1998</label>
<inclusion> presenting for hip fracture repair, and if haemoglobin < 10 g/dL in the immediate postoperative period (defined as time from end of anaesthesia to 11:59 p.m. 3 days after surgery counted from 12:00 midnight on first day after surgery) </inclusion>
<exclusion> people who refused transfusion because of religious beliefs, had mul- tiple trauma or had symptoms of anaemia Mean (SD) age in the liberal transfusion threshold: 81.3 (8.1) years; range 50-94 years Mean (SD) age in the restrictive transfusion threshold: 83.3 (10.8) years; range 32-95 years Number of men per intervention: 9/11</exclusion>
</doc>
<doc>
<label>Carson 2011</label>
<inclusion> people aged ≥ 50 years who were undergoing primary surgical repair of a hip fracture and who had clinical evidence of a history of ischaemic heart disease, ECG evidence of previous myocardial infarction, a history or presence of congestive heart failure or peripheral vascular disease, or a history of stroke or transient ischaemic attack) or risk factors for cardiovascular disease (see below) were eligible if they had a haemoglobin concentration of < 10 g/dL within 3 days after surgery After December 2005, people with any of the following cardiovascular criteria were eligible regardless of haemoglobin concentration: 1. history of or treatment for hypertension 2. diabetes mellitus 3. hypercholesterolaemia (cholesterol level > 200 mg/dL or a low density lipoprotein cholesterol level > 130 mg/dL) 4. current tobacco use 5. creatinine level > 2.0 mg/dL </inclusion>
<exclusion> 1. inability to walk without human assistance before hip fracture 2. declining blood transfusions 3. having multiple trauma (defined as having had or planning to undergo surgery for non-hip-related traumatic injury) 4. having a pathological hip fracture associated with cancer 5. history of clinically recognised acute myocardial infarction within 30 days before randomisation 6. having previously participated in the trial with a contralateral hip fracture 7. having symptoms associated with anaemia (e.g. ischaemic chest pain) 8. actively bleeding at the time of potential randomisation Mean (SD) age in the liberal transfusion threshold: 81.8 (8.8) years Mean (SD) age in the restrictive transfusion threshold: 81.5 (9.0) years Number of men per intervention: 250/239</exclusion>
</doc>
<doc>
<label>Foss 2009</label>
<inclusion> 1. primary hip fracture occurring in the community 2. people > 65 years old 3. independent pre-fracture walking function 4. community dwelling 5. intact cognitive status </inclusion>
<exclusion> 1. multiple fracture 2. pre-fracture terminal condition 3. alcoholism 4. chronic transfusion needs 5. acute cardiac or other acute severe medical conditions 6. contraindication to epidural analgesia Mean (SD) age in the liberal transfusion threshold: 81 (6.8) years Mean (SD) age in the restrictive transfusion threshold: 81 (7.3) years Number of men per intervention: 14/14</exclusion>
</doc>
<doc>
<label>Gregersen 2015</label>
<inclusion> . clinical diagnosis of hip fracture . surgery treatment . postoperative anaemia: 6-7 mmol/L up to the 6th day post operation . aged ≥ 65 years . admitted from nursing home or sheltered housing facilities for unilateral hip fracture surgery . written assent </inclusion>
<exclusion> . active cancer . pathological fractures . inability to understand or speak Danish without an interpreter . red blood cell transfusion refusal . fluid overload . irregular erthrocyte antibodies . previous participation in a trial Mean (SD) age in the liberal transfusion threshold: 88 (6.9) years Mean (SD) age in the restrictive transfusion threshold: 86 (6.8) years Number of men per intervention: 34/36</exclusion>
</doc>
<doc>
<label>Palmer 1998</label>
<inclusion> . people whose haemoglobin concentration fell between 8 and 10 g/dL </inclusion>
<exclusion> . not stated Age not given</exclusion>
</doc>
<doc>
<label>Parker 2013</label>
<inclusion> . people with a proximal femoral (hip) fracture and haemoglobin measured on the first or second day after surgery as between 8.0 and 9.5 g/dL, and no definite symptoms of anaemia were present </inclusion>
<exclusion> . age < 60 years . people unwilling or unable to provide written informed consent . multiple trauma (incompletely defined: “either more than two other fractures”) . people treated conservatively . people treated with percutaneous screw fixation . pathological fractures from tumours . postoperative haemoglobin > 9.5 g/dL or < 8.0 g/dL Mean age in the liberal transfusion threshold: 84.4 years; range 60-104 years Mean age in the restrictive transfusion threshold: 84.2 years; range 60-97 years</exclusion>
</doc>
<doc>
<label>Feagan 2007</label>
</doc>
<doc>
<label>Korzenik 2005a</label>
</doc>
<doc>
<label>Valentine 2009</label>
</doc>
<doc>
<label>Ding 2012</label>
</doc>
<doc>
<label>Fang 1987</label>
<exclusion> not stated Baseline characteristics: comparable (statistical analysis)</exclusion>
</doc>
<doc>
<label>He 2004</label>
<exclusion> not stated Baseline characteristics: not stated</exclusion>
</doc>
<doc>
<label>Jiang 1988</label>
</doc>
<doc>
<label>Liu 2007a</label>
<exclusion> not stated Baseline characteristics: comparable (statistical analysis)</exclusion>
</doc>
<doc>
<label>Liu 2013</label>
</doc>
<doc>
<label>Mao 2003a</label>
<inclusion> heart failure; (1) age 41 to 70 years; (2) heart failure class 2-3; not taking digitalis or drugs affecting the metabolization of digoxin within one week; liver and kidney function were normal, normal electrolyte </inclusion>
<exclusion> acute myocardial infarction, acute respiratory insufficiency of PHD, serious mitral stenosis in sinus rhythm, or HCM with obstruction; combined with diabetes, hyperthyroidism Baseline characteristics: comparable (statistical analysis)</exclusion>
</doc>
<doc>
<label>Su 2012</label>
</doc>
<doc>
<label>Wan 2012</label>
<exclusion> serious left ventricular systolic dysfunction in Echocardiography; acute myocardial infarction; serious disease such as liver and renal insufficiency; allergic con- stitution or be allergic to this drug and various drugs; drug allergies; pregnant or breast- feeding women Setting: inpatients Baseline characteristics: comparable (statistical analysis)</exclusion>
</doc>
<doc>
<label>Wang 2010a</label>
</doc>
<doc>
<label>Zhai 2009</label>
<exclusion> age > 70, heart failure caused by acute myocardial infarction, acute pulmonary edema, congenital heart disease, valvular heart disease, hyperthyroid heart, liver/renal failure Baseline characteristics: comparable (statistical analysis)</exclusion>
</doc>
<doc>
<label>Zhang 2002</label>
<exclusion> CHD, RHD, congenital heart disease Baseline characteristics: comparable (statistical analysis)</exclusion>
</doc>
<doc>
<label>Zhao 2006</label>
<inclusion> (1) age from 40 to 70 years; (2) hear class 2~3; (3) no digitalis used in the last week and no high salt diet; (4) blood electrolytes, liver, kidney no obvious abnormalities </inclusion>
<exclusion> (1) age >70 or < 40 years, (2) AMI, hypertrophic obstructive car- diomyopathy, high blood pressure 3 class. (3) combined with diabetes, hyperthyreosis Baseline characteristics: comparable (statistical analysis), specific data on baseline char- acters were provided</exclusion>
</doc>
<doc>
<label>Angermann 2007</label>
</doc>
<doc>
<label>Antonicelli 2008</label>
</doc>
<doc>
<label>Balk 2008</label>
</doc>
<doc>
<label>Barth 2001</label>
</doc>
<doc>
<label>Blum 2007 (MCCD)</label>
</doc>
<doc>
<label>Capomolla 2004</label>
</doc>
<doc>
<label>Cleland 2005 (Telemon)</label>
</doc>
<doc>
<label>Cleland 2005(Struct Tele)</label>
</doc>
<doc>
<label>de Lusignan 2001</label>
</doc>
<doc>
<label>DeBusk 2004</label>
</doc>
<doc>
<label>DeWalt 2006</label>
</doc>
<doc>
<label>Galbreath 2004</label>
</doc>
<doc>
<label>Gattis 1999 (PHARM)</label>
</doc>
<doc>
<label>GESICA 2005 (DIAL)</label>
</doc>
<doc>
<label>Giordano 2009</label>
</doc>
<doc>
<label>Goldberg 2003 (WHARF)</label>
</doc>
<doc>
<label>Kielblock 2007</label>
</doc>
<doc>
<label>Krum 2009 (CHAT)</label>
</doc>
<doc>
<label>Laramee 2003</label>
</doc>
<doc>
<label>Mortara 2009 (Struct Tele)</label>
</doc>
<doc>
<label>Mortara 2009 (Telemon)</label>
</doc>
<doc>
<label>Rainville 1999</label>
</doc>
<doc>
<label>Ramachandran 2007</label>
</doc>
<doc>
<label>Riegel 2002</label>
</doc>
<doc>
<label>Riegel 2006</label>
</doc>
<doc>
<label>Sisk 2006</label>
</doc>
<doc>
<label>Soran 2008</label>
</doc>
<doc>
<label>Tsuyuki 2004</label>
</doc>
<doc>
<label>Villani 2007 (ICAROS)</label>
</doc>
<doc>
<label>Wakefield 2008</label>
</doc>
<doc>
<label>Woodend 2008</label>
</doc>
<doc>
<label>Zugck 2008 (HiTel)</label>
</doc>
<doc>
<label>Chen 2011</label>
</doc>
<doc>
<label>Dai 2011</label>
</doc>
<doc>
<label>Di 2012</label>
</doc>
<doc>
<label>Dong 2012</label>
</doc>
<doc>
<label>Huang 2010</label>
</doc>
<doc>
<label>Li 2004</label>
</doc>
<doc>
<label>Liang 2010</label>
</doc>
<doc>
<label>Wang 2009a</label>
</doc>
<doc>
<label>Wang 2010</label>
</doc>
<doc>
<label>Wu 2010</label>
</doc>
<doc>
<label>Xiao 2007</label>
</doc>
<doc>
<label>Yang 2009a</label>
</doc>
<doc>
<label>Yao 2006</label>
</doc>
<doc>
<label>Zhang 2009a</label>
</doc>
<doc>
<label>Zheng 2010</label>
</doc>
<doc>
<label>Zhou 2007b</label>
</doc>
<doc>
<label>Arfvidsson 1990</label>
</doc>
<doc>
<label>BOA 2000</label>
</doc>
<doc>
<label>Cole 1993</label>
</doc>
<doc>
<label>Edmondson 1994</label>
</doc>
<doc>
<label>Jivegard 2005</label>
</doc>
<doc>
<label>Johnson 2002</label>
</doc>
<doc>
<label>Kretschmer 1992</label>
</doc>
<doc>
<label>Logason 2001</label>
</doc>
<doc>
<label>Norgren 2004</label>
</doc>
<doc>
<label>Nydahl 1992</label>
</doc>
<doc>
<label>Samama 1994</label>
</doc>
<doc>
<label>Sarac 1998</label>
</doc>
<doc>
<label>Schneider 1979</label>
</doc>
<doc>
<label>Swedenborg 1996</label>
</doc>
<doc>
<label>Abel 1983</label>
</doc>
<doc>
<label>Ali 1997</label>
</doc>
<doc>
<label>Apipan 2010</label>
</doc>
<doc>
<label>Auer 2004</label>
</doc>
<doc>
<label>Babin-Ebell 1996</label>
</doc>
<doc>
<label>Bayliff 1999</label>
</doc>
<doc>
<label>Bert 2001</label>
</doc>
<doc>
<label>Booth 2004</label>
</doc>
<doc>
<label>Burns 1988</label>
</doc>
<doc>
<label>But 2006</label>
</doc>
<doc>
<label>Coleman 1980</label>
</doc>
<doc>
<label>Connolly 2003</label>
</doc>
<doc>
<label>Cork 1995</label>
</doc>
<doc>
<label>Cucchiara 1986</label>
</doc>
<doc>
<label>Daudon 1986</label>
</doc>
<doc>
<label>De Azevedo Lúcio 2003</label>
</doc>
<doc>
<label>DIPOM - Juul 2006</label>
</doc>
<doc>
<label>Dy 1998</label>
</doc>
<doc>
<label>Evrard 2000</label>
</doc>
<doc>
<label>Forlani 2002</label>
</doc>
<doc>
<label>Gibson 1988</label>
</doc>
<doc>
<label>Gomes 1999</label>
</doc>
<doc>
<label>Graham 1996</label>
</doc>
<doc>
<label>Gupta 2011</label>
</doc>
<doc>
<label>Hammon 1984</label>
</doc>
<doc>
<label>Harrison 1987</label>
</doc>
<doc>
<label>Inada 1989</label>
</doc>
<doc>
<label>Ivey 1983</label>
</doc>
<doc>
<label>Jacquet 1994</label>
</doc>
<doc>
<label>Jakobsen 1992</label>
</doc>
<doc>
<label>Jakobsen 1997</label>
</doc>
<doc>
<label>Janssen 1986</label>
</doc>
<doc>
<label>Kawaguchi 2010</label>
</doc>
<doc>
<label>Khuri 1987</label>
</doc>
<doc>
<label>Kurian 2001</label>
</doc>
<doc>
<label>Lai 2006</label>
</doc>
<doc>
<label>Lamb 1988</label>
</doc>
<doc>
<label>Lee 2010</label>
</doc>
<doc>
<label>Liu 1986</label>
</doc>
<doc>
<label>Liu 2006</label>
</doc>
<doc>
<label>Magnusson 1986</label>
</doc>
<doc>
<label>Mangano 1996</label>
</doc>
<doc>
<label>Martinussen 1988</label>
</doc>
<doc>
<label>Marwick 2009</label>
</doc>
<doc>
<label>Matangi 1985</label>
</doc>
<doc>
<label>Matangi 1989</label>
</doc>
<doc>
<label>Materne 1985</label>
</doc>
<doc>
<label>Matsuura 2001</label>
</doc>
<doc>
<label>Miller 1990</label>
</doc>
<doc>
<label>Miller 1991</label>
</doc>
<doc>
<label>Mohr 1981</label>
</doc>
<doc>
<label>Moon 2011</label>
</doc>
<doc>
<label>Myhre 1984</label>
</doc>
<doc>
<label>Neary 2006</label>
</doc>
<doc>
<label>Neustein 1994</label>
</doc>
<doc>
<label>Nyström 1993</label>
</doc>
<doc>
<label>Ogawa 2013</label>
</doc>
<doc>
<label>Oka 1980</label>
</doc>
<doc>
<label>Ormerod 1984</label>
</doc>
<doc>
<label>Osada 2012</label>
</doc>
<doc>
<label>Oxorn 1990</label>
</doc>
<doc>
<label>Paull 1997</label>
</doc>
<doc>
<label>Pfisterer 1997</label>
</doc>
<doc>
<label>POBBLE 2005</label>
</doc>
<doc>
<label>POISE 2008</label>
</doc>
<doc>
<label>Raby 1999</label>
</doc>
<doc>
<label>Reves 1990</label>
</doc>
<doc>
<label>Rubin 1987</label>
</doc>
<doc>
<label>Sakaguchi 2012</label>
</doc>
<doc>
<label>Salazar 1979</label>
</doc>
<doc>
<label>Sandler 1990</label>
</doc>
<doc>
<label>Sezai 2011</label>
</doc>
<doc>
<label>Sezai 2012</label>
</doc>
<doc>
<label>Shukla 2010</label>
</doc>
<doc>
<label>Silverman 1982</label>
</doc>
<doc>
<label>Stephenson 1980</label>
</doc>
<doc>
<label>Stone 1988</label>
</doc>
<doc>
<label>Sun 2011</label>
</doc>
<doc>
<label>Suttner 2009</label>
</doc>
<doc>
<label>Suttorp 1991</label>
</doc>
<doc>
<label>Vecht 1986</label>
</doc>
<doc>
<label>Wallace 1998</label>
</doc>
<doc>
<label>Wenke 1999</label>
</doc>
<doc>
<label>White 1984</label>
</doc>
<doc>
<label>Whitehead 1980</label>
</doc>
<doc>
<label>Williams 1982</label>
</doc>
<doc>
<label>Yang 2006</label>
</doc>
<doc>
<label>Yang 2008</label>
</doc>
<doc>
<label>Zaugg 1999</label>
</doc>
<doc>
<label>AMTG 1985</label>
</doc>
<doc>
<label>Bergler-Klein 1992</label>
</doc>
<doc>
<label>Cowley 1993</label>
</doc>
<doc>
<label>Cowley 1994</label>
</doc>
<doc>
<label>Dies 1989</label>
</doc>
<doc>
<label>EMTG 1990</label>
</doc>
<doc>
<label>EPOCH 2002</label>
</doc>
<doc>
<label>ESG 2000</label>
</doc>
<doc>
<label>FACET 1993</label>
</doc>
<doc>
<label>IRG 1991</label>
</doc>
<doc>
<label>Lardoux 1987</label>
</doc>
<doc>
<label>MMTG 1989</label>
</doc>
<doc>
<label>OPC-8212 MRG 1990</label>
</doc>
<doc>
<label>PICO 1996</label>
</doc>
<doc>
<label>PMRG 1992</label>
</doc>
<doc>
<label>PROMISE 1991</label>
</doc>
<doc>
<label>REFLECT 1993</label>
</doc>
<doc>
<label>REFLECT II 1991</label>
</doc>
<doc>
<label>VEST 1998</label>
</doc>
<doc>
<label>VSG 1993</label>
</doc>
<doc>
<label>WESG 1991</label>
</doc>
<doc>
<label>Batist 2001</label>
</doc>
<doc>
<label>Brambilla 1986</label>
</doc>
<doc>
<label>Chan 2004</label>
</doc>
<doc>
<label>FESG 1988</label>
</doc>
<doc>
<label>Gasparini 1991</label>
</doc>
<doc>
<label>Harris 2002</label>
</doc>
<doc>
<label>IMBSWE 1988</label>
</doc>
<doc>
<label>Mouridsen 1984</label>
</doc>
<doc>
<label>Balaban 2008</label>
</doc>
<doc>
<label>Bolas 2004</label>
<exclusion> those transferred to another hospital, admitted or transferred to a nursing home, patient or caregiver unable to communicate with pharmacist, any mental illness or alcohol related admission, or home visit, or follow up was declined on admission Number of patients recruited: T = 119, C = 124 Mean age: T = 73 years, C = 75 years Sex: T = female 41/119 (%), C = 42/124 (%) Living alone: T = 27/119, C = 34/124</exclusion>
</doc>
<doc>
<label>Evans 1993</label>
</doc>
<doc>
<label>Harrison 2002</label>
</doc>
<doc>
<label>Hendriksen 1990</label>
</doc>
<doc>
<label>Jack 2009</label>
</doc>
<doc>
<label>Kennedy 1987</label>
</doc>
<doc>
<label>Laramee 2003</label>
</doc>
<doc>
<label>Moher 1992</label>
</doc>
<doc>
<label>Naji 1999</label>
</doc>
<doc>
<label>Naughton 1994</label>
</doc>
<doc>
<label>Naylor 1994</label>
</doc>
<doc>
<label>Nazareth 2001</label>
</doc>
<doc>
<label>Pardessus 2002</label>
</doc>
<doc>
<label>Parfrey 1994</label>
</doc>
<doc>
<label>Preen 2005</label>
</doc>
<doc>
<label>Rich 1993</label>
</doc>
<doc>
<label>Rich 1995</label>
<exclusion> residence outside the catchment area for the Jewish Hospital Home Care, planned discharge to a long-term care facility, severe dementia, severe psychiatric illness, anticipated survival of less than 3 months, refusal to participate, logistic or dis- cretionary reasons (e.g. participation in the pilot study) Number recruited: T = 142 C = 140 (recruited between July 1990 and June 1994)</exclusion>
</doc>
<doc>
<label>Shaw 2000</label>
</doc>
<doc>
<label>Sulch 2000</label>
</doc>
<doc>
<label>Weinberger 1996</label>
</doc>
<doc>
<label>Barr 1995</label>
</doc>
<doc>
<label>Boccanelli 1986</label>
</doc>
<doc>
<label>Burr 1977</label>
</doc>
<doc>
<label>Cheitlin 1991</label>
</doc>
<doc>
<label>Cowley 1986</label>
</doc>
<doc>
<label>Dalhstrom 1986</label>
</doc>
<doc>
<label>De Jong 1994</label>
</doc>
<doc>
<label>Haerer 1989</label>
</doc>
<doc>
<label>Myers 1982</label>
</doc>
<doc>
<label>Nordrehaug 1992</label>
</doc>
<doc>
<label>Richardson 1987</label>
</doc>
<doc>
<label>Sherman 1986</label>
</doc>
<doc>
<label>Sievert 1989</label>
</doc>
<doc>
<label>Walma 1997</label>
</doc>
<doc>
<label>ALLHAT 2002</label>
<inclusion> stage 1 or 2 hypertension, 55 years or older, 1 additional risk factor for CHD events Excluded: individual with a history of hospitalized or treated symptomatic HF and/or left ventricular ejection fraction of < 35%</inclusion>
</doc>
<doc>
<label>Ariff 2006</label>
<inclusion> uncontrolled essential hypertension </inclusion>
<exclusion> evidence of accelerated hypertension, MI or stroke within previous 6 months, DM, or any other condition that precluded participation</exclusion>
</doc>
<doc>
<label>Buus 2004</label>
<inclusion> people with sitting DBP of 100mmHg-120 mmHg. People suspected of secondary hypertension underwent isotope renography, spiral computed tomographic scan of the renal arteries, or urinary sampling of catecholamines, but none showed signs of secondary hypertension, and all were included Excluded: not reported</inclusion>
</doc>
<doc>
<label>Buus 2007</label>
</doc>
<doc>
<label>Dahlöf 1993</label>
<inclusion> sitting DBP of 100 mmHg-120 mmHg </inclusion>
<exclusion> symptoms or signs of ischemic heart disease or secondary hypertension</exclusion>
</doc>
<doc>
<label>Dahlöf 2002</label>
<inclusion> men and women, aged 21-80 years, with mild to moderate essential hypertension and ECG-documented LVH assessed up to 30 days before enrolment. Eligible participants had trough sitting DBP of 95-115 mmHg or sitting SBP of 160 mmHg-200 mmHg, or both, while receiving placebo for 2-4 weeks, and a left ventricular mass index (LVMI) > 120 g/m2 for men and > 105 g/m2 for women </inclusion>
<exclusion> a LV end-diastolic dimension > 60 mm, irrespective of the LVMI, systolic dysfunction or significant valvular disease</exclusion>
</doc>
<doc>
<label>Dalla 2004</label>
<inclusion> mild to moderate hypertensive people aged from 40-70 years, affected by T2DM with the presence of persistent microalbuminuria </inclusion>
<exclusion> arterial hypertension outside the range specified above; secondary arterial hypertension; orthostatic hypotension (SBP decrease > 20 mmHg after standing for 2 min); AER < 20 μg/min, ≥ 20 μg/min not persistent, > 200 μg/min; HbA1c > 10%; cardiac insufficiency (classes NYHA III-IV); arrhythmias; valvular disease; CHDs; unstable angina pectoris; complete left bundle branch block; HR < 50 or > 100 bpm; acute MI or cerebrovascular accident 3 months prior to recruitment; transaminases > 2 times the normal limit; serum creatinine > 141.4 μmol/L; anemia (hemoglobin <10 g/dL); hypertensive retinopathy grade III-IV; obesity (body mass index > 35 kg/m2 ); known hypersensitivity to dihydropyridine derivates or to ACE-inhibitors</exclusion>
</doc>
<doc>
<label>Derosa 2004</label>
</doc>
<doc>
<label>Derosa 2005</label>
<inclusion> T2DM; mild hypertension (DBP > 90 mmHg and < 105 mmHg) </inclusion>
<exclusion> secondary hypertension; malignant hypertension; unstable angina; MI; and/or liver/renal function abnormalities</exclusion>
</doc>
<doc>
<label>Derosa 2014</label>
<inclusion> outpatients of both sex, aged < 65 years, with a first diagnosis of essential hypertension and naïve to antihypertensive treatment Excluded: secondary hypertension, severe hypertension (SBP >180 mmHg or DBP >110 mmHg), hypertrophic cardiomyopathies due to aetiologies other than hypertension, history of heart failure or a left ventricular ejection fraction (LVEF) ≤50%, history of angina, stroke, transient ischaemic cerebral attack, coronary artery bypass surgery or myocardial infarction any time prior to visit 1, concurrent symptomatic arrhythmia, liver dysfunction (AST or ALT values exceeding 2-fold the upper limit), creatinine >1.5 mg/dL and known hypersensitivity to the study drugs. Pregnant women (Continued) as well as women of childbearing potential were excluded. Patients with endocrine, infective or inflammatory disorders were excluded, as well as were those taking anti- inflammatory medications</inclusion>
</doc>
<doc>
<label>Devereux 2001</label>
<inclusion> seated SBP of 140 mmHg and/or DBP of 90 mmHg (Korotkoff phase 5) for previous 4 weeks if taking antihypertensive medications or 150 mmHg and/or 90 mmHg, respectively, if unmedicated </inclusion>
<exclusion> people with LV ejection fraction ,40%, severe valvular disease, or coexisting cardiomyopathy on screening ECG. Initially, people receiving treatment with ACE inhibitors or CCBs were excluded</exclusion>
</doc>
<doc>
<label>Esnault 2008</label>
</doc>
<doc>
<label>Estacio 1998</label>
<inclusion> participants enrolled in the ABCD Trial were between the ages of 40 and 74 years at the time of recruitment and were identified according to diagnosis-related groups from the pharmacy and billing lists of participating healthcare systems in the Denver metropolitan area. All participants in the ABCD Trial had NIDDM, diagnosed according to criteria based on those of the WHO report of 1985. All enrolled subjects had DBP of 80 mmHg or higher and were receiving no antihypertensive medications at the time of randomization </inclusion>
<exclusion> a known allergy to dihydropyridine CCBs or ACE inhibitors; MI or cerebrovascular accident within the previous 6 months; coronary-artery bypass surgery within the previous 3 months; unstable angina pectoris within the previous 6 months; (Continued) New York Heart Association class III or IV CHF; an absolute need for therapy with ACE inhibitors or CCBs; were receiving hemodialysis or peritoneal dialysis; or serum creatinine concentration > 3 mg/dL (265 μmol/L)</exclusion>
</doc>
<doc>
<label>Fogari 2012</label>
<inclusion> consecutive outpatients of either sex, age 40-80 years, with stage I hypertension; in sinus rhythm, but with ≥ 2 ECG-documented episodes of symptomatic AF in the previous 6 months, each lasting > 60 min but < 7 days and terminating spontaneously </inclusion>
<exclusion> ECG evidence of (LVH; treatment with ARBs, ACE inhibitors, or antiarrhythmic agents; cardioversion within the previous 3 months; secondary hyper- tension; MI or stroke in the preceding 6 months; CHF; coronary heart disease; valvular disease; cardiac surgery during the previous 6 months; significant thyroid, pulmonary, renal, or hepatic disease;pregnancy or fertile woman; and known hypersensitivity or con- traindications to the study medications</exclusion>
</doc>
<doc>
<label>Gerritsen 1998</label>
<inclusion> people with NIDDM and hypertension who were being treated by general practitioners in the Rotterdam area; DM diagnosed by general practitioner. Participants were being treated with diet or drugs (either an oral hypoglycemic or insulin) ; metabolic control had to be acceptable and was defined as an HbA1c level < 11.5% </inclusion>
<exclusion> class III or IV CHF, uncontrolled arrhythmias or severe or unstable angina pectoris; MI or stroke during the previous 3 months; history of other major illnesses or known intolerance to dihydropyridines or ACE inhibitors</exclusion>
</doc>
<doc>
<label>Gottdiener 1998</label>
</doc>
<doc>
<label>Hajjar 2013</label>
<inclusion> DBP 95 mmHg-109 mmHg </inclusion>
<exclusion> not reported (Continued)</exclusion>
</doc>
<doc>
<label>Hauf-Zachariou 1993</label>
<inclusion> essential hypertension with a DBP of 95 mmHg-114 mmHg and dyslipidemia </inclusion>
<exclusion> secondary hypertension; unstable angina; gross hepatic or renal im- pairment; insulin-dependent or unstable DM; or other major diseases</exclusion>
</doc>
<doc>
<label>Hayoz 2012</label>
</doc>
<doc>
<label>Himmelmann 1996</label>
<inclusion> DBP 95 mmHg-115 mmHg </inclusion>
<exclusion> not reported</exclusion>
</doc>
<doc>
<label>Hughes 2008</label>
<inclusion> untreated hypertension (previously untreated or antihypertensive treat- ment discontinued for at least 1 year) </inclusion>
<exclusion> accelerated hypertension; secondary hypertension; DM; familial hy- percholesterolemia; HF or any other significant concomitant disease</exclusion>
</doc>
<doc>
<label>IDNT 2001</label>
<inclusion> aged 30-70 years, a documented diagnosis of T2DM, hypertension, and proteinuria, with urinary protein excretion of at least 900 mg/24 hours; serum creatinine concentration 1.0 mg/dL-3.0 mg/dL (88 μmol/L and 265 μmol/L) in women and 1.2 mg/dL-3.0 mg/dL (106 μmol/L and 265 μmol/L) in men </inclusion>
<exclusion> not reported</exclusion>
</doc>
<doc>
<label>LIFE 2002</label>
<inclusion> previously treated or untreated hypertension and ECG signs of LVH Trough sitting SBP 160 mmHg-200 mmHg, DBP 95 mmHg-115 mmHg, or both </inclusion>
<exclusion> secondary hypertension; MI or stroke within the previous 6 months; angina pectoris requiring treatment with beta-blockers or calcium-antagonists; HF or LV ejection fraction of ≤ 40%; or a disorder that, in the treating physician’s opinion, required treatment with losartan or another angiotensin-II type 1-receptor antagonist, atenolol or another beta-blocker, HCTZ, or ACE inhibitors</exclusion>
</doc>
<doc>
<label>Malmqvist 2002</label>
</doc>
<doc>
<label>Ostman 1998</label>
<inclusion> NIDDM in stable blood glucose control, essential hypertension </inclusion>
<exclusion> CHF; MI; angina pectoris treated with drugs other than nitrates; hemodynamically serious valvular heart disease and secondary or malignant hyperten- sion; treatment with thiazides or lipid-lowering agents, or both, in the preceding 12 months; treatments with loop-diuretics in the preceding 3 months; chronic therapy with non-steroidal anti-inflammatories. Serum levels of AST or ALT > 2 μcat/L; hyper- lipoproteinemia; cholesterol > 8 mM; triglycerides > 4 mM; proteinuria (> 0.5 g/L)</exclusion>
</doc>
<doc>
<label>Parrinello 2009</label>
</doc>
<doc>
<label>Pedersen 1997</label>
<inclusion> a diagnosis of essential hypertension (ESH stage 1 or 2 hypertension) established by history and physical examination, together with the absence of clinical findings suggestive of a secondary hypertension, according to ESH guidelines </inclusion>
<exclusion> other CV diseases (defined as MI or angina pectoris, heart block, valvular disease, HF and claudication); concomitant LVH (defined according to ECG criteria); other target organ damage (including hypertensive retinopathy); micro- or macroalbuminuria or renal diseases; insulin-dependent or NIDDM; electrolyte imbal- ances; alcoholism or psychiatric problems, or both; taking antihypertensive drugs; or contraindications to beta-blockers</exclusion>
</doc>
<doc>
<label>Petersen 2001</label>
<inclusion> men and women aged 18-65 years; chronic glomerulonephritis ver- (Continued) ified by renal biopsy; creatinine clearance 15 ml/min-130 ml/min; and arterial hyper- tension with a DBP between 90 mmHg-110 mmHg, calculated as the mean value of measurement on 3 different days after discontinuation of antihypertensive treatment for 2 weeks </inclusion>
<exclusion> nephrotic syndrome; extracapillary glomerulonephritis; systemic dis- ease with glomerulonephritis; liver disease; DM; HF; pregnancy; and unwillingness to participate Withdrawal criteria during the study were: development of exclusion criteria; progression to end-stage renal disease; DBP > 110 mmHg at 3 consecutive visits in the outpatient clinic; and side effects</exclusion>
</doc>
<doc>
<label>Roman 1998</label>
<inclusion> seated DBP of 95 mmHg-114 mmHg </inclusion>
<exclusion> not reported</exclusion>
</doc>
<doc>
<label>Ruggenenti 2004</label>
</doc>
<doc>
<label>Schiffrin 1994</label>
<inclusion> hypertensive men who were untreated or had not received antihyper- tensive medication for at least 6 months; 25-50 years old </inclusion>
<exclusion> people who smoked > 5 cigarettes/day; abnormal fasting blood glucose level; serum creatinine concentration > 150 μmol/L; or any other systemic disease</exclusion>
</doc>
<doc>
<label>Schmieder 2009</label>
</doc>
<doc>
<label>Schneider 2004</label>
<inclusion> men and women aged between 25-65 years;SBP of 150 mmHg-200 mmHg or a DBP of 95 mmHg-115 mmHg and mild target organ damage defined as intima media thickness of the common carotid artery on the leading side ≥ 0.8 mm and ≤1.5 mm </inclusion>
<exclusion> known or suspected secondary hypertension; coronary heart disease; cerebrovascular disease; peripheral vascular disease; renovascular disease; insulin-depen- dent DM; uncontrolled non-insulin-dependent DM; history of intolerance to atenolol, irbesartan, other angiotensin receptor blockers, HCTZ, or amlodipine; and pretreatment with an ACE inhibitor or an angiotensin receptor blocker within the last 6 months</exclusion>
</doc>
<doc>
<label>Schram 2005</label>
<inclusion> for the run-in period were: T2DM ≥ 6 months (WHO criteria 1985) ; age 35-70 years; “Caucasian ethnicity”; and urinary albumin excretion < 100 mg/24 hours. Patients with a sitting BP > 140/90 mmHg and < 190/120 mmHg after the run- in period had an ECG. Participants were included if LVMI 490 g/m2 in men or 470 g/ m2 in women </inclusion>
<exclusion> pregnancy or planning a pregnancy; a history of MI, angina pectoris, coronary artery bypass surgery, angioplasty, stroke, CHF, malignancy or other serious illnesses; serum creatinine > 140 mmol/L; body mass index 435 kg/m2; alcohol or drug abuse, or both; or participation in other clinical trials</exclusion>
</doc>
<doc>
<label>Seedat 1998</label>
<inclusion> T2DM with hypertension and DBP 95 mmHg-115 mmHg </inclusion>
<exclusion> albuminuria < 200 mg/min (300 mg in 24 hours) or macroalbumin- uria > 3.5 g/24 hours; severe complications of hypertension such as stroke, HF, renal failure; severe diabetic retinopathy (neovascularization, vitreous hemorrhages or retinal detachment); contraindications to beta-blockers or ACE inhibitors; people with poor metabolic control; and women with childbearing potential</exclusion>
</doc>
<doc>
<label>Sørensen 1998</label>
<inclusion> type I DM with hypertension and diabetic nephropathy </inclusion>
<exclusion> not reported</exclusion>
</doc>
<doc>
<label>Tarnow 1999</label>
<inclusion> hypertensive people between the ages of 18-55 years with a GFR > 40 ml/min·1.73m2, and had developed diabetes before the age of 41 years </inclusion>
<exclusion> not reported</exclusion>
</doc>
<doc>
<label>Tedesco 1999</label>
</doc>
<doc>
<label>Terpstra 2004</label>
<inclusion> people with previously untreated mild to moderate hypertension </inclusion>
<exclusion> office BP > 220/115 mmHg; unstable BP after placebo treatment period, defined as the differences in DBP or SBP before placebo treatment of 10 mmHg or 20 mmHg, respectively; secondary hypertension of any etiology; angina pectoris; manifest coronary artery disease; current or recent history of CHF; hemodynamically significant valvular heart disease; cardiac arrhythmias; renal insufficiency; and insulin- dependent DM</exclusion>
</doc>
<doc>
<label>TOHMS 1993</label>
</doc>
<doc>
<label>VALUE 2004</label>
<inclusion> men and women aged 45-69 years, DBP 90 mmHg-99 mmHg at both of the first 2 eligibility visits and averaged 90 mmHg-99 mmHg over the 3 eligibility visits </inclusion>
<exclusion> use of > 1 type of antihypertensive drug; inability to obtain a techni- cally satisfactory baseline ECG; angina; at least 50% of meals eaten away from home; unwillingness or inability to make nutritional changes; CV disease; life threatening ill- ness; LVH</exclusion>
</doc>
<doc>
<label>Zeltner 2008</label>
<inclusion> men or women of any racial background, 50 years of age and older, (Continued) with CV risk factors or disease according to an algorithm based on age and sex </inclusion>
<exclusion> renal artery stenosis; pregnancy; acute MI; percutaneous trans luminal coronary angioplasty or coronary artery bypass graft within the past 3 months; clinically relevant valvular disease; cerebrovascular accident in the past 3 months; severe hepatic disease; severe chronic renal failure; CHF requiring ACE inhibitor therapy; monotherapy with beta-blockers for both coronary artery disease and hypertension</exclusion>
</doc>
<doc>
<label>Aldamiz-Echevarria 2007</label>
<exclusion> Inclusion . All patients had been hospitalised for HF . Lived in area covered by the collaborating home care unit . Sufficient family support Exclusion . Severe cognitive deficits . Advanced psychiatric disease . Non-cardiological terminal disease . COPD</exclusion>
</doc>
<doc>
<label>Atienza 2004</label>
<inclusion> All patients with congestive heart failure discharged from cardi- ology wards of three hospitals in Spain were eligible. HF diagnosis based on the presence of symptoms and signs of heart failure with objective evidence of major cardiac dysfunc- tion at rest. All patients had been hospitalised for HF </inclusion>
<exclusion> . expected survival < 3 months . discharge to a nursing home or long term care facility . living > 30km from hospital . impossible to contact by phone . dementia or psychiatric illness . on a waiting list for invasive cardiology or heart surgery on discharge</exclusion>
</doc>
<doc>
<label>Blue 2001</label>
<inclusion> Patients admitted as an emergency to the acute medical admissions unit at one hospital with HF due to LV systolic dysfunction. All patients had been hospitalised for HF Study </inclusion>
<exclusion> 1. Unable to give informed consent or to comply with the intervention. 2. Acute MI (unless they had a previous history of CHF). 3. Co-morbidity (such as advanced malignancy) likely to lead to death or readmission in the near future. 4. Awaiting cardiac surgery. 5. Planned discharge to long term residential care. 6. Residence outside the hospital catchment area.</exclusion>
</doc>
<doc>
<label>Capomolla 2002</label>
<inclusion> 1. Patients with CHF referred for admission to the Heart Failure Unit at one centre or the Heart Transplantation Programme (unclear if at the same centre) 2.A diagnosis of CHF supported by clinical history, physical signs and symptoms, and by LVEF <40% All patients had been hospitalised for HF Study </inclusion>
<exclusion> None given.</exclusion>
</doc>
<doc>
<label>Cline 1998</label>
<inclusion> 1. Patients hospitalised primarily because of heart failure. 2. Heart failure diagnosed on symptoms and signs with ”at least one objective sign present on admission such as pulmonary rales, peripheral oedema, congestion on CXR, or a 3rd heart sound“. 3. Aged 65-84 years. Study </inclusion>
<exclusion> 1. The presence of other serious disease that either prevented participation or was ex- pected to significantly influence quality of life, morbidity or mortality in the following year. 2. Forseeable follow up problems including residence outside the hospital catchment area. 3. Serious alcohol or drug abuse. 4. Psychiatric disease. 5. Inability to understand or answer study questionnaire. 6. Participation in another clinical trial. 7. Discretion of treating physician.</exclusion>
</doc>
<doc>
<label>De Busk 2004</label>
<inclusion> Hospitalised with a provisional diagnosis of heart failure in study hospitals as indicated by new onset or worsening heart failure on the basis of 1) shortness of breath (dyspnoea t a rest, orthopnoea or paroxysmal nocturnal dyspnoea) </inclusion>
<exclusion> Scheduled for coronary artery bypass surgery or valvular surgery Undergone cardiac surgery in preceding 8 weeks Serum creatinine value > = 5 mg/dl Receiving dialysis Awaiting renal Tx History sever pulmonary disease on home O2 1 or more additional diagnoses expected to result in death within the year Cognitive mental deficits Substance abuse Severe psychiatric disorders Expected to move from area within 1 year</exclusion>
</doc>
<doc>
<label>Del Sindaco 2007</label>
<exclusion> Inclusion: . 70 years or older . Discharged home after hospitalisation due to heart failure . NYHA III-IV for at least 24 hours requiring IV therapy on admission . Diagnosis determined according to ECS guidelines (Remme et al. Eur H J 2001;22:1527-1560). Exclusion: . Valvular heart disease requiring planned surgical correction . Active substance abuse . Severe gait impairment . Confined to bed . Severe dementia . Psychiatric disease likely to limit compliance . Co-existent non-cardiac disease likely to reduce life expectancy . Need for long term IV inotropic therapy . Unwillingness to provide informed consent . Living in a nursing home Living outside the area served by the clinical sites.</exclusion>
</doc>
<doc>
<label>Doughty 2002</label>
<inclusion> Patients admitted to general medical wards with a primary diagnosis of heart failure Study </inclusion>
<exclusion> 1. Surgically remediable cause for heart failure. 2. Consideration for heart transplantation. 3. Terminal cancer. 4. Participation in another trial. 5. Inability to provide informed consent.</exclusion>
</doc>
<doc>
<label>Ducharme 2005</label>
<inclusion> seen at the emergency department of or admitted to the Montreal Heart Institute with a primary diagnosis of congestive heart failure . radiologic confirmation of congestive heart failure or known impaired LVEF (< 45%) </inclusion>
<exclusion> . a primary diagnosis of acute myocardial infarction . discharge to a chronic care facility, scheduled cardiac surgery . unwillingness to sign informed consent or to attend the outpatient clinic . participation in another research trial . residence in an outlying area</exclusion>
</doc>
<doc>
<label>Holland 2007</label>
<exclusion> Inclusion: . adults (aged over 18 years), admitted as an emergency in which heart failure was an important ongoing clinical condition, i.e. all patients had been hospitalised for HF . prescribed two or more drugs (from any drug class) on discharge Exclusion: . living in a residential or nursing home . awaiting surgery for ischaemic or valvular heart disease . awaiting heart transplantation . terminal malignancy</exclusion>
</doc>
<doc>
<label>Jaarsma 2000</label>
<inclusion> 1. Patients admitted to the cardiology unit of one hospital with HF symptoms and diagnosis verified with Boston score. 2. NYHA III or IV. 3. HF diagnosis for longer than 3 months. 4. Age 50 years or older. 5. Dutch literate. Study </inclusion>
<exclusion> 1. Coexisting, severe, chronic debilitating disease. 2. Discharge to a nursing home. 3. Psychiatric diagnosis. 4. CABG, angioplasty or valve replacement in past 6 months or expected to have such treatment in next 3 months</exclusion>
</doc>
<doc>
<label>Jaarsma 2008</label>
<exclusion> Inclusion: . Patient admitted to hospital with heart failure NYHA functional class II- IV . Aged 18 years or older . Evidence of structural underlying heart disease as shown at cardiovascular imaging . Systolic and diastolic dysfunction (preserved LVEF) . Stable on standard HF medication before discharge Exclusion: . concurrent inclusion in another study or HF clinic . inability to complete the questionnaires . invasive procedure or cardiac surgery intervention performed within the last 6 months . such procedure or intervention planned to be performed within the next 3 months . ongoing evaluation for heart transplantation . inability or unwillingness to give informed consent</exclusion>
</doc>
<doc>
<label>Kasper 2002</label>
<inclusion> 1. Admitted to one of two hospitals with a primary diagnosis of NYHA class III/IV CHF. 2. English speaking. 3. Permission from patient’s ’primary physician’ 4. Judged to be at high risk of CHF readmission, i.e. one or more of the following criteria: “Age >70 years. ”LVEF <35%. “One or more other hospital admission for CHF in previous year. ”Ischaemic cardiomyopathy. “Peripheral oedema at hospital discharge. ”Less than 3kg weight loss while in the hospital. “Peripheral vascular disease. 5. Or any one of the following during the index admission: ”Pulmonary capillary wedge pressure >25 mmHg. “Cardiac index <2.0 l/min/m2. ”SBP >180 mmHg. “DBP >100 mmHg. Study </inclusion>
<exclusion> 1. Valvular heart disease requiring surgery. 2. Active substance abuse. 3. Cardiomyopathy (peripartum, hypertrophic with LV outflow tract obstruction or restrictive). Constrictive pericarditis. 4. Psychiatric disease. 5. Dementia likely to limit compliance. 6. Non-cardiac illness likely to cause repeat hospital admission. 7. Heart transplantation likely to occur within six months. 8. Uncorrected thyroid disease. 9. Serum creatinine => 3.0 mg/dl. 10. Long term home intravenous inotropic therapy. 11. Cardiac surgery or MI during the index admission. 12. Active participation in another research trial. 13. Residence in a nursing home, rehabilitation facility or outside the area served by the two hospitals</exclusion>
</doc>
<doc>
<label>Kimmelstiel 2004</label>
<exclusion> Inclusion: . Patients were enrolled during an index HF hospitalisation or within 2 weeks of discharge. . Patients with HF resulting from ischemic heart disease, dilated cardiomyopathy, valvular heart disease (either surgically treated or deemed inoperable), or hypertensive heart disease. Exclusion: . noncardiac debilitating illness such as active malignancy . severe liver disease . severe renal insufficiency (creatinine 3.0 mg/dL) . dementia . obstructive lung disease requiring hospitalisation . angina at rest or as the principal cause of activity limitation . myocardial infarction or revascularization procedure during the index hospitalisation or within the preceding 30 days . planned revascularization or valvular surgery . restrictive myopathy . pericardial constriction . hypertrophic cardiomyopathy</exclusion>
</doc>
<doc>
<label>Krumholz 2002</label>
<inclusion> 1. Age 50 or over 2. Needed to have either admission diagnosis of heart failure or radiological signs of heart failure on admission chest x-ray. All patients had been hospitalised for HF 3. Reviewed within three days to verify additional set of criteria derived from NHANES- 1 Study </inclusion>
<exclusion> 1. Patients transferred from other hospitals or nursing homes. 2. Patients with HF secondary to high output states or non-cardiac disease. 3. Patients with another terminal illness (e.g. expected survival < 6/12)</exclusion>
</doc>
<doc>
<label>Kwok 2008</label>
<exclusion> Inclusion: . hospitalised with a principal diagnosis of CHF . age older than 60 . residing within the region and had at least one hospital admission for CHF in the 12 months prior to the index admission. Exclusion: . communication problems but without caregivers . residing in a nursing home . terminal disease with a life expectancy of less than six months</exclusion>
</doc>
<doc>
<label>Lopez 2006</label>
<exclusion> Inclusion: . patients admitted to the General Hospital of Vic and the Municipal Hospital of Badalona for heart failure (HF) who met 2 major or 1 major and 2 minor Framingham criteria Exclusion: . regularly living out of the area of influence of the hospital . regularly living in an old people’s home . moved to a social-health centre or to other centres for acute patients . suffering any type of dementia or disabling psychiatric disease . refusing to participate in the study</exclusion>
</doc>
<doc>
<label>Mejhert 2004</label>
<exclusion> Inclusion: . All patients 60 years of age or older hospitalised with heart failure according to New York Heart Association (NYHA) class II - IV and left ventricular systolic dysfunction by echocardiography Exclusion: . acute myocardial infarction or unstable angina pectoris within the previous three months . valvar stenosis . dementia . severe concomitant disease . refusal to participate</exclusion>
</doc>
<doc>
<label>Naylor 2004</label>
<exclusion> Inclusion: . all patients aged 65 and older admitted to study hospitals from their homes between February 1997 and January 2001 with a diagnosis of heart failure (diagnosis- related group 127 validated at discharge) were screened for participation . speak English . be alert and oriented . be reachable by telephone after discharge . reside within a 60-mile radius service area of the admitting hospital Exclusion: . end-stage renal disease</exclusion>
</doc>
<doc>
<label>Nucifora 2006</label>
<exclusion> Inclusion: . Aged 85 or younger . admitted to internal medicine department with a diagnosis of HF during recruitment period . HF diagnosed by 2 major or 1 major and 2 minor Frammingham criteria Exclusion: . Chronic cor pulmonale . Terminal illness in addition to HF . Severe dementia or other psychiatric illness . Indication for surgical therapy in the next 6 months . Refusal to participate</exclusion>
</doc>
<doc>
<label>Rainville 1999</label>
<inclusion> 1. All patients with heart failure in their admission diagnoses and with a history of heart failure. 2. Age 50 years or older. Study </inclusion>
<exclusion> 1.“A more significant concomitant disease (e.g. unstable angina, cardiac arrhythmia, COPD). 2. Living in long-term care facility. 3. Significant psychiatric illness. 4. Long term renal dialysis. 5. Life expectancy < 3 months. 6. No home phone. 7. Had a language barrier.</exclusion>
</doc>
<doc>
<label>Stewart 1999a</label>
<inclusion> 1. Admitted to tertiary care hospital under cardiologist and at least one previous ad- mission for acute heart failure (pulmonary congestion or oedema evident on CXR with acute dyspnoea at rest). 2. NYHA class II-IV. 3. LVEF =< 55%. 4. Age =>55 years. 5. To be discharged home. 6. Lives within hospital catchment area. Study </inclusion>
<exclusion> 1. Terminal disease. 2. Valvular disease suitable for surgery. 3. Intended heart transplantation. 4. Heart failure precipitated by extensive, reversible ischaemia. 5. Home address outside hospital catchment area.</exclusion>
</doc>
<doc>
<label>Stromberg 2003</label>
</doc>
<doc>
<label>Thompson 2005</label>
<exclusion> Inclusion: . Acute admission to hospital with a diagnosis of CHF. . Objective evidence (e.g. echocardiography or coronary angiography) of impaired left ventricular systolic function as evidenced by a left ventricular ejection fraction (LVEF) of at least 45% immediately prior to study recruitment. . Discharged to home. Exclusion: . awaiting an elective cardiac procedure with the intent to reverse the cause of underlying heart failure (e.g. coronary artery bypass surgery for coronary artery stenosis) . terminal illness other than CHF</exclusion>
</doc>
<doc>
<label>Tsuyuki 2004</label>
<exclusion> Inclusion: . Consecutive patients older than age 18 years, admitted to a hospital with a most responsible, primary, secondary, or complicating diagnosis of HF were eligible to participate in the study. Exclusion: . known secondary causes of HF (i.e., correctable causes as anaemia or hyperthyroidism) . preserved systolic function . were taking an angiotensin-II antagonist because of known intolerance or contraindication to ACE inhibitors . had a terminal illness with a life expectancy less than 6 months . cognitive impairment . were unable to communicate because of language barriers, . were attending a specialized HF clinic for medical management, . were participating in a HF clinical trial . absolute contraindication to ACE inhibitors . patients residing outside the region of the participating hospital . those discharged to a setting where patients were not responsible for own medication administration</exclusion>
</doc>
<doc>
<label>ADEPT 2001</label>
</doc>
<doc>
<label>ARCH-J 2003</label>
</doc>
<doc>
<label>CHARM-Added 2003</label>
</doc>
<doc>
<label>CHARM-Alternative 2003</label>
</doc>
<doc>
<label>CHARM-Preserved 2003</label>
</doc>
<doc>
<label>Crozier 1995</label>
</doc>
<doc>
<label>Dickstein 1995</label>
</doc>
<doc>
<label>ELITE 1997</label>
</doc>
<doc>
<label>ELITE II 2000</label>
</doc>
<doc>
<label>Hamroff 1999</label>
</doc>
<doc>
<label>HEAVEN 2002</label>
</doc>
<doc>
<label>I-PRESERVE 2008</label>
</doc>
<doc>
<label>Lang 1997</label>
</doc>
<doc>
<label>Mazayev 1998</label>
</doc>
<doc>
<label>Mitrovic 2003</label>
</doc>
<doc>
<label>REPLACE 2001</label>
</doc>
<doc>
<label>RESOLVD 1999</label>
</doc>
<doc>
<label>Sharma 2000, III-Int’l</label>
</doc>
<doc>
<label>Sharma 2000, III-US</label>
</doc>
<doc>
<label>SPICE 2000</label>
</doc>
<doc>
<label>STRETCH 1999</label>
</doc>
<doc>
<label>Tonkon 2000</label>
</doc>
<doc>
<label>V-HeFT 1999</label>
</doc>
<doc>
<label>Val-HeFT 2001</label>
</doc>
<doc>
<label>Ahlner-Elmqvist 2008</label>
<exclusion> non-Swedish speaking, mentally or physically unable to fill in questionnaires Number of patients (allocated according to their preference): 297 (119 intervention and 178 control) Diseases: cancer (297) Patient characteristics: median age 67 years intervention, 68 years control; 48% female intervention, 54% female control; 29% lived alone Number of caregivers (consented): 204 (102 in each group) Caregiver characteristics: median age 63 years intervention, 65 years control; 64% female; 77% spouses Deaths at end of study: 117 intervention (98%) and 163 control (92%) Withdrawals/other drop-outs: “no patients are lost for follow-up”</exclusion>
</doc>
<doc>
<label>Aiken 2006</label>
</doc>
<doc>
<label>Axelsson 1998</label>
</doc>
<doc>
<label>Bakitas 2009</label>
<exclusion> impaired cognition, axis I psychiatric disorder, active substance use Number of patients (randomised): 322 (161 intervention and 161 control) Diseases (outcome sample): cancer (279): gastrointestinal (119), lung (93), genitouri- nary (37), breast (30) Patient characteristics (outcome sample): mean age 65.4 years intervention, 65.2 years control; 39.8% female Number of caregivers ( ): 220 (116 intervention and 104 control) Caregiver characteristics (outcome sample of 198 caregivers): mean age 58.0 years intervention, 59.9 years control; 77% female; 71% spouse/partner Deaths at end of study: 231 (72%); 112 intervention (70%) and 119 control (74%) Withdrawals/other drop-outs: 57 patients (18%): 29 intervention (18%) and 28 con- trol (17%) (reasons not stated); 134 caregivers (61%): 66 intervention (57%) and 68 control (65%) (due to withdrawal, refusal or completion of initial form of the question- naire)</exclusion>
</doc>
<doc>
<label>Brumley 2007</label>
</doc>
<doc>
<label>Buckingham 1978</label>
</doc>
<doc>
<label>Grande 1999</label>
<exclusion> emergency cases without usual care and those enrolled in periods where service was ’empty’ (these were given the intervention without entering trial) Number of patients (randomised): 241 Diseases (outcome sample of 229 patients): cancer (198), non-cancer (31) Patient characteristics: mean age 72.1 years intervention, 72.6 years control; 50.2% female; 20.6% lived alone Number of caregivers (randomised): 198 Caregiver characteristics (subsample of 96 bereaved caregivers): mean age 63.6 years intervention, 62.3 years control; 49.0% female; 71.9% spouses Deaths at end of study: 229 (95%); 186 intervention and 43 control Withdrawals/other drop-outs: 13 patients who were still alive at end of study and 31 with no caregiver were excluded from caregiver after death follow-ups; non-response from 55 caregivers to 6 weeks after death questionnaire; 102 caregiver drop-outs at 6 months after death (83 did not agree to take part and 19 non-responses)</exclusion>
</doc>
<doc>
<label>Greer 1986</label>
</doc>
<doc>
<label>Gómez-Batiste 2010</label>
<exclusion> unavailable on the telephone Number of patients (included): 265 (158 intervention and 107 control) Diseases: cancer (265) Patient characteristics: mean age 72.2 years; 39% female (Continued) Deaths at end of study: 43 (drop-outs) Withdrawals/other drop-outs: 19 (14 due to severe impairment, 5 reasons not stated)</exclusion>
</doc>
<doc>
<label>Harding 2004</label>
<exclusion> lack of fluency in spoken English Number of patients (initial inclusion): 77 (40 intervention and 37 control) Diseases (baseline sample): cancer (63), HIV (4), MND (2), Bechet’s disease (1), CHF (1), Leigh’s syndrome (1), Parkinson’s disease (1) Patient characteristics: mean age 65 years Number of caregivers (initial inclusion): 77 (40 intervention and 37 control) Caregiver characteristics: mean age 59.2 years; 69% female Deaths at end of study: not stated Withdrawals/other drop-outs: 4 intervention caregivers (unable to do baseline mea- sures)</exclusion>
</doc>
<doc>
<label>Higginson 2009</label>
<exclusion> very urgent needs or rapid deterioration (immediate referral to service offered) Number of patients (randomised): 52 (26 intervention and 26 control) Diseases: MS (52) Patient characteristics: mean age 53 years; 69% female; 17.3% lived alone Number of caregivers (randomised): 52 (26 intervention and 26 control) Caregiver characteristics: not stated Deaths at end of study: 4 (1 in the intervention and 3 in the control) Withdrawals/other drop-outs: 2 controls (1 protocol violation, 1 severely ill)</exclusion>
</doc>
<doc>
<label>Hudson 2005</label>
<exclusion> no caregiver living with patient, patient with intellectual or psychiatric illness or lack of English language skills Diseases: cancer (106) Number of caregivers (randomised): 106 (54 intervention and 52 control) Caregiver characteristics: mean age 60.78 years; 65.1% female Deaths at end of study: not stated Withdrawals/other drop-outs: 34 intervention and 27 control (non-response to ques- tionnaire)</exclusion>
</doc>
<doc>
<label>Hughes 1992</label>
</doc>
<doc>
<label>Jordhøy 2000</label>
<exclusion> haematological malignant disorders other than lymphomas, patient not informed about their diagnosis and that the disease was incurable, participation in other trials with quality of life as outcome, unable to fill in questionnaire Number of patients (randomised): 434 (235 intervention and 199 control) Diseases: cancer (434): gastrointestinal (181), lung (52), breast and female genitals (67), prostate and male genitals (41), kidney or vesica (29), lymphomas (13), skin (12), others (39) Patient characteristics: median age 70 years intervention, 69 years control; 47% female; 32.5% lived alone Number of caregivers (consented): 313 (183 intervention and 130 control) Caregiver characteristics: median age 57.6 years intervention, 53.9 years control; 68. 3% female Deaths at end of study: 395 (219 intervention (93%) and 176 control (88%)) Withdrawals/other drop-outs: 6 intervention and 10 control (reasons not stated)</exclusion>
</doc>
<doc>
<label>McCorkle 1989</label>
<exclusion> judged by physi- cian as too ill to participate, receiving standard home nursing care in prior 6 months, enrolled in home health agency Number of patients (randomised): 166; (outcome sample): 78; 24 intervention, 27 control1, 26 control2 (group for 1 patient not stated) Diseases: cancer (166); all primary site lung Patient characteristics: aged 18-89 years; 37% female Number of caregivers (eligible): 127; (outcome sample): 46 Caregiver characteristics: not stated Deaths at end of study: 87 (52%) Withdrawals/other drop-outs: 24 patients (11 too sick to handle interviews, 5 caregivers refused interview, 3 caregiver or patients or both unable to cope with questions, 3 patients moved out of King County, 2 unknown); 81 caregivers at bereavement follow-up (30 refused, 9 did not complete first interview, 21 patients still alive, 10 lost to follow-up, 11 incomplete data)</exclusion>
</doc>
<doc>
<label>McKegney 1981</label>
<exclusion> patients mentally incompetent Number of patients (allocated): 199 (98 intervention and 101 control) Diseases: cancer (199) Patient characteristics (primary outcome sample of 83 patients): mean age 58.7 years intervention, 56.1 years control; 42% female Deaths at end of study: 139 (70%) Withdrawals/other drop-outs: not stated</exclusion>
</doc>
<doc>
<label>McMillan 2007</label>
<exclusion> patient low level of consciousness (assessed by admission team), excessively debilitated (≥ 40 score on Palliative Performance Scale) or actively (Continued) dying, admitted to inpatient hospice or assisted-living facility or nursing home; patient and caregiver < sixth grade education, unable to read or understand English, ≥ 7 in Short Portable Mental Status Questionnaire, caregiver in active treatment for cancer themselves Number of patients (randomised): 329 (111 intervention, 109 control1, 109 control2) Diseases: cancer (329) Patient characteristics: mean age 70.84 years intervention, 71.02 years control1 and 70.12 years control2; 39.9% female Number of caregivers (randomised): 329 (111 intervention, 109 control1, 109 control2) Caregiver characteristics: mean age 63.06 years intervention, 61.53 years control1, 59. 98 years control2; 85.4% female Deaths at end of study: not stated Withdrawals/other drop-outs: “Most commonly, attrition was due to patient decline (29%) or death (21%), and the caregiver feeling overwhelmed (23%), which was largely associated with patients’ worsening condition”</exclusion>
</doc>
<doc>
<label>McWhinney 1994</label>
</doc>
<doc>
<label>Rabow 2004</label>
<exclusion> non-melanoma skin cancers, dementia, psychosis, enrolled in hospice care, unable to complete a written survey in English or Spanish Number of patients (allocated): 90 (50 intervention and 40 control) Diseases: cancer (30), CHF (31), COPD (29) Patient characteristics: mean age 67.9 years intervention, 69.4 years control; 64% female; 43.3% lived alone Deaths at end of study: 15 (17%); 10 intervention (20%) and 5 control (13%) Withdrawals/other drop-outs: 5 in the intervention (6%) and 4 in the control (10%) (Continued) (reasons not stated)</exclusion>
</doc>
<doc>
<label>Tramarin 1992</label>
</doc>
<doc>
<label>Walsh 2007</label>
<exclusion> caregiver lack of English skills Number of patients (randomised): 271 (137 intervention and 134 control) Diseases: cancer (271): lung (79), gastrointestinal (55), genitourinary (40), head and neck (24), breast (18), others (55) Patient characteristics: not stated Number of caregivers (randomised): 271 (137 intervention and 134 control) Caregiver characteristics: mean age 56.3 years; 79% female Deaths at end of study: 109 (40%); 47 intervention (34%) and 62 control (46%) Withdrawals/other drop-outs: 21 intervention and 18 control (refusals)</exclusion>
</doc>
<doc>
<label>Ward 1987</label>
</doc>
<doc>
<label>Zimmer 1985</label>
<exclusion> primary psychiatric illness, unable to fill in questionnaires Number of patients (randomised): 167 (85 intervention and 82 control); (baseline): 158 (82 intervention and 76 control) ; 22% intervention and 18% control classified as terminal (subanalysis performed) Diseases (overall baseline sample): cancer (21% intervention, 17% control), stroke (12% intervention, 17% control), arthritis/rheumatism (9% intervention, 12% control), oth- ers, all below 10% (59% intervention, 54% control); those classified as terminal were “largely cancer” patients Patient characteristics: mean age 76 years, median age 77 years; 68% female; 23.2% intervention patients and 18.4% controls lived alone Deaths at end of study: 48 (29 intervention and 19 control, including 3 patients who died before the initial interview) Withdrawals/other drop-outs: 21: 5 drop-outs/changed their minds and 1 patient moved away before initial interview; 15 drop-outs after initial interview (17 deliberate dropped out: 4 intervention and 13 control)</exclusion>
</doc>
<doc>
<label>Bellone 2004</label>
</doc>
<doc>
<label>Bellone 2005</label>
</doc>
<doc>
<label>Bersten 1991</label>
</doc>
<doc>
<label>Crane 2004</label>
</doc>
<doc>
<label>Delclaux 2000</label>
</doc>
<doc>
<label>Kelly 2002</label>
</doc>
<doc>
<label>L’Her 2004</label>
<exclusion> Glasgow Coma Scale less or similar 7, SpO2 similar or less 85% despite oxygen, hemodynamic instability, chronic respiratory insufficiency</exclusion>
</doc>
<doc>
<label>Levitt 2001</label>
</doc>
<doc>
<label>Liesching 2003</label>
</doc>
<doc>
<label>Lin 1991</label>
</doc>
<doc>
<label>Lin 1995</label>
</doc>
<doc>
<label>Masip 2000</label>
</doc>
<doc>
<label>Mehta 1997</label>
</doc>
<doc>
<label>Nava 2003</label>
</doc>
<doc>
<label>Park 2001</label>
</doc>
<doc>
<label>Park 2004</label>
</doc>
<doc>
<label>Räsänen 1985</label>
</doc>
<doc>
<label>Sharon 2000</label>
</doc>
<doc>
<label>Takeda 1997</label>
<exclusion> complicated with aspiration and/or pneumonia, immediate need for endotracheal in- tubation, shock, and life-threatening hypoxia at study entry</exclusion>
</doc>
<doc>
<label>Takeda 1998</label>
<exclusion> complicated with aspiration and/or pneumonia, immediate need for endotracheal intubation, shock, and life-threatening hypoxia at study entry</exclusion>
</doc>
<doc>
<label>Thys 2002</label>
</doc>
<doc>
<label>Aaberge 2000</label>
<inclusion> participants with an earlier angiogram and refusing CABG or PTCA, NYHA angina class III or IV </inclusion>
<exclusion> mild symptoms (angina class under III), age > 75 years, confirmed non-reversible ischaemia, ejection fraction < 30%, general poor health status, inability to undergo study tests or refusal to participate in a RCT</exclusion>
</doc>
<doc>
<label>Allen 1999</label>
<inclusion> Refractory angina CCS class IV, not amenable to CABG or PTCA, reversible ischaemia determined by myocardial perfusion scanning, and ejection fraction > 25% </inclusion>
<exclusion> contraindication to general anaesthesia, severe chronic obstructive pulmonary disease, need of continued use of intravenous antianginal medication, inabil- ity to undergo dipyridamole-thallium stress scintigraphy, non Q-wave myocardial in- farction in the previous two weeks, need of anticoagulant treatment, severe arrhythmias, and decompensated congestive heart failure</exclusion>
</doc>
<doc>
<label>Burkhoff 1999</label>
<inclusion> CCS angina class III-IV, ejection fraction > 30%, reversible perfusion defects on dypiridamolle-thallium stress test, with at least one region of protected my- ocardium, angiographically defined Exclusions: myocardial infarction in the previous 3 months, admitted to hospital for unstable angina in the last 21 days, severe symptomatic heart failure, ventricular arrhyth- mias, cardiac transplant or judged to be poor surgical candidate</inclusion>
</doc>
<doc>
<label>Frazier 1999</label>
<inclusion> CCS class III-IV angina, refractory to medical treatment, reversible ischaemia and coronary disease not amenable to CABG or PTCA Excluded patients with ejection fraction under 20% or with a concurrent major disease</inclusion>
</doc>
<doc>
<label>Jones 1999</label>
<inclusion> CCS angina class 3-4, on maximal tolerated doses of at least two medications, and having areas of viable ischaemic myocardium by dypiridamole-thallium testing </inclusion>
<exclusion> patients with left main coronary artery lesions greater than 70% without open bypasses to the anterior descending or circumflex arteries; patients with congestive heart failure; patients with obstructive pulmonary disease when, in opinion of the principal investigator, it would affect exercise testing</exclusion>
</doc>
<doc>
<label>Schofield 1999</label>
<inclusion> reversible ischaemia on radionuclide myocardial perfusion scan Exclussion criteria: unable to do treadmill exercise testing, ejection fraction < 30%, were suitable for conventional revascularization, were on intravenous therapy to control angina, or life expectancy < 12 months because of non-cardiac disorder</inclusion>
</doc>
<doc>
<label>van der Sloot 2004</label>
<inclusion> angina NYHA class 3-4, refractory to conventional treatments and with detectable reversible myocardial ischaemia </inclusion>
<exclusion> not reported</exclusion>
</doc>
<doc>
<label>Balk 1992</label>
<inclusion> all consecutive heart transplant recipients </inclusion>
<exclusion> not specified Intervention therapy: ALG (horse lymphocyte-specific IgG2, Lymphoglobulin, Institut Merieux) started postoperatively 1-2 h after arrival at ICU, 425 lymphocytotoxic units daily (0.5 ml//kg body weight) for 7 days Control therapy: muromonab-CD3 (OKT3, Ortho Pharmaceutical, Raritan NJ), started postoperatively 1-2 h after arrival at ICU, 5 mg daily for 7 days Concomittant immunosuppressive treatment: cyclosporine, started at day 5 azathioprine corticosteroids Survival, rejection, adverse events, infections, cancer Follow-up period: 15 months (range 3-25 months)</exclusion>
</doc>
<doc>
<label>Beniaminovits 2000</label>
<inclusion> adult, consecutive non-sensitized recipients of first cardiac transplants </inclusion>
<exclusion> recipients of previous allografts or had a positive cross-match for T- cell lymphocytes</exclusion>
</doc>
<doc>
<label>Bolling 1989</label>
</doc>
<doc>
<label>Bonaros 2006</label>
</doc>
<doc>
<label>Carrier 2007</label>
<inclusion> participant on the waiting list for heart transplantation </inclusion>
<exclusion> unclear</exclusion>
</doc>
<doc>
<label>Costanzo-Nordin 1990</label>
</doc>
<doc>
<label>De Santo 2004</label>
</doc>
<doc>
<label>Faggian 2010</label>
<inclusion> primary heart transplant recipients </inclusion>
<exclusion> recipient of a second transplant; previous cancer; pregnancy or female participant of childbearing potential not using a medically approved, effective form of contraception during the study; recent history of systemic infection, severe diarrhoea, active peptic ulcer or gastro-intestinal diseases interfering with the absorption of oral immunosuppressive agents; previous treatment with ALG or monoclonal antibodies; history of drug addiction, psychiatric disorder, or behavioural attitude interfering with compliance to therapy; recent enrolment in other trials of immunosuppressive drugs Primary: incidence of acute rejection episodes at 6 months (ISHLT ≥1b), bouts of steroid-resistant rejection, and time to first rejection Secondary: survival, graft atherosclerosis, infections, cancer Follow-up period: mean follow-up 32.8 ± 8.9 months</exclusion>
</doc>
<doc>
<label>Hershberger 2005</label>
<inclusion> primary heart transplantation, age > 13 years, first cardiac allograft </inclusion>
<exclusion> known need of cytolytic therapy or requiring ventricular assist device after surgery</exclusion>
</doc>
<doc>
<label>Ippoliti 1991</label>
</doc>
<doc>
<label>Kobashigawa 1993</label>
<inclusion> adult participants undergoing heart transplantation, preoperative serum creatinine level of 1.4 mg/dl or less </inclusion>
<exclusion> iv inotrope support in the immediate preoperative period</exclusion>
</doc>
<doc>
<label>Kormos 1990</label>
</doc>
<doc>
<label>Macdonald 1993</label>
</doc>
<doc>
<label>Mattei 2007</label>
<inclusion> participants between 18-65 years of age undergoing a primary heart transplant with a cold ischaemia time < 6 h </inclusion>
<exclusion> receipt of a graft from a donor > 60 years of age, or with documented coronary disease or other heart disease; a previous or multiple-organ transplant; unstable haemodynamic status at the time of randomisation; creatinine level more than 250 μmol/ L</exclusion>
</doc>
<doc>
<label>Mehra 2005</label>
</doc>
<doc>
<label>Menkis 1992</label>
</doc>
<doc>
<label>Mullen 2005</label>
<inclusion> all adult participants listed for heart transplantation between June 2001 and April 2005 </inclusion>
<exclusion> emergency surgery; previous transplant; multiple-organ transplant including heart-lung transplant; active infection; hepatitis C; high positive panel reactive antibodies (> 15%); known sensitivity to daclizumab, ATG or mouse antigens; expected inability to be followed at the study centre for a full year; and inability to give informed consent</exclusion>
</doc>
<doc>
<label>Schnetzler 2002</label>
<inclusion> first heart transplantation, participants between 16-60 years of age, written informed consent </inclusion>
<exclusion> second graft transplantation; serious concomitant diseases or severe thrombocytopenia; viral, fungal, or bacterial infections upon inclusion; pregnancy or lactation; previous treatment with rabbit polyclonal anti-lymphocytic preparations</exclusion>
</doc>
<doc>
<label>Segovia 2006</label>
</doc>
<doc>
<label>van Gelder 1996</label>
<inclusion> participants between 18-70 years of age undergoing orthotopic primary heart transplantation </inclusion>
<exclusion> donor age > 60 years; previous use of basiliximab, OKT3, or any other immunomodulator within 4 weeks before transplant; history of cancer within 5 years before transplantation; ABO incompatibility between participant and donor; severe systemic infection; pregnancy, lactation or non-use of contraceptives for women of child- bearing age; seropositivity for HIV or hepatitis B or C; unresolved history of drug abuse; leukocyte count below 3000/mm3 or platelet count below 7000/mm3 ; serum creatinine higher than 3 mg/dL; multiple organ transplant procedure or previous transplantation Intervention therapy: basiliximab, 20 mg iv bolus on days 0 and 4 Control therapy: OKT3, 5 mg/kg single daily dose days 0-7 Concomittant immunosuppressive treatment: cyclosporin, started up to 48 h after transplantation mycophenolate mofetil, started 72 h after transplantation corticosteroids</exclusion>
</doc>
<doc>
<label>van Gelder 2004</label>
<inclusion> not specified </inclusion>
<exclusion> not specified</exclusion>
</doc>
<doc>
<label>Wollenek 1989</label>
</doc>
<doc>
<label>AMDSG</label>
<inclusion> People with a monocular one line drop in Snellen visual acuity not attributable to cataract, amblyopia, systemic or ophthalmic disease AND clinically observable drusen, RPE disruption and loss of macular reflex. </inclusion>
<exclusion> Greater than one year use of vitamins; ex-prisoners of war, chronic alcoholics with tobacco/nutritional amblyopia or gastrointestinal absorption disorders</exclusion>
</doc>
<doc>
<label>AREDS</label>
<inclusion> 20/32 or better in at least one eye; ocular media clear and therefore able to obtain adequate stereoscopic fundus photographs; at least one eye free from eye disease that could complicate assessment of AMD. </inclusion>
<exclusion> Illness or disorders that would make long term follow-up or compliance with study protocol unlikely or difficult</exclusion>
</doc>
<doc>
<label>Holz 1993</label>
</doc>
<doc>
<label>Kaiser 1995</label>
<inclusion> People with nonserous AMD. All participants had regional atrophy of the pigment epithelium. Corrected visual acuity was between 20/100 and 20/25 with distance correction of less than four dioptres. </inclusion>
<exclusion> People with diabetes mellitus, endocrine problems, cardiac dysrhythmia, cardial infarc- tion or hypotension, other ocular disorders</exclusion>
</doc>
<doc>
<label>Newsome 1988</label>
<inclusion> Macular degeneration: clinically visible drusen with varying degrees of pigmentary change with visual acuity in one eye of 20/80 or better. </inclusion>
<exclusion> Cataract reducing vision more than one line; other known serious eye disease; diabetes mellitus; other known systematic/metabolic disease or congenital condition which might interfere with results</exclusion>
</doc>
<doc>
<label>Stur 1996</label>
<inclusion> Exudative AMD in one eye (defined as angiographic evidence of classic or occult choroidal neovascularisation or RPE detachment) and early ARM with visual acuity 20/40 or better in other eye (early ARM: macular drusen with no angiographic evidence of exudative lesion). </inclusion>
<exclusion> Dense senile cataract; any other eye disease which could produce significant and per- manent loss of visual acuity during follow up; physical status that could prevent follow up; history of serious systemic or metabolic disease</exclusion>
</doc>
<doc>
<label>VECAT</label>
<inclusion> Lens and retina of at least one eye available for documentation. </inclusion>
<exclusion> Previous cataract surgery or advanced cataract in both eyes; steroid or anticoagulation use; serious disease; regular use or sensitivity to vitamin E</exclusion>
</doc>
<doc>
<label>Veterans LAST study</label>
<inclusion> Atrophic AMD diagnosed by ophthalmoscopy and at least one visual abnormality: reduced contrast sensitivity, photo-stress glare recovery deficit or deficit on Amsler grid. Clear ocular media, free of any other ocular/systemic disease that could affect central or parafoveal macular visual function. </inclusion>
<exclusion> Cataract or retinal surgery within 6 months, photosensitizing drugs, taken lutein supplements within the previous six months</exclusion>
</doc>
<doc>
<label>Wang 2004</label>
</doc>
<doc>
<label>Ang 2008</label>
</doc>
<doc>
<label>Assmus 2006</label>
</doc>
<doc>
<label>Assmus 2012</label>
</doc>
<doc>
<label>Chen 2006</label>
</doc>
<doc>
<label>Erbs 2005</label>
</doc>
<doc>
<label>Hendrikx 2006</label>
</doc>
<doc>
<label>Honold 2012</label>
</doc>
<doc>
<label>Hu 2011</label>
</doc>
<doc>
<label>Kang 2006</label>
</doc>
<doc>
<label>Losordo 2007</label>
</doc>
<doc>
<label>Losordo 2011</label>
</doc>
<doc>
<label>Patel 2005</label>
</doc>
<doc>
<label>Perin 2011</label>
</doc>
<doc>
<label>Perin 2012a</label>
</doc>
<doc>
<label>Perin 2012b</label>
</doc>
<doc>
<label>Pokushalov 2010</label>
</doc>
<doc>
<label>Tse 2007</label>
</doc>
<doc>
<label>Turan 2011</label>
</doc>
<doc>
<label>Van Ramshorst 2009</label>
</doc>
<doc>
<label>Wang 2009</label>
</doc>
<doc>
<label>Wang 2010</label>
</doc>
<doc>
<label>Yao 2008</label>
</doc>
<doc>
<label>Zhao 2008</label>
</doc>
<doc>
<label>Austin 2005</label>
</doc>
<doc>
<label>Belardinelli 1999</label>
</doc>
<doc>
<label>Belardinelli 2012</label>
</doc>
<doc>
<label>Bocalini 2008</label>
</doc>
<doc>
<label>DANREHAB 2008</label>
</doc>
<doc>
<label>Davidson 2010</label>
</doc>
<doc>
<label>Dracup 2007</label>
</doc>
<doc>
<label>Gary 2010 (comp)</label>
</doc>
<doc>
<label>Gary 2010 (exalone)</label>
</doc>
<doc>
<label>Giannuzzi 2003</label>
</doc>
<doc>
<label>Gielen 2003</label>
</doc>
<doc>
<label>Gottlieb 1999</label>
</doc>
<doc>
<label>Hambrecht 1995</label>
</doc>
<doc>
<label>Hambrecht 1998</label>
</doc>
<doc>
<label>Hambrecht 2000</label>
</doc>
<doc>
<label>HF ACTION 2009</label>
</doc>
<doc>
<label>Jolly 2009</label>
</doc>
<doc>
<label>Jónsdóttir 2006a</label>
</doc>
<doc>
<label>Keteyian 1996</label>
</doc>
<doc>
<label>Klecha 2007</label>
</doc>
<doc>
<label>Klocek 2005 (Const)</label>
</doc>
<doc>
<label>Klocek 2005 (Prog)</label>
</doc>
<doc>
<label>Koukouvou 2004</label>
</doc>
<doc>
<label>McKelvie 2002</label>
</doc>
<doc>
<label>Mueller 2007</label>
</doc>
<doc>
<label>Myers 2000</label>
</doc>
<doc>
<label>Nilsson 2008</label>
</doc>
<doc>
<label>Norman 2012</label>
</doc>
<doc>
<label>Passino 2006</label>
</doc>
<doc>
<label>Pozehl 2008</label>
</doc>
<doc>
<label>Wall 2010</label>
</doc>
<doc>
<label>Willenheimer 2001</label>
</doc>
<doc>
<label>Witham 2005</label>
</doc>
<doc>
<label>Witham 2012</label>
</doc>
<doc>
<label>Yeh 2011</label>
</doc>
<doc>
<label>Arora 1999</label>
</doc>
<doc>
<label>Ballerini 2002</label>
</doc>
<doc>
<label>Caskey 2003</label>
</doc>
<doc>
<label>Cass 2002</label>
</doc>
<doc>
<label>Chen 2010</label>
</doc>
<doc>
<label>Chow 2008</label>
</doc>
<doc>
<label>Curtis 2002</label>
</doc>
<doc>
<label>Dogan 2005</label>
</doc>
<doc>
<label>Ellis 1998</label>
</doc>
<doc>
<label>Fan 2002</label>
</doc>
<doc>
<label>Gallego 2003</label>
</doc>
<doc>
<label>Goransson 2001</label>
</doc>
<doc>
<label>Hasegawa 2009</label>
</doc>
<doc>
<label>Helal 2010</label>
</doc>
<doc>
<label>Herget-Rosenthal 2010</label>
</doc>
<doc>
<label>Hoffmann 2006</label>
</doc>
<doc>
<label>Inaguma 2011</label>
</doc>
<doc>
<label>Jungers 1997</label>
</doc>
<doc>
<label>Kazmi 2004</label>
</doc>
<doc>
<label>Lin 2003</label>
</doc>
<doc>
<label>Lorenzo 2004</label>
</doc>
<doc>
<label>Mezei 2010</label>
</doc>
<doc>
<label>Nakamura 2007</label>
</doc>
<doc>
<label>Pena 2006</label>
</doc>
<doc>
<label>Ratcliffe 1984</label>
</doc>
<doc>
<label>Ravani 2003</label>
</doc>
<doc>
<label>Roubicek 2000</label>
</doc>
<doc>
<label>Sabath 2003</label>
</doc>
<doc>
<label>Schmidt 1998</label>
</doc>
<doc>
<label>Selim 2007</label>
</doc>
<doc>
<label>Shiao 2008</label>
</doc>
<doc>
<label>Shin 2007</label>
</doc>
<doc>
<label>Stack 2003</label>
</doc>
<doc>
<label>Stoves 2001</label>
</doc>
<doc>
<label>Van Biesen 1997</label>
</doc>
<doc>
<label>Wijewickrama 2010</label>
</doc>
<doc>
<label>Winkelmayer 2001</label>
</doc>
<doc>
<label>Winkelmayer 2007</label>
</doc>
<doc>
<label>Yanay 2010</label>
</doc>
<doc>
<label>Yokoyama 2009</label>
</doc>
<doc>
<label>Adarsh 2008</label>
</doc>
<doc>
<label>Berman 2004</label>
</doc>
<doc>
<label>Keogh 2003</label>
</doc>
<doc>
<label>Khatta 2000</label>
</doc>
<doc>
<label>Kocharian 2009</label>
</doc>
<doc>
<label>Morisco 1993</label>
</doc>
<doc>
<label>Munkholm 1999</label>
</doc>
<doc>
<label>CHARISMA 2006</label>
</doc>
<doc>
<label>CURE 2001</label>
</doc>
<doc>
<label>Arrigo 2008</label>
</doc>
<doc>
<label>Ashe 1993</label>
</doc>
<doc>
<label>Beckie 2010</label>
</doc>
<doc>
<label>Cossette 2012</label>
</doc>
<doc>
<label>Daltroy 1985</label>
</doc>
<doc>
<label>Dolansky 2011</label>
</doc>
<doc>
<label>Duncan 2002</label>
</doc>
<doc>
<label>Hillebrand 1995</label>
</doc>
<doc>
<label>Izawa 2005</label>
</doc>
<doc>
<label>Jolly 1999</label>
</doc>
<doc>
<label>McPaul 2007</label>
</doc>
<doc>
<label>Moore 2006</label>
</doc>
<doc>
<label>Oldridge 1983</label>
</doc>
<doc>
<label>Pack 2013</label>
</doc>
<doc>
<label>Parry 2009</label>
</doc>
<doc>
<label>Price 2012</label>
</doc>
<doc>
<label>Sniehotta 2006</label>
</doc>
<doc>
<label>Wyer 2001</label>
</doc>
<doc>
<label>Aronow 1977</label>
<inclusion> essential hypertension </inclusion>
<exclusion> coronary artery disease; cerebrovascular disease; heart failure; renal disease; hepatic disease</exclusion>
</doc>
<doc>
<label>Aronow 1978</label>
<inclusion> Essential hypertension </inclusion>
<exclusion> not reported</exclusion>
</doc>
<doc>
<label>Fernandez 1980</label>
<inclusion> essential hypertension; supine or standing diastolic blood pressure 90- 120 mm Hg </inclusion>
<exclusion> grade III or IV hypertensive retinopathy; heart failure; acute myocar- dial infarction; arrhythmias; angina pectoris; impaired liver or kidney function; blood dyscrasias; positive results of Coomb’s test; allergy to any study drug; previous stroke; insulin-dependent diabetes mellitus; serum potassium less than 3.5 mmol/L; pregnant patients; malignant diseases; any other condition at investigator’s discretion</exclusion>
</doc>
<doc>
<label>Ferrara 1984</label>
<inclusion> essential hypertension </inclusion>
<exclusion> target organ damage secondary to hypertension</exclusion>
</doc>
<doc>
<label>Johnson 1990</label>
<inclusion> essential hypertension; untreated supine diastolic blood pressure 90- 105 mm Hg </inclusion>
<exclusion> not reported</exclusion>
</doc>
<doc>
<label>Lepantalo 1984</label>
<inclusion> essential hypertension; intermittent claudication </inclusion>
<exclusion> not reported</exclusion>
</doc>
<doc>
<label>Mroczek 1974</label>
<inclusion> essential hypertension; diastolic blood pressure greater than 95 mm Hg </inclusion>
<exclusion> not reported</exclusion>
</doc>
<doc>
<label>Paran 1993</label>
<inclusion> Average sitting diastolic blood pressure of 95-119 mm Hg on two consecutive visits while on placebo for first two to four weeks </inclusion>
<exclusion> secondary hypertension; “hypertensive complications”</exclusion>
</doc>
<doc>
<label>Petrie 1976</label>
<inclusion> age 21-65; supine DBP greater than 105 mm Hg and less than 125 mm Hg </inclusion>
<exclusion> history of recent myocardial infarction; evidence of cardiac failure, heart block, or gross ischemia; grade III or IV retinopathy; diabetes mellitus; gout; impaired liver function; creatinine clearance less than 60 mL/min; on any other drug treatment</exclusion>
</doc>
<doc>
<label>Schnaper 1975</label>
<inclusion> at least 21 years old; diagnosis of essential hypertension or renal hy- pertension not amenable to surgical treatment; presence of sustained baseline supine diastolic blood pressure between 95-115 mm Hg </inclusion>
<exclusion> labile hypertension; pregnant women; cerebrovascular accident or acute myocardial infarction in past year; receiving a sedative or a tranquillizer; receiving an investigational drug; secondary hypertension</exclusion>
</doc>
<doc>
<label>Tiwari 1982</label>
<inclusion> essential hypertension; sustained diastolic blood pressure greater than 95 mm Hg </inclusion>
<exclusion> secondary hypertension; pregnant patients; myocardial infarction or cerebrovascular accident in past six months; accelerated hypertension; hepatic or renal dysfunction</exclusion>
</doc>
<doc>
<label>Yodfat 1993</label>
<inclusion> essential hypertension; sitting diastolic blood pressure 95-105 mm Hg </inclusion>
<exclusion> secondary hypertension; malignant hypertension; unstable angina; recent myocardial infarction; any clinically relevant cardiovascular disease; any abnormal laboratory findings (including liver function tests and creatinine levels up to 1.5 mg/100 mL)</exclusion>
</doc>
<doc>
<label>Botoni 2007</label>
</doc>
<doc>
<label>Diniz 2004</label>
<inclusion> . Age 18 to 65 years . NYHA: II to IV . Ejection fraction and left ventricular fraction using isotopic ventriculography: ≤ 35% . All of the patients already using digitalis, diuretics, angiotensin converting enzyme inhibitors and spironolactone, and may or may not be using amiodarone and anticoagulant 10) </inclusion>
<exclusion> . Functional class IV requiring use of vasoactive drugs . Severe bradycardia smaller or equal to 50 beats per minute . Blocks atrioventricular the second or third degree, without permanent pacemaker . Systolic blood pressure less than or equal to 60 mmHg . Comorbidities such as renal insufficiency (creatinine greater than or equal to 3.0) or hepatic serious bronchial asthma or chronic obstructive pulmonary disease . Pregnant or not using contraception.</exclusion>
</doc>
<doc>
<label>Farley 2002a</label>
</doc>
<doc>
<label>Farley 2002b</label>
</doc>
<doc>
<label>Romano 2004</label>
</doc>
<doc>
<label>Tu 2009</label>
</doc>
<doc>
<label>AASK</label>
</doc>
<doc>
<label>ABCD</label>
</doc>
<doc>
<label>ALLHAT</label>
</doc>
<doc>
<label>ASCOT-BPLA</label>
</doc>
<doc>
<label>CONVINCE</label>
</doc>
<doc>
<label>ELSA</label>
</doc>
<doc>
<label>FACET</label>
</doc>
<doc>
<label>IDNT</label>
</doc>
<doc>
<label>INSIGHT</label>
</doc>
<doc>
<label>INVEST</label>
</doc>
<doc>
<label>MIDAS</label>
</doc>
<doc>
<label>NICS-EH</label>
</doc>
<doc>
<label>NORDIL</label>
</doc>
<doc>
<label>SHELL</label>
</doc>
<doc>
<label>STOP-Hypertension-2</label>
</doc>
<doc>
<label>TOMHS</label>
</doc>
<doc>
<label>VALUE</label>
</doc>
<doc>
<label>VHAS</label>
</doc>
<doc>
<label>Blackwood 1990</label>
</doc>
<doc>
<label>Dig captopril 1988</label>
</doc>
<doc>
<label>Dig milrinone 1989</label>
</doc>
<doc>
<label>DIG study 1997</label>
</doc>
<doc>
<label>Dig xamoterol 1988</label>
</doc>
<doc>
<label>DIMT 1993</label>
</doc>
<doc>
<label>Fleg 1982</label>
</doc>
<doc>
<label>Guyatt 1988</label>
</doc>
<doc>
<label>Lee 1982</label>
</doc>
<doc>
<label>PROVED 1993</label>
</doc>
<doc>
<label>Pugh 1989</label>
</doc>
<doc>
<label>RADIANCE 1993</label>
</doc>
<doc>
<label>Taggart 1983</label>
</doc>
<doc>
<label>Adam 1982</label>
</doc>
<doc>
<label>Anderson 1980</label>
</doc>
<doc>
<label>Beil 1977</label>
</doc>
<doc>
<label>Butland 1983</label>
</doc>
<doc>
<label>Chang 2010</label>
</doc>
<doc>
<label>Dorow 1986a</label>
</doc>
<doc>
<label>Dorow 1986b</label>
</doc>
<doc>
<label>Fenster 1983</label>
</doc>
<doc>
<label>Fogari 1990</label>
</doc>
<doc>
<label>Hawkins 2009</label>
</doc>
<doc>
<label>Lammers 1985a</label>
</doc>
<doc>
<label>Macquin-Mavier 1988</label>
</doc>
<doc>
<label>McGavin 1978</label>
</doc>
<doc>
<label>Perks 1978</label>
</doc>
<doc>
<label>Ranchod 1982</label>
</doc>
<doc>
<label>Schanning 1976</label>
</doc>
<doc>
<label>Sinclair 1979</label>
</doc>
<doc>
<label>Sorbini 1982</label>
</doc>
<doc>
<label>Tivenius 1976</label>
</doc>
<doc>
<label>van der Woude 2005</label>
</doc>
<doc>
<label>von Wichert 1982</label>
</doc>
<doc>
<label>Wunderlich 1980</label>
</doc>
<doc>
<label>Casper 1991</label>
</doc>
<doc>
<label>Hortobagyi 1989</label>
</doc>
<doc>
<label>Lipshultz 2002</label>
</doc>
<doc>
<label>Shapira 1990</label>
</doc>
<doc>
<label>Steinherz 1993</label>
</doc>
<doc>
<label>Zalupski 1991</label>
</doc>
<doc>
<label>Anderson 81</label>
</doc>
<doc>
<label>Ballantyne 82</label>
</doc>
<doc>
<label>Bell 99</label>
</doc>
<doc>
<label>Bengtsson 83</label>
</doc>
<doc>
<label>Bertie 92</label>
</doc>
<doc>
<label>Bethell 90</label>
</doc>
<doc>
<label>Carlsson 98 CABG</label>
</doc>
<doc>
<label>Carlsson 97</label>
</doc>
<doc>
<label>Carlsson 98 AMI</label>
</doc>
<doc>
<label>Carson 82</label>
</doc>
<doc>
<label>Engblom</label>
</doc>
<doc>
<label>Erdman 86</label>
</doc>
<doc>
<label>Fletcher 94</label>
</doc>
<doc>
<label>Fridlund 91</label>
</doc>
<doc>
<label>Heller 93</label>
</doc>
<doc>
<label>Holmback 94</label>
</doc>
<doc>
<label>Kentala 72</label>
</doc>
<doc>
<label>Krachler 97</label>
</doc>
<doc>
<label>Lewin 92</label>
</doc>
<doc>
<label>Lifestyle Heart</label>
</doc>
<doc>
<label>Miller/DeBusk 1A</label>
</doc>
<doc>
<label>Miller/DeBusk 1B</label>
</doc>
<doc>
<label>Miller/DeBusk 2A</label>
</doc>
<doc>
<label>Miller/DeBusk 2B</label>
</doc>
<doc>
<label>NEHDP</label>
</doc>
<doc>
<label>Oldridge 91</label>
</doc>
<doc>
<label>PRECOR</label>
</doc>
<doc>
<label>Schuler/Niebauer</label>
</doc>
<doc>
<label>SCRIP</label>
</doc>
<doc>
<label>Sivarajan 82</label>
</doc>
<doc>
<label>Sivarajan 82 ex plus</label>
</doc>
<doc>
<label>Speccia 96</label>
</doc>
<doc>
<label>Stern 83</label>
</doc>
<doc>
<label>Taylor 97</label>
</doc>
<doc>
<label>Vecchio 81</label>
</doc>
<doc>
<label>Vermuelen 83</label>
</doc>
<doc>
<label>WHO Balatonfured</label>
</doc>
<doc>
<label>WHO Brussels</label>
</doc>
<doc>
<label>WHO Bucharest</label>
</doc>
<doc>
<label>WHO Budapest</label>
</doc>
<doc>
<label>WHO Dessau</label>
</doc>
<doc>
<label>WHO Erfut</label>
</doc>
<doc>
<label>WHO Ghent</label>
</doc>
<doc>
<label>WHO Helsinki</label>
</doc>
<doc>
<label>WHO Kaunas</label>
</doc>
<doc>
<label>WHO Prague</label>
</doc>
<doc>
<label>WHO Rome</label>
</doc>
<doc>
<label>WHO Tel Aviv</label>
</doc>
<doc>
<label>WHO Warsaw</label>
</doc>
<doc>
<label>Wilhelmson 75</label>
</doc>
<doc>
<label>Worsornu 96</label>
</doc>
<doc>
<label>Ahmedzai 2004</label>
</doc>
<doc>
<label>Booth 1996</label>
</doc>
<doc>
<label>Bruera 1993</label>
</doc>
<doc>
<label>Bruera 2003</label>
</doc>
<doc>
<label>Chua 1996</label>
</doc>
<doc>
<label>Meecham Jones 1995</label>
</doc>
<doc>
<label>Moore 1992</label>
</doc>
<doc>
<label>Restrick 1992</label>
</doc>
<doc>
<label>Avery</label>
</doc>
<doc>
<label>Boon</label>
</doc>
<doc>
<label>Capucci</label>
</doc>
<doc>
<label>Channon</label>
</doc>
<doc>
<label>CTOPP</label>
</doc>
<doc>
<label>Davis</label>
</doc>
<doc>
<label>Deharo</label>
</doc>
<doc>
<label>Hargreaves</label>
</doc>
<doc>
<label>Heldman</label>
</doc>
<doc>
<label>Höijer</label>
</doc>
<doc>
<label>Kamalvand</label>
</doc>
<doc>
<label>Kenny</label>
</doc>
<doc>
<label>Kristensson</label>
</doc>
<doc>
<label>Lau (1)</label>
</doc>
<doc>
<label>Lau (2)</label>
</doc>
<doc>
<label>Linde-Edelstam</label>
</doc>
<doc>
<label>Lukl</label>
</doc>
<doc>
<label>Mattioli</label>
</doc>
<doc>
<label>Menozzi</label>
</doc>
<doc>
<label>Mitsuoka</label>
</doc>
<doc>
<label>MOST</label>
</doc>
<doc>
<label>Oldroyd</label>
</doc>
<doc>
<label>PASE</label>
</doc>
<doc>
<label>Perrins</label>
</doc>
<doc>
<label>Rediker</label>
</doc>
<doc>
<label>Saner and Fricker</label>
</doc>
<doc>
<label>Sulke 1991</label>
</doc>
<doc>
<label>Sulke 1992</label>
</doc>
<doc>
<label>Sulke 1994</label>
</doc>
<doc>
<label>Wharton</label>
</doc>
<doc>
<label>Yee</label>
</doc>
<doc>
<label>Asberg 2000 (4mg/kg/d)</label>
</doc>
<doc>
<label>Bendix 1996 (2.5mg/kg/d)</label>
</doc>
<doc>
<label>De Lima 1998 (20mg/kd/d)</label>
</doc>
<doc>
<label>Dougados 1988(4.6mg/kg/d)</label>
</doc>
<doc>
<label>Ellis 1986 14mg/kg/d</label>
</doc>
<doc>
<label>Ellis 1991</label>
</doc>
<doc>
<label>Ellis 1991 5mg-7.5mg/kg/d</label>
</doc>
<doc>
<label>Ellis 1991 A 3 mg/kg/d</label>
</doc>
<doc>
<label>Engst 1989 (5mg/kg/d)</label>
</doc>
<doc>
<label>Hansen 1997 (10mg/kg/d)</label>
</doc>
<doc>
<label>Lock 1996 (5 mg/kg/d)</label>
</doc>
<doc>
<label>Minuk1988(5.1-6.4mg/kg/d)</label>
</doc>
<doc>
<label>Nizankowska 1995 (2.5mg)</label>
</doc>
<doc>
<label>Reitamo 1993 (2.5mg/kg/d)</label>
</doc>
<doc>
<label>Sowden 1991 (5mg/kg/d)</label>
</doc>
<doc>
<label>Sturrock 1994 (15-20mg)</label>
</doc>
<doc>
<label>Sturrock 1995 (10mg/kg/d)</label>
</doc>
<doc>
<label>Tugwell 1990 (3.8mg/kg/d)</label>
</doc>
<doc>
<label>Wolinsky 1990 (6mg/kg/d)</label>
</doc>
<doc>
<label>Belardinelli 1992</label>
</doc>
<doc>
<label>Belardinelli 1995</label>
</doc>
<doc>
<label>Belardinelli 1999</label>
</doc>
<doc>
<label>Cider 1997</label>
</doc>
<doc>
<label>Coats 1990</label>
</doc>
<doc>
<label>Coats 1992</label>
</doc>
<doc>
<label>Dubach et al studies</label>
</doc>
<doc>
<label>Gottlieb 1999</label>
</doc>
<doc>
<label>Hambrecht 1995</label>
</doc>
<doc>
<label>Hambrecht 1998</label>
</doc>
<doc>
<label>Hambrecht 2000</label>
</doc>
<doc>
<label>Jette 1991</label>
</doc>
<doc>
<label>Keteyian 1996</label>
</doc>
<doc>
<label>Kiilavuori 1996</label>
</doc>
<doc>
<label>Maiorana 2000</label>
</doc>
<doc>
<label>Meyer 1996</label>
</doc>
<doc>
<label>Oka 2000</label>
</doc>
<doc>
<label>Owen 2000</label>
</doc>
<doc>
<label>Parnell 2002</label>
</doc>
<doc>
<label>Ponikowski 1997</label>
</doc>
<doc>
<label>Pu 2001</label>
</doc>
<doc>
<label>Quittan 1999</label>
</doc>
<doc>
<label>Teo 1995 EXERT</label>
</doc>
<doc>
<label>Tyni-Lenne 1997</label>
</doc>
<doc>
<label>Tyni-Lenne 2001</label>
</doc>
<doc>
<label>Tyni-Lenne/Gordon 96</label>
</doc>
<doc>
<label>Wielenga 1998</label>
</doc>
<doc>
<label>Wielenga 1999 CHANGE</label>
</doc>
<doc>
<label>Willenheimer 1998</label>
</doc>
<doc>
<label>Battersby 2007</label>
</doc>
<doc>
<label>Frosch 2011</label>
</doc>
<doc>
<label>Glasgow 2005a</label>
</doc>
<doc>
<label>Hart 1978</label>
</doc>
<doc>
<label>Hiss 2007</label>
</doc>
<doc>
<label>Katon 2010a</label>
</doc>
<doc>
<label>Kennedy 2013</label>
</doc>
<doc>
<label>Liu 2012</label>
</doc>
<doc>
<label>Ludman 2007</label>
</doc>
<doc>
<label>Naik 2011</label>
</doc>
<doc>
<label>Schillinger 2009</label>
</doc>
<doc>
<label>Shearer 2007</label>
</doc>
<doc>
<label>Stanhope 2013</label>
</doc>
<doc>
<label>Thom 2013</label>
</doc>
<doc>
<label>Tsay 2004</label>
</doc>
<doc>
<label>Van der Wulp 2012</label>
</doc>
<doc>
<label>Wilson 2010</label>
</doc>
<doc>
<label>Wolever 2010</label>
</doc>
<doc>
<label>Zoffmann 2006</label>
</doc>
<doc>
<label>Study</label>
</doc>
<doc>
<label>Aaronson 2004</label>
</doc>
<doc>
<label>Alexander 1995</label>
</doc>
<doc>
<label>Bödigheimer 1994</label>
</doc>
<doc>
<label>Eichstädt 2001</label>
</doc>
<doc>
<label>Förster 1994</label>
</doc>
<doc>
<label>Hanak 1983</label>
</doc>
<doc>
<label>Iwamoto 1981</label>
</doc>
<doc>
<label>Leuchtgens 1993</label>
</doc>
<doc>
<label>O’Connolly 1987</label>
</doc>
<doc>
<label>O’Conolly 1986</label>
</doc>
<doc>
<label>Schmidt 1994</label>
</doc>
<doc>
<label>Tauchert 2002 (HD)</label>
</doc>
<doc>
<label>Tauchert 2002 (LD)</label>
</doc>
<doc>
<label>Weikl 1996</label>
</doc>
<doc>
<label>Zapfe 2001</label>
</doc>
<doc>
<label>Anderson 1950</label>
</doc>
<doc>
<label>Griffith 1952</label>
</doc>
<doc>
<label>Harvey 1950</label>
</doc>
<doc>
<label>WASH 2004</label>
</doc>
<doc>
<label>De’oliveira 1997</label>
<inclusion> Setting: Hospital . Country: USA . DM: Type 2 . Hypertensive SBP > 140 mm Hg and DBP > 90 mm Hg on at least 3 outpatient visits . Mean BMI: 30 ± 1 . Number (treatment/control): 9/10 . Mean age ± SD: 55 ± 2 years ◦ Treatment/control: 56 ± 3 years/55 ± 2 years . Sex (M/F): 16/3 ◦ Treatment: 7/2 ◦ Control: 9/1 </inclusion>
<exclusion> Age < 30 years</exclusion>
</doc>
<doc>
<label>Dodson ̇P 1989</label>
<inclusion> Setting: Hospital . Country: UK . Hypertension SBP > 160 mm Hg or DBP > 95 mm Hg . DM: type 2 . No past or current history of treatment with insulin . Number (treatment/control): 17/17 . Mean age (SD) ◦ Treatment: 61.9 (7.5) years ◦ Control: 61.1 (6.3) years . Sex (M/F) ◦ Treatment: 12/5 ◦ Control: 11/6 </inclusion>
<exclusion> DKD or hypertensive kidney disease (proteinuria or raised serum creatinine concentration), cardiac failure, pregnancy</exclusion>
</doc>
<doc>
<label>Dodson ̇X 1989</label>
<inclusion> Setting: Hospital . Country: UK . Hypertension SBP > 160 mm Hg or DBP > 95 mm Hg . DM: type 2 . No past or current history of treatment with insulin . Number: 9 . Mean age (SD): 62 (6.5) years . Sex (M/F): 6/3 </inclusion>
<exclusion> DKD or hypertensive kidney disease (proteinuria or raised serum creatinine concentration), cardiac failure, pregnancy</exclusion>
</doc>
<doc>
<label>Houlihan ̇Losartan 2002</label>
<inclusion> Setting: Hospital . Country: Australia . SBP > 130 mm Hg and/or DBP > 85 mm Hg . DM: type 2 . AER 10-200 μg/min . HbA1c < 11.0% . Number (placebo/losartan): 10/10 . Mean age (SD) ◦ Placebo: 63.1 (3.9) years ◦ Losartan: 60.6 (3.7) years . Sex (M/F) ◦ Placebo: 9/1 ◦ Losartan: 10/0 </inclusion>
<exclusion> Serious systemic illness; substance abuse; 24 hour urinary sodium > 100 mmol/24 h; SBP > 165 mm Hg, DBP > 100 mm Hg; plasma Cr > 200 μmol/L, long-term use of NSAID; UTIs; BMI > 35 kg/m2; intolerance of ACEi.</exclusion>
</doc>
<doc>
<label>Houlihan ̇Placebo 2002</label>
<inclusion> Setting: Hospital . Country: Australia . SBP > 130 mm Hg and/or DBP > 85 mm Hg . DM: type 2 . AER 10-200 μg/min . HbA1c < 11.0% . Number (placebo/losartan): 10/10 . Mean age (SD) ◦ Placebo: 63.1 (3.9) years ◦ Losartan: 60.6 (3.7) years . Sex (M/F) ◦ Placebo: 9/1 ◦ Losartan: 10/0 </inclusion>
<exclusion> Serious systemic illness; substance abuse; 24 hour urinary sodium > 100 mmol/24 h; SBP > 165 mm Hg, DBP > 100 mm Hg; plasma Cr > 200 μmol/L, long-term use of NSAID; UTIs; BMI > 35 kg/m2; intolerance of ACEi.</exclusion>
</doc>
<doc>
<label>Imanishi ̇Micro 2001</label>
<inclusion> Country: Japan . Setting: Hospital . DM: type 2 with simple retinopathy divided into microalbuminuria and normoalbuminuria . Number (normoalbuminuria/microalbuminuria): 8/8 . Mean age ± SD ◦ Normoalbuminuria: 59 ± 11 years ◦ Microalbuminuria: 61 ± 10 years . Sex (M/F) ◦ Normoalbuminuria: 5/3 ◦ Microalbuminuria: 4/4 </inclusion>
<exclusion> Non-diabetic kidney disease; heart disease; UTI; SCr > 97.4 μmol/L</exclusion>
</doc>
<doc>
<label>Imanishi ̇Normo 2001</label>
<inclusion> Country: Japan . Setting: Hospital . DM: type 2 with simple retinopathy divided into microalbuminuria and normoalbuminuria . Number (normoalbuminuria/microalbuminuria): 8/8 . Mean age ± SD ◦ Normoalbuminuria: 59 ± 11 years ◦ Microalbuminuria: 61 ± 10 years . Sex (M/F) ◦ Normoalbuminuria: 5/3 ◦ Microalbuminuria: 4/4 </inclusion>
<exclusion> Non-diabetic kidney disease; heart disease; UTI; SCr > 97.4 μmol/L</exclusion>
</doc>
<doc>
<label>Lopes De Faria 1997</label>
<inclusion> Country: UK . Setting: Hospital . Normoalbuminuria, normotensive, aged 18-55 years, body weight within 20% of ideal . DM: IDDM . Number: 10 . Age: 30 ± 3 years . Sex (M/F): 7/3 </inclusion>
<exclusion> Patients on drugs other than insulin</exclusion>
</doc>
<doc>
<label>Luik 2002</label>
<inclusion> Country: The Netherlands . DM: Type 1 . BP < 140/85 mm Hg . Number: 24 . Age: 28.8 ± 6 years . Sex (M/F): 15/9</inclusion>
</doc>
<doc>
<label>Miller 1995</label>
<inclusion> Country: Canada . Setting: Hospital . IDDM < 5 years . Number: 9 . Age: 25.6 ± 1.5 years (range 21-31) . Sex (M/F): 9/0</inclusion>
</doc>
<doc>
<label>Miller 1997</label>
<inclusion> Country: Canada . Setting: Hospital . Early IDDM (duration. 2.8 ± 0.4 years) . Number: 12 . Age: 23 ± 2 years . Se (M/F): 12/0</inclusion>
</doc>
<doc>
<label>Mulhauser 1996</label>
<inclusion> Setting: Hospital . Country: Germany . IDDM > 5 years . Number (treatment/control): 8/8 . Mean age ± SD ◦ Treatment: 35 ± 11 years ◦ Control: 27 ± 9 years . Sex (M/F) ◦ Treatment: 5/3 ◦ Control: 7/1 </inclusion>
<exclusion> UTI; drugs (including oral contraceptives); pregnancy</exclusion>
</doc>
<doc>
<label>Petrie 1998</label>
<inclusion> Country: UK . Setting: Hospital . BMI 28.6 ± 3.9 kg/m2, fasting plasma glucose 9.0 ± 2.2 mmol/L (range 5.7-12.4 mmol/L), HbA1c 5.7 ± 0.8% (normal range 3.4-4.9%), total cholesterol 5.76 ± 1.25 mmol/L . DM: median duration 12 months (range 4-92) . Number: 9 . Mean age ± SD: 57 ± 9.7 years . Sex (M/F): 8/1</inclusion>
</doc>
<doc>
<label>Trevisan ̇Micro 1998</label>
<inclusion> Setting: Hospital . Country: Italy . IDDM, duration (mean ± SE) 24 ± 4 years . Number: 7 . Age (mean ± SE): 38 ± 5 years . Sex (M/F): 6/1 </inclusion>
<exclusion> . No drugs other than insulin, non-DKD, endocrine disease, liver disease</exclusion>
</doc>
<doc>
<label>Trevisan ̇Normo 1998</label>
<inclusion> Setting: Hospital . Country: Italy . IDDM, duration (mean ± SE) 22 ± 4 years . Number: 9 . Age (mean ± SE): 42 ± 4 years . Sex (M/F): 6/3 </inclusion>
<exclusion> . No drugs other than insulin, non-diabetic kidney disease, endocrine disease, liver disease</exclusion>
</doc>
<doc>
<label>Vedovato ̇Micro 2004</label>
<inclusion> Country: Italy . Setting: hospital . DM: type 2 . BP < 140/90 mm Hg; divided into two groups: with and without microalbuminuria . Number: 20 . Age: 57 ± 1 years . Sex (M/F): 15/5 </inclusion>
<exclusion> On antihypertensives</exclusion>
</doc>
<doc>
<label>Vedovato ̇Normo 2004</label>
<inclusion> Country: Italy . Setting: hospital . DM: type 2BP < 140/90 mm Hg; divided into two groups: with and without microalbuminuria . Number: 21 . Age: 60 ± 2 years . Sex (M/F): 16/5 </inclusion>
<exclusion> On antihypertensives</exclusion>
</doc>
<doc>
<label>Yoshioka ̇Adva ̇alb 1998</label>
<inclusion> Country: Japan . Setting: Hospital . DM: type 2 . Number: 19 ◦ Divided into 3 groups: normoalbuminuria (8), microalbuminuria (7), advanced albuminuria (4) . Age: 60 ± 2 years . Sex (M/F): 11/8 </inclusion>
<exclusion> Heart disease; non-diabetic kidney disease; UTI, SCr > 1.0 mg/dL; BP > 160/95 mm Hg; on antihypertensives.</exclusion>
</doc>
<doc>
<label>Yoshioka ̇Micro 1998</label>
<inclusion> Country: Japan . Setting: Hospital . DM: type 2 . Number: 19 ◦ Divided into 3 groups: normoalbuminuria (8), microalbuminuria (7), advanced albuminuria (4) . Age: 60 ± 2 years . Sex (M/F): 11/8 </inclusion>
<exclusion> Heart disease; non-diabetic kidney disease; UTI, SCr > 1.0 mg/dL; BP > 160/95 mm Hg; on antihypertensives.</exclusion>
</doc>
<doc>
<label>Yoshioka ̇Normo 1998</label>
<inclusion> Country: Japan . Setting: Hospital . DM: type 2 . Number: 19 ◦ Divided into 3 groups: normoalbuminuria (8), microalbuminuria (7), advanced albuminuria (4) . Age: 60 ± 2 years . Sex (M/F): 11/8 </inclusion>
<exclusion> Heart disease; non-diabetic kidney disease; UTI, SCr > 1.0 mg/dL; BP > 160/95 mm Hg; on antihypertensives.</exclusion>
</doc>
<doc>
<label>Fang 1987</label>
<exclusion> not state. Baseline characteristics:comparable (statistical analysis)</exclusion>
</doc>
<doc>
<label>He 2004</label>
<exclusion> not state Baseline characteristics: not state.</exclusion>
</doc>
<doc>
<label>Liu 2007a</label>
</doc>
<doc>
<label>Mao 2003a</label>
<inclusion> heart failure; (1) age 41-70 years; (2) heart failure class 2-3; not taking digitalis or drugs affecting the metabolization of digoxin within 1 week; liver and kidney function were normal, normal electrolyte. </inclusion>
<exclusion> acute myocardial infarction, or acute respiratory insufficiency of PHD, or serious mitral stenosis in sinus rhythm, or HCM with obstruction; (3) diabetes, hyperthyroidism Baseline characteristics:comparable (statistical analysis)</exclusion>
</doc>
<doc>
<label>Zhang 2002</label>
<exclusion> CHD, RHD, congenital heart disease, Baseline characteristics: comparable(statistical analysis)</exclusion>
</doc>
<doc>
<label>Zhao 2006</label>
<inclusion> (1) age from 40 to 70 years; (2) hear class 2~3; (3) no Digitalis used in the last week and no high salt diet; (4) blood electrolytes , liver, kidney no obvious abnormalities; </inclusion>
<exclusion> (1) age>70 or <40, (2)AMI, hypertrophic obstructive cardiomyopathy, high blood pressure 3 class. (3) combined with diabetes,hyperthyreosis Baseline characteristics: not state.</exclusion>
</doc>
<doc>
<label>CHARISMA 2006</label>
</doc>
<doc>
<label>CURE 2001</label>
</doc>
<doc>
<label>Adam 1982</label>
</doc>
<doc>
<label>Bauer 1994</label>
</doc>
<doc>
<label>Benson 1978</label>
</doc>
<doc>
<label>Butland 1983</label>
</doc>
<doc>
<label>Chatterjee 1986</label>
</doc>
<doc>
<label>Chodosh 1988</label>
</doc>
<doc>
<label>Dorow 1986c</label>
</doc>
<doc>
<label>Doshan 1986a</label>
</doc>
<doc>
<label>Doshan 1986b</label>
</doc>
<doc>
<label>Ellis 1981</label>
</doc>
<doc>
<label>Falliers 1986</label>
</doc>
<doc>
<label>Fenster 1983</label>
</doc>
<doc>
<label>Fogari 1990</label>
</doc>
<doc>
<label>Greefhorst 1984</label>
</doc>
<doc>
<label>Johnsson 1975</label>
</doc>
<doc>
<label>Lammers 1984</label>
</doc>
<doc>
<label>Lammers 1985a</label>
</doc>
<doc>
<label>Lammers 1986a</label>
</doc>
<doc>
<label>Lammers 1988</label>
</doc>
<doc>
<label>Lawrence 1982</label>
</doc>
<doc>
<label>Lofdahl 1981</label>
</doc>
<doc>
<label>Nicolaescu 1973</label>
</doc>
<doc>
<label>Nicolescu 1972</label>
</doc>
<doc>
<label>Ruffin 1979</label>
</doc>
<doc>
<label>Skinner 1975b</label>
</doc>
<doc>
<label>Tantucci 1990</label>
</doc>
<doc>
<label>van den Bergh 1981</label>
</doc>
<doc>
<label>van Zyl 1989</label>
</doc>
<doc>
<label>Study</label>
</doc>
<doc>
<label>Barr 1995</label>
</doc>
<doc>
<label>Boccanelli 1986</label>
</doc>
<doc>
<label>Burr 1977</label>
</doc>
<doc>
<label>Cheitlin 1991</label>
</doc>
<doc>
<label>Cowley 1986</label>
</doc>
<doc>
<label>Dalhstrom 1986</label>
</doc>
<doc>
<label>De Jong 1994</label>
</doc>
<doc>
<label>Haerer 1989</label>
</doc>
<doc>
<label>Myers 1982</label>
</doc>
<doc>
<label>Nordrehaug 1992</label>
</doc>
<doc>
<label>Richardson 1987</label>
</doc>
<doc>
<label>Sherman 1986</label>
</doc>
<doc>
<label>Sievert 1989</label>
</doc>
<doc>
<label>Walma 1997</label>
</doc>
<doc>
<label>Carmenini 1994</label>
</doc>
<doc>
<label>Ferraro 1996</label>
</doc>
<doc>
<label>Gordon 1995</label>
</doc>
<doc>
<label>Grazioli 1992</label>
</doc>
<doc>
<label>Kuethe 2006</label>
</doc>
<doc>
<label>Maggi 1990</label>
</doc>
<doc>
<label>Pedone 1984</label>
</doc>
<doc>
<label>Pedone 1984-2</label>
</doc>
<doc>
<label>Ruda 1988</label>
</doc>
<doc>
<label>Samarenko 1987</label>
</doc>
<doc>
<label>Zochowski 1994</label>
</doc>
<doc>
<label>Agmy 2008</label>
</doc>
<doc>
<label>Bautin 2005</label>
</doc>
<doc>
<label>Bellone 2004</label>
</doc>
<doc>
<label>Bellone 2005</label>
</doc>
<doc>
<label>Bersten 1991</label>
</doc>
<doc>
<label>Crane 2004</label>
</doc>
<doc>
<label>Delclaux 2000</label>
</doc>
<doc>
<label>Ferrari 2007</label>
</doc>
<doc>
<label>Ferrari 2010</label>
<exclusion> STEMI (patients with unstable angina/Non- ST elevation MI were included in the study protocol),haemodynamic instability (systolic arterial pressure 90 mmHg), need for immediate ETI (respiratory arrest, bradypnoea), Inability to protect the airways, impaired sensorium (severe agitation or unconsciousness) , COPD, exacerbation, pulmonary embolism, pneumonia, recent oesophageal-gastric surgery, gastrointestinal bleeding, facial deformities, hematological malignancy or cancer with ECOG performance status > 2.</exclusion>
</doc>
<doc>
<label>Ferrer 2003</label>
<exclusion> hypercapnia (PaCO2 of more than 45 mm Hg) on admission; need for emergency intubation; recent oesophageal, facial, or cranial trauma or surgery; severely decreased consciousness (a Glasgow coma score of 11 or less); severe haemodynamic instability despite fluid repletion and use of vasoactive agents; a lack of cooperation; tracheotomy or other upper airway disorders; severe ven- tricular arrhythmia or myocardial ischaemia; active upper gastrointestinal bleeding; an inability to clear respiratory secretions; and more than one severe organ dysfunction in addition to respiratory failure</exclusion>
</doc>
<doc>
<label>Fontanella 2010</label>
</doc>
<doc>
<label>Frontin 2010</label>
<inclusion> 18 years or older with clinical symptoms of ACPE such as orthopnoea, diffuse crackles without evidence of pulmonary aspiration or infection, pulse oximetry (SpO2) less than 90% and a respiratory rate greater than 25 breaths per minute. Excluded patients: cardiovascular collapse or an impaired level of consciousness, acute myocardial infarction, or if they had an immediate need for intubation. Patient with a history of gastric surgery (b8 days) and patients vomiting were also excluded</inclusion>
</doc>
<doc>
<label>Gray 2008</label>
</doc>
<doc>
<label>Kelly 2002</label>
</doc>
<doc>
<label>L’Her 2004</label>
<exclusion> Glasgow Coma Scale less or similar 7, SpO2 similar or less 85% despite oxygen, haemodynamic instability, chronic respiratory insufficiency</exclusion>
</doc>
<doc>
<label>Levitt 2001</label>
</doc>
<doc>
<label>Liesching 2003</label>
</doc>
<doc>
<label>Lin 1991</label>
</doc>
<doc>
<label>Lin 1995</label>
</doc>
<doc>
<label>Martin-Bermudez 2002</label>
</doc>
<doc>
<label>Masip 2000</label>
</doc>
<doc>
<label>Mehta 1997</label>
</doc>
<doc>
<label>Moritz 2007</label>
</doc>
<doc>
<label>Nava 2003</label>
</doc>
<doc>
<label>Park 2001</label>
</doc>
<doc>
<label>Park 2004</label>
</doc>
<doc>
<label>Räsänen 1985</label>
</doc>
<doc>
<label>Sharon 2000</label>
</doc>
<doc>
<label>Takeda 1997</label>
<exclusion> complicated with aspiration and/or pneumonia, im- mediate need for endotracheal intubation, shock, and life-threatening hypoxia at study entry</exclusion>
</doc>
<doc>
<label>Takeda 1998</label>
<exclusion> compli- cated with aspiration and/or pneumonia, immediate need for endotracheal intubation, shock, and life-threatening hypoxia at study entry</exclusion>
</doc>
<doc>
<label>Thys 2002</label>
</doc>
<doc>
<label>Weitz 2007</label>
</doc>
<doc>
<label>Budman 1998</label>
</doc>
<doc>
<label>Casper 1991</label>
</doc>
<doc>
<label>Escherich 2007</label>
</doc>
<doc>
<label>Fountzilas 2008</label>
</doc>
<doc>
<label>Heidenreich 2004</label>
</doc>
<doc>
<label>Hortobagyi 1989</label>
</doc>
<doc>
<label>Linden 2007</label>
</doc>
<doc>
<label>Lipshultz 2002</label>
</doc>
<doc>
<label>Shapira 1990</label>
</doc>
<doc>
<label>Steinherz 1993</label>
</doc>
<doc>
<label>Zalupski 1991</label>
</doc>
<doc>
<label>Els 2006</label>
<inclusion> typical clinical signs of a larger supratentorial infarction . signal changes in early diffusion - weighted and perfusion-weighted MRI . age < 65 years . no pre-existing disability . no dementia . no tegmental syndrome </inclusion>
<exclusion> not implicitly stated</exclusion>
</doc>
<doc>
<label>Hindman 1999</label>
<inclusion> Patients with intracranial aneurysms who had a pre-hospitalization or pre-SAH Rankin disability score of 0 or 1 . Patients with acute SAH with a World Federation of Neurosurgical Surgeons score of I, II or III </inclusion>
<exclusion> Intubated at the time of enrolment . Cryoglobulinaemia . Severe Raynuad’s disease . Sickle cell disease . Another disorder considered to be a contraindication to hypothermia . Entered into a blinded trial of any drug which may affect neurologic outcome</exclusion>
</doc>
<doc>
<label>Qiu 2007</label>
<inclusion> History of traumatic brain injury . Brain injury confirmed by sequential CT scanning within 6 hours after trauma . Glasgow Coma Scale scores of 8 or less </inclusion>
<exclusion> Pregnancy . Age < 19 years or > 65 years . Multiple trauma . Haemorrhagic shock . Absent brain stem reflex on initial examination . Previous disabling neurologic disease</exclusion>
</doc>
<doc>
<label>Todd 2005</label>
<inclusion> Age 18 years or more . Subarachnoid haemorrhage with a radiologically demonstrated intracranial aneurysm within 14 days of surgery . World Federation of Neuroligical Surgeons score of I, II or III . Rankin Score 0 or 1 before haemorrhage </inclusion>
<exclusion> Body mass index > 35 . Cold related disorder . Endotracheal tube in situ</exclusion>
</doc>
<doc>
<label>Chen 2008</label>
</doc>
<doc>
<label>Silber 2004</label>
</doc>
<doc>
<label>Eimer 1985</label>
</doc>
<doc>
<label>Harrison (unpublished)</label>
</doc>
<doc>
<label>Man 1986</label>
</doc>
<doc>
<label>Navigante (unpublished)</label>
</doc>
<doc>
<label>Navigante 2006</label>
</doc>
<doc>
<label>Shivaram 1989</label>
</doc>
<doc>
<label>Woodcock 1981</label>
</doc>
<doc>
<label>Chang 2006</label>
<exclusion> Inclusion: Veterans registered into a retired home in Northern Taiwan. Exclusion: Bed-ridden veterans, high serum creatinine (i.e. >=3.5mg/dL)</exclusion>
</doc>
<doc>
<label>HPT 1989</label>
<exclusion> Inclusion: Men and women aged 25-49yrs; DBP 78-89mmHg Exclusion: Use of antihypertensive medication, evidence of CVD, BMI >=0.0035kg/ cm2 , dietary requirements incompatible with any of the interventions, drank 21 or more alcoholic drinks per week, pregnant women, unable to comply with the protocol requirements</exclusion>
</doc>
<doc>
<label>Morgan 1978</label>
<exclusion> Inclusion: Males with borderline hypertension on admission to hospital or outpatient visit Exclusion: Malignant disease, severe psychiatric disturbances, severe physical incapacity or a disease likely to be fatal in the next two years, serum-creatinine levels >0.18mmol/ l, abnormal liver-function tests, in cardiac failure or on diuretic therapy</exclusion>
</doc>
<doc>
<label>TOHP I 1992</label>
<exclusion> Inclusion: aged 30-54: mean DBP 80-89mmHg without antihypertensive medication; ability to complete and return a satisfactory 24-hour urine collection and food frequency questionnaire Exclusion: Long list of exclusion criteria, generally designed to eliminate patients with: evidence of medically diagnosed hypertension (DBP >= 90mmHg or use of BP med- ications within 2mths of first evaluation), cardiovascular or other life-threatening or disabling diseases, gross obesity (BMI>36.14), a contraindication to any of the phase I interventions, or might have difficulty complying with the treatment or follow-up re- quirements of the trial</exclusion>
</doc>
<doc>
<label>TOHP II 1997</label>
<exclusion> Inclusion: 30-54 year old adults with no evidence of medically diagnosed hypertension who were moderately overweight (men: between 26.1-37.4kg/m2 ; women: between 24. 4-37.4kg/m2 ), and had average DBP between 83-89mmHg, and an SBP <140mmHg. Participants also had to demonstrate compliance with the more difficult data collection tasks Exclusion: Evidence of current hypertension. History of CVD, diabetes mellitus, ma- lignancy other than nonmelanoma skin cancer during the past 5yrs, or any other serious life-threatening illness that requires regular medical treatment. Current use of prescrip- tion medications that affect BP, as well as non-prescription diuretics. Serum creatinine level >= 1.7mg/dL for men or 1.5mg/dL for women, or casual serum glucose >=200mg/ dL. Current alcohol intake >21 drinks/wk. Pregnancy, or intent to become pregnant during the study. Plans to move or inability to cooperate</exclusion>
</doc>
<doc>
<label>TONE 1998</label>
<exclusion> Inclusion: Healthy, aged 60-80yrs, SBP <145mm Hg &DBP <85mm Hg while tak- ing a single antihypertensive medication or a single combination regimen consisting of a diuretic agent and a non-diuretic agent. Individuals taking two antihypertensive medications were also eligible if they were successfully weaned off one of them during the screening phase. Independencein activities of daily living. Capacity to alter diet and physical activity in accordance with the requirements of any TONE intervention Exclusion: Diagnosis or treatment of cancer within the last 5yrs; treatment with diuret- ics, ACE-inhibitors, or digitalis for CHF or unknown reason; drug therapy with nitrates, beta blockers, or calcium channel blockers for CHD or reason other than hypertension; MI or stroke within 6mths; “active” CHD (e.g. angina pectoris); CHF; atrial fibrilla- tion; second- or third-degree heart block without permanent pacemaker; drug therapy for ventricular arrhythmias; self-report of heart valve replacement; clinically important valvular heart disease; insulin dependent diabetes mellitus; severe hypertension; current or recent (within 6mths) drug therapy for asthma or chronic obstructive lung disease; use of corticosteroid therapy for >1mth; serious mental or physical illness; unexplained or involuntary weight loss (>=4.5kg) during the previous year; BMI<21 in men or women, or >33 in men or >37 in women; serum creatinine >2mg/dL; non-fasting blood glucose level of >260mg/dL; hyperkalemia (>5.5mmol/L); anaemia (Hb level <110g/L); >14 alcoholic drinks per week (assessed by self-report); severe visual or hearing impairment; other reason making it difficult for the participant to comply fully with any part of the study protocol</exclusion>
</doc>
<doc>
<label>A-COMET-I 2006</label>
</doc>
<doc>
<label>A-COMET-II 2006</label>
</doc>
<doc>
<label>A-STAR 2006</label>
</doc>
<doc>
<label>AFFIRM Substudy 2003</label>
</doc>
<doc>
<label>AFIB 1997</label>
</doc>
<doc>
<label>Aliot 1996</label>
</doc>
<doc>
<label>ASAP 2003</label>
</doc>
<doc>
<label>ATHENA 2009</label>
</doc>
<doc>
<label>Bellandi 2001</label>
</doc>
<doc>
<label>Benditt 1999</label>
</doc>
<doc>
<label>Byrne-Quinn 1970</label>
</doc>
<doc>
<label>Carunchio 1995</label>
</doc>
<doc>
<label>Channer 2004</label>
</doc>
<doc>
<label>DAFNE 2003</label>
</doc>
<doc>
<label>DAPHNE 2008</label>
</doc>
<doc>
<label>DIAMOND 2001</label>
</doc>
<doc>
<label>Dogan 2004</label>
</doc>
<doc>
<label>DYONISOS 2010</label>
</doc>
<doc>
<label>EMERALD 2000</label>
</doc>
<doc>
<label>EURIDIS ADONIS 2007</label>
</doc>
<doc>
<label>FAPIS 1996</label>
</doc>
<doc>
<label>GEFACA 2001</label>
</doc>
<doc>
<label>Hillestad 1971</label>
</doc>
<doc>
<label>Hohnloser 1995</label>
</doc>
<doc>
<label>Juul-Moller 1990</label>
</doc>
<doc>
<label>Kalusche 1994</label>
</doc>
<doc>
<label>Karlson 1998</label>
</doc>
<doc>
<label>Kochiadakis 2000</label>
</doc>
<doc>
<label>Kochiadakis 2004a</label>
</doc>
<doc>
<label>Kochiadakis 2004b</label>
</doc>
<doc>
<label>Kuhlkamp 2000</label>
</doc>
<doc>
<label>Lloyd 1984</label>
</doc>
<doc>
<label>Naccarelli 1996</label>
</doc>
<doc>
<label>Nergardh 2007</label>
</doc>
<doc>
<label>Niu 2006</label>
</doc>
<doc>
<label>Okishige 2000</label>
</doc>
<doc>
<label>PAFAC 2004</label>
</doc>
<doc>
<label>PITAGORA 2008</label>
</doc>
<doc>
<label>Plewan 2001</label>
</doc>
<doc>
<label>PRODIS 1996</label>
</doc>
<doc>
<label>RAFT 2003</label>
</doc>
<doc>
<label>Reimold 1993</label>
</doc>
<doc>
<label>Richiardi 1992</label>
</doc>
<doc>
<label>SAFE-T 2005</label>
</doc>
<doc>
<label>SAFIRE-D 2000</label>
</doc>
<doc>
<label>Singh 1991</label>
</doc>
<doc>
<label>SMART 2002</label>
</doc>
<doc>
<label>SOCESP 1999</label>
</doc>
<doc>
<label>Sodermark 1975</label>
</doc>
<doc>
<label>SOPAT 2004</label>
</doc>
<doc>
<label>Steinbeck 1988</label>
</doc>
<doc>
<label>Stroobandt 1997</label>
</doc>
<doc>
<label>SVA-4 2008</label>
</doc>
<doc>
<label>Van Gelder 1989</label>
</doc>
<doc>
<label>Villani 1992</label>
</doc>
<doc>
<label>Vitolo 1981</label>
</doc>
<doc>
<label>Fang 1987</label>
<exclusion> not stated Baseline characteristics: comparable (statistical analysis)</exclusion>
</doc>
<doc>
<label>He 2004</label>
<exclusion> not stated Baseline characteristics: not stated</exclusion>
</doc>
<doc>
<label>Jiang 1988</label>
<exclusion> not stated Baseline characteristics: comparable (statistical analysis)</exclusion>
</doc>
<doc>
<label>Liu 2007a</label>
</doc>
<doc>
<label>Mao 2003a</label>
<inclusion> heart failure; (1) age 41-70 years; (2) heart failure class 2-3; not taking digitalis or drugs affecting the metabolization of digoxin within 1 week; liver and kidney function were normal, normal electrolyte </inclusion>
<exclusion> acute myocardial infarction, or acute respiratory insufficiency of PHD, or serious mitral stenosis in sinus rhythm, or HCM with obstruction; (3) diabetes, hyperthyroidism Baseline characteristics: comparable (statistical analysis)</exclusion>
</doc>
<doc>
<label>Wang 2010a</label>
<exclusion> acute myocardial infarction,acute inflammation,chronic renal failure, chronic liver disease, chronic bronchitis, and other organic heart disease Baseline characteristics: comparable (statistical analysis)</exclusion>
</doc>
<doc>
<label>Zhai 2009</label>
</doc>
<doc>
<label>Zhang 2002</label>
<exclusion> CHD, RHD, congenital heart disease Baseline characteristics: comparable (statistical analysis)</exclusion>
</doc>
<doc>
<label>Zhao 2006</label>
<inclusion> (1) age from 40 to 70 years; (2) hear class 2~3; (3) no Digitalis used in the last week and no high salt diet; (4) blood electrolytes, liver, kidney no obvious abnormalities </inclusion>
<exclusion> (1) age>70 or <40, (2)AMI, hypertrophic obstructive cardiomyopathy, high blood pressure 3 class. (3) combined with diabetes,hyperthyreosis Baseline characteristics: comparable (statistical analysis), specific data on baseline char- acters were provided</exclusion>
</doc>
<doc>
<label>Blackwell 2010</label>
<inclusion> women ≥ 18 years of age with histologically or cytologically con- firmed BC. Patients must have metastatic disease that progressed on their most recent treatment regimen, which must have contained trastuzumab. Tumours with ErbB2 gene amplification as measured by fluorescence in situ hybridisation or ErbB2 over-expression as measured by immunohistochemistry (3+). Patients must have received prior anthra- cycline- and taxane-based regimens in either the adjuvant or metastatic setting. Eligible patients had at least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) or bone-only disease. ECOG performance status of ≤ 2; ade- quate haematologic, renal and hepatic function; and a cardiac ejection fraction within the institutional normal range. Written informed consent </inclusion>
<exclusion> see inclusion criteria HER2+: 100%</exclusion>
</doc>
<doc>
<label>Gasparini 2006</label>
<inclusion> women over-expressing HER2/neu by the Hercep Test assay (score 2+ or 3+), measurable disease, age ≥ 18 years, performance status ≤ 2 according to the ECOG scale, life expectancy > 3 months and adequate organ function, defined as follows: LVEF > 50% or within normal limits, AST and ALT levels ≤ 2.5 times the normal value, total bilirubin < 1.5 the normal value, serum creatinine levels ≤ 1.5 mg/dl, neutrophils ≥ 2000/mm3 , platelets ≥ 100.000 mm3 , haemoglobin > 10 g/dl. Patients may have received an anthracycline and/or taxane-containing regimen given as adjuvant chemotherapy and relapsed > 12 months following the end of chemotherapy </inclusion>
<exclusion> patients were excluded if they had received previous chemotherapy for metastatic disease, brain, leptomeningeal or bone metastases as the only site of disease, a positive history for other types of cancer, with the exception of in situ cervix cancer radically resected and non melanoma skin cancer, prior history of myocardial infarction, unstable angina pectoris, cardiac insufficiency, uncontrolled arrhythmia or hypertension, peripheral neuropathy of grade ≥ 2 or pregnancy HER2+: 100%</exclusion>
</doc>
<doc>
<label>Huober 2012</label>
<inclusion> postmenopausal women with newly diagnosed hormone receptor- positive MBC or LABC defined as ER and/or PgR ≥ 10 fmol/mg cytosol protein, or ≥ 10% of the tumour cells positive as assessed by immunohistochemical evaluation of the primary tumour. For the trastuzumab and control arms, the primary tumour had to reveal HER2 over-expression defined as 3+ staining by IHC or HER2 amplification (ratio > 2) by FISH or an equivalent method. No prior treatment for metastatic or locally advanced breast cancer; LVEF ≥ 50% at baseline; adequate hepatic, renal and bone marrow function; an ECOG performance status of 0 or 1. Furthermore, patients were required to have at least 1 measurable tumour lesion (patients with bone only disease were eligible) </inclusion>
<exclusion> clinical or radiological signs of CNS metastasis; inflammatory breast cancer; other concurrent or previous malignant disease; uncontrolled cardiac diseases; prior anti-HER2 therapy apart from trastuzumab in the adjuvant setting HER2+: 61.3% (57/93). We considered HER2+ women alone</exclusion>
</doc>
<doc>
<label>Kaufman 2009</label>
<inclusion> postmenopausal women over-expressing HER2/neu by the Hercep Test assay (score 2+ or 3+), and/or fluorescence in situ hybridisation positive with two-fold amplification, hormone receptor-positive (ER-positive and/or PgR-positive). Previous treatment with tamoxifen as adjuvant or hormonal therapy or anastrozole was permitted. Other requirements included a LVEF greater than 50%; adequate baseline hepatic, renal and bone marrow function; an ECOG performance status of 0 to 1; and measurable or evaluable disease </inclusion>
<exclusion> prior chemotherapy for MBC or adjuvant chemotherapy within 6 months, clinical or radiologic evidence of CNS metastases; history of another malig- nancy, CHF or uncontrolled cardiac disease (angina, arrhythmias, hypertension); un- controlled serious intercurrent illness; and severe dyspnoea at rest. Patients with previous radiotherapy to indicator lesions were excluded from the response evaluation HER2+: not reported</exclusion>
</doc>
<doc>
<label>Marty 2005</label>
<inclusion> women age 18 to 70 years with HER2 over-expression (IHC 3+) and/ or gene amplification (FISH positive) who had not previously received chemotherapy for metastatic disease. Patients could have received prior (neo)adjuvant anthracyclines (max- imum cumulative dose, 360 mg/m2 doxorubicin or 750 mg/m2 epirubicin). Baseline LVEF had to be more than 50%. Hormonal therapy had to be discontinued before the first dose of study drug. Previous radiotherapy was allowed only if treatment had ended at least 14 days before enrolment into the trial and the patient had fully recovered from all acute adverse effects. ECOG performance status of ≤ 2, life expectancy ≥ 12 weeks, and at least one bidimensionally measurable lesion (according to WHO criteria). Bone marrow, renal and hepatic function: haemoglobin ≥ 10 g/dL and no blood transfusion within the previous 2 weeks; neutrophil count ≥ 2.0 x 109 cells/L; platelet count ≥ 100 x 109 cells/L; no evidence of myelodysplastic syndrome or abnormal bone marrow reserve; creatinine ≤ 1.5 x upper limit of normal (ULN) or creatinine clearance ≥ 60 mL/min; total bilirubin less than 1 x ULN; AST and/or ALT ≤ 2.5 x ULN; and alkaline phosphatase ≤ 5 x ULN (patients with AST and/or ALT > 1.5 x ULN concomitantly with alkaline phosphatase > 2.5 x ULN were ineligible for the study) </inclusion>
<exclusion> patients who had received prior chemotherapy for their metastatic disease or any prior taxanes or anti-HER therapy were excluded. Patients who had brain or leptomeningeal metastases, significant cardiac insufficiency (New York Heart Association III or IV), myocardial infarction within the previous 6 months, unstable angina pectoris, uncontrolled arrhythmia, or advanced pulmonary disease or severe dyspnoea at rest due to complications of advanced malignancy, or who required supplementary oxygen therapy, were ineligible for the trial HER2+: group 1: 97%; group 2: 94%</exclusion>
</doc>
<doc>
<label>Slamon 2001</label>
<inclusion> women over-expressing HER2 who had not previously received che- motherapy for metastatic disease. Only patients who had weak-to-moderate staining of the entire tumour cell membrane for HER2 (referred to as a score of 2+) or more than moderate staining (referred to as a score of 3+) in more than 10% of tumour cells on immunohistochemical analysis were eligible </inclusion>
<exclusion> patients were excluded if they had bilateral breast cancer, untreated brain metastases, osteoblastic bone metastases, pleural effusion or ascites as the only evidence of disease, a second type of primary cancer, or a Karnofsky score of less than 60, if they were pregnant or had received any type of investigational agent within 30 days before the study began HER2+: 100%</exclusion>
</doc>
<doc>
<label>von Minckwitz 2009</label>
<inclusion> women with pathologically confirmed, HER2-positive, locally ad- vanced or metastatic breast cancer. HER2 status was considered positive if over-expres- sion was detected in either the primary or metastatic tumour tissue by local immunohis- tochemistry (grade 3+ staining intensity) or by fluorescence in situ hybridisation. Du- ration of previous trastuzumab treatment had to be 12 weeks or greater, and the time since the end of the last trastuzumab cycle had to be less than 6 weeks. Patients could have received up to 1 chemotherapy drug for metastatic disease. Karnofsky performance status of 60% or greater; a life expectancy of greater than 3 months; and adequate hae- matologic, renal, hepatic and cardiac function sonographically confirmed by a LVEF of 50% or greater. Written informed consent </inclusion>
<exclusion> see inclusion criteria HER2+: 100%</exclusion>
</doc>
<doc>
<label>Blue 2001</label>
<inclusion> Patients admitted as an emergency to the acute medical admissions unit at one hospital with HF due to LV systolic dysfunction Study </inclusion>
<exclusion> 1. Unable to give informed consent or to comply with the intervention. 2. Acute MI (unless they had a previous history of CHF). 3. Co-morbidity (such as advanced malignancy) likely to lead to death or re-admission in the near future. 4. Awaiting cardiac surgery. 5. Planned discharge to long term residential care. 6. Residence outside the hospital catchment area.</exclusion>
</doc>
<doc>
<label>Capomolla 2002</label>
<inclusion> 1. Patients with CHF referred for admission to the Heart Failure Unit at one centre or the Heart Trans- plantation Programme (unclear if at the same centre) 2.A diagnosis of CHF supported by clinical history, physical signs and symptoms, and by LVEF <40% Study </inclusion>
<exclusion> None given.</exclusion>
</doc>
<doc>
<label>Cline 1998</label>
<inclusion> 1. Patients hospitalised primarily because of heart failure. 2. Heart failure diagnosed on symptoms and signs with “at least one objective sign present on admission such as pulmonary rales, peripheral oedema, congestion on CXR, or a 3rd heart sound”. 3. Aged 65-84 years. Study </inclusion>
<exclusion> 1. The presence of other serious disease that either prevented participation or was expected to significantly influence quality of life, morbidity or mortality in the following year. 2. Forseeable follow up problems including residence outside the hospital catchment area. 3. Serious alcohol or drug abuse. 4. Psychiatric disease. 5. Inability to understand or answer study questionnaire. 6. Participation in another clinical trial. 7. Discretion of treating physician.</exclusion>
</doc>
<doc>
<label>Doughty 2002</label>
<inclusion> Patients admitted to general medical wards with a primary diagnosis of heart failure Study </inclusion>
<exclusion> 1. Surgically remediable cause for heart failure. 2. Consideration for heart transplantation. 3. Terminal cancer. 4. Participation in another trial. 5. Inability to provide informed consent.</exclusion>
</doc>
<doc>
<label>Ekman 1998</label>
<inclusion> 1. Inpatient on medical ward. 2. Boston criteria score 8. 3. NYHA III or IV at index hospitalisation. 4. Age 65 years or older. 5. Residence in hospital catchment area. Study </inclusion>
<exclusion> 1. Large MI during preceding 8 weeks (new Q wave or serum CK-MB >100 μkat . l-1). 2. In “need of specialist treatment”. S 3. Serum creatinine >300 μmol . l-1. 4. Needing permanent nursing home care. 5.“Serious or life threatening co-morbidity”. 6. Communication problems.</exclusion>
</doc>
<doc>
<label>Harrison 2002</label>
<inclusion> 1. Patients admitted with heart failure to the two study units in one centre during recruitment period. 2. Residing in the residential home care radius (60km). 3. Admitted for more than 24 hours. 4. Patients expected to be discharged with home nursing care French or English speaking. 5. Not cognitively impaired (score <8 on Short Portable Mental Status Exam) Study </inclusion>
<exclusion> 1. Coming from or being discharged to a long term care facility. 2. On life support, having palliative care or in intensive care. 3. Died shortly after admission</exclusion>
</doc>
<doc>
<label>Jaarsma 2000</label>
<inclusion> 1. Patients admitted to the cardiology unit of one hospital with HF symptoms and diagnosis verified with Boston score. 2. NYHA III or IV. 3. HF diagnosis for longer than 3 months. 4. Age 50 years or older. 5. Dutch literate. Study </inclusion>
<exclusion> 1. Coexisting, severe, chronic debilitating disease. 2. Discharge to a nursing home. 3. Psychiatric diagnosis. 4. CABG, angioplasty or valve replacement in past 6 months or expected to have such treatment in next 3 months</exclusion>
</doc>
<doc>
<label>Kasper 2002</label>
<inclusion> 1. Admitted to one of two hospitals with a primary diagnosis of NYHA class III/IV CHF. 2. English speaking. 3. Permission from patient’s ’primary physician’ 4. Judged to be at high risk of CHF re-admission, ie one or more of the following criteria: ”Age >70 years. “LVEF <35%. ”One or more other hospital admission for CHF in previous year. “Ischaemic cardiomyopathy. ”Peripheral oedema at hospital discharge. “Less than 3kg weight loss while in the hospital. ”Peripheral vascular disease. 5. Or any one of the following during the index admission: “Pulmonary capillary wedge pressure >25 mmHg. ”Cardiac index <2.0 l/min/m2. “SBP >180 mmHg. ”DBP >100 mmHg. Study </inclusion>
<exclusion> 1. Valvular heart disease requiring surgery. 2. Active substance abuse. 3. Cardiomyopathy (peripartum, hypertrophic with LV outflow tract obstruction or restrictive). Constric- tive pericarditis. 4. Psychiatric disease. 5. Dementia likely to limit compliance. 6. Non-cardiac illness likely to cause repeat hospital admission. 7. Heart transplantation likely to occur within six months. 8. Uncorrected thyroid disease. 9. Serum creatinine => 3.0 mg/dl. 10. Long term home intravenous inotropic therapy. 11. Cardiac surgery or MI during the index admission. 12. Active participation in another research trial. 13. Residence in a nursing home, rehabilitation facility or outside the area served by the two hospitals</exclusion>
</doc>
<doc>
<label>Krumholz 2002</label>
<inclusion> 1. Age 50 or over 2. Needed to have either admission diagnosis of heart failure or radiological signs of heart failure on admission chest x-ray. 3. Reviewed within three days to verify additional set of criteria derived from NHANES-1 Study </inclusion>
<exclusion> 1. Patients transferred from other hospitals or nursing homes. 2. Patients with HF secondary to high output states or non-cardiac disease. 3. Patients with another terminal illness (e.g. expected survival < 6/12)</exclusion>
</doc>
<doc>
<label>Laramee 2003</label>
<inclusion> 1. All patients admitted to the hospital with clinical signs and symptoms of CHF and: either moderate-to- severe left ventricular dysfunction or, radiographic evidence of pulmonary congestion and symptomatic improvement following diuresis. 2. At risk for early readmission for CHF, defined as one or more of the following: “ history of CHF; ”’documented knowledge of deficits of treatment plan or disease process’; “potential or ongoing lack of adherence to treatment plan; ”previous CHF admission; “living alone; ”four or more hospitalisations in the last five years. Study </inclusion>
<exclusion> 1. Discharge to a long term care facility. 2. Planned cardiac surgery. 3. Cognitive impairment. 4. Anticipated survival of fewer than three months. 5. Long-term haemodialysis.</exclusion>
</doc>
<doc>
<label>McDonald 2002</label>
<inclusion> 1. Age over 18 years. 2. Admitted to one hospital through accident and emergency with a diagnosis of heart failure confirmed by a cardiologist based on the presence of 4 criteria: history and clinical examination, CXR, echocardiography and response to initial therapy Study </inclusion>
<exclusion> Heart failure in the presence of MI or unstable angina. Requiring immediate valve surgery. Patients “in which heart failure was not considered to be the primary problem”. “Illnesses which would compromise survival” over the next 12 weeks. Cognitive impairment. Resident in a nursing home. Significant hearing/visual impairment. Living abroad. Not English speaking.</exclusion>
</doc>
<doc>
<label>Rainville 1999</label>
<inclusion> 1. All patients with heart failure in their admission diagnoses and with a history of heart failure. 2. Age 50 years or older. Study </inclusion>
<exclusion> 1.”A more significant concomitant disease (e.g. unstable angina, cardiac arrythmia, COPD). 2. Living in long-term care facility. 3. Significant psychiatric illness. 4. Long term renal dialysis. 5. Life expectancy < 3 months. 6. No home phone. 7. Had a language barrier.</exclusion>
</doc>
<doc>
<label>Rich 1993</label>
<inclusion> 1. All patients admitted with CHF identified by: definite radiographic evidence of pulmonary congestion determined independently by both a staff radiologist and a staff cardiologist; or a typical history and physical findings of CHF in conjunction with symptomatic improvement following diuresis. 2. One or more of four independent risk factors for re-admission: four or more hospitalisations in the preceding five years, previous history of CHF, hypercholesterolaemia (<150 mg/dl), R bundle branch block on admitting ECG. 3. Aged over 70 years. Study </inclusion>
<exclusion> 1. Patients defined as low risk for re-admission based on the absence of each of four independent risk factors for (see above). 2. Death during initial hospitalisation. 3. Residence outside the hospital catchment area. 4. Planned discharge to a nursing home or other chronic care facility. 5. Non-cardiac illness likely to result in non-preventable re-admission (e.g. terminal malignancy). 6. Severe mental incapacity. 7. Psychiatric disturbance. 8. Physician refusal. 9. Logistic and discretionary reasons.</exclusion>
</doc>
<doc>
<label>Rich 1995</label>
<inclusion> 1. All admitted patients in whom CHF was identified by: definite radiographic evidence of pulmonary congestion; or a typical history and physical findings of CHF in conjunction with definite clinical im- provement following diuresis. 2. Age over 70 years. 3. One or more of four independent risk factors for re-admission: four or more hospitalisations in the preceding 5 years; previous history of CHF; CHF precipitated by either an acute MI or uncontrolled hypertension (SBP>= 200mm Hg, DBP >= 105 mm Hg) Study </inclusion>
<exclusion> “Patients defined as low risk for re-admission based on the absence of each of the four independent risk factors for re-admission listed above. ”Anticipated survival < 3 months. “Residence outside hospital catchment area. ”Planned discharge to a nursing home or other chronic care facility. “Severe dementia. ”Severe psychiatric illness. “Physician refusal. ”Logistic and discretionary reasons (including participation in the 1993 feasibility study)</exclusion>
</doc>
<doc>
<label>Riegel 2002</label>
<inclusion> 1. Confirmed clinical diagnosis of HF as the primary reason for hospitalisation. 2. English or Spanish speaking. Study </inclusion>
<exclusion> 1. Cognitive impairment. 2. Psychiatric illness. 3. Severe renal failure. 4. Terminal disease (e.g. cancer and/or acquired immunodeficiency syndrome). 5. Discharge to a long term care facility. 6. Previous enrolment in a HF disease management programme.</exclusion>
</doc>
<doc>
<label>Stewart 1999a</label>
<inclusion> 1. Admitted to tertiary care hospital under cardiologist and at least one previous admission for acute heart failure (pulmonary congestion or oedema evident on CXR with acute dyspnoea at rest). 2. NYHA class II-IV. 3. LVEF =< 55%. 4. Age =>55 years. 5. To be discharged home. 6. Lives within hospital catchment area. Study </inclusion>
<exclusion> 1. Terminal disease. 2. Valvular disease suitable for surgery. 3. Intended heart transplantation. 4. Heart failure precipitated by extensive, reversible ischaemia. 5. Home address outside hospital catchment area.</exclusion>
</doc>
<doc>
<label>Galetta 2005</label>
</doc>
<doc>
<label>Gallegos-Castorena 2007</label>
</doc>
<doc>
<label>Iarussi 1994</label>
</doc>
<doc>
<label>Kalay 2006</label>
</doc>
<doc>
<label>Kraft 1990</label>
</doc>
<doc>
<label>Lipshultz 2004</label>
</doc>
<doc>
<label>Lopez 1998</label>
</doc>
<doc>
<label>Marty 2006</label>
</doc>
<doc>
<label>Milei 1987</label>
</doc>
<doc>
<label>Myers 1983</label>
</doc>
<doc>
<label>Schwartz 2009</label>
</doc>
<doc>
<label>Speyer 1992</label>
</doc>
<doc>
<label>Swain 1997a(088001)</label>
</doc>
<doc>
<label>Swain 1997a(088006)</label>
</doc>
<doc>
<label>Venturini 1996</label>
</doc>
<doc>
<label>Wagdi 1995</label>
</doc>
<doc>
<label>Waldner 2006</label>
</doc>
<doc>
<label>Wexler 1996</label>
</doc>
<doc>
<label>CAPRIE 1996</label>
</doc>
<doc>
<label>HOT</label>
</doc>
<doc>
<label>Huynh</label>
</doc>
<doc>
<label>Throm Prev Trial ’00</label>
</doc>
<doc>
<label>Throm Prev Trial ’98</label>
</doc>
<doc>
<label>Colivicchi 2002</label>
<inclusion> (1) angiographic evidence of severe and diffuse coronary artery dis- ease, that was not amenable to direct revascularization by coronary artery bypass grafting or percutaneous transluminal coronary angioplasty, as determined by a cardiac surgeon and an interventional cardiologist during the index admission; (2) objective evidence of symptomatic reversible myocardial ischemia (0.1 mV ST-segment depression on the electrocardiogram) at a low exercise workload (4 METs) while receiving medical treat- ment (2 antianginal medications at maximal tolerated doses), as assessed by treadmill ergometry (Bruce’s protocol) before discharge; and (3) left ventricular ejection fraction 35% </inclusion>
<exclusion> Presence of congestive heart failure, the need for continuous use of intravenous antianginal medications, and the presence of any major concurrent illness</exclusion>
</doc>
<doc>
<label>de Lemos 2004</label>
<inclusion> Patients with ACS, between the ages of 21 and 80 years with either non-ST-elevation ACS; total cholesterol of 250 mg/dL (6.48 mmol/L) or lower; stabilized for at least 12 consecutive hours within 5 days after symptom onset, and meeting at least one of the following high-risk characteristics: age older than 70 years, diabetes mellitus, prior history of coronary artery disease, peripheral arterial disease, or stroke; elevation of serum creatine kinase-MB or troponin levels; recurrent angina with ST-segment changes; electrocardiographic evidence of ischemia on a predischarge stress test; or multivessel coronary artery disease determined by coronary angiography. , </inclusion>
<exclusion> On statins at time of randomization, coronary artery bypass graft surgery planned, or PCI planned within the following 2 weeks; ALT level higher than 20% above the upper limit of normal; an increased risk for myopathy due to renal impairment (serum creatinine level >2.0 mg/dL) or concomitant therapy with agents known to enhance myopathy risk, such as fibrates, cyclosporine, macrolide antibiotics, azole antifungals, amiodarone, or verapamil; or a prior history of non exercise-related elevations in creatine kinase level or nontraumatic rhabdomyolysis</exclusion>
</doc>
<doc>
<label>ESTABLISH 2004</label>
<inclusion> ACS with significant stenosis on initial coronary angiography and received PCI. Acute Coronary Syndrome was defined as high-risk unstable angina, non- ST-elevated myocardial infarction (MI) or ST-elevated MI. MI was diagnosed by the rise (2 times) in serum creatine phosphokinase and positivity for troponin T </inclusion>
<exclusion> Failed PCI, diseased bypass graft, recommended CABG, cardiogenic shock, and administration of lipid-lowering drugs (statin, clofibrate, probucol or analog, nicotinic acid, or other prohibited drug) before enrollment</exclusion>
</doc>
<doc>
<label>FACS 2010</label>
<inclusion> ST elevation ACS must have resting chest pain less than 12 hours before admission and either ≥ 1 mm ST-segment elevation in 2 or more continuous leads or new left bundle branch block on ECG. Those with non-ST elevation ACS must have resting chest pain during the previous 48 hours and either ≥ 1 mm ST segment depression or negative T waves in 2 or more continuous leads </inclusion>
<exclusion> <18 years of age or if they have concomitant active liver disease or persistent elevation of transaminases (> 3 times the upper limit of normal), a history of lipid-lowering therapy less than 30 days before the index event or a known allergy to fluvastatin or to any additives present in the drug. Other exclusions include inability to ingest oral medication, unwillingness to be followed for the duration of the study, muscle disease (e.g., myositis), and creatine kinase ≥ 5 times the upper limit of normal due to conditions other than myocardial infarction. Women of childbearing potential who are pregnant, nursing or who are not using effective contraception</exclusion>
</doc>
<doc>
<label>FLORIDA 2002</label>
<inclusion> new or markedly increased chest pain lasting longer than 30 min, or a new pathological Q wave of 0·04 s duration, or 25% of the corresponding R wave amplitude, both in at least two contiguous leads </inclusion>
<exclusion> age <18 years, use of lipid-lowering agents within the previous 3 months, a high triglyceride level of >4·5 mmol/l, known familial dyslipidaemia, severe renal failure, known hepatic disease, signs and symptoms of severe heart failure (New York Heart Association class IV), a scheduled percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and co medication that influences the ST- segment (digoxin, quinidine or tricyclic antidepressants), atrial fibrillation, WPW syn- drome, complete left bundle-branch block, known pre-existent ST-segment deviations before the qualifying AMI, left ventricular hypertrophy with a pattern of strain or pres- ence of a permanent pacemaker</exclusion>
</doc>
<doc>
<label>L-CAD 2000</label>
<inclusion> total cholesterol of >200 to <400 mg/dl and low-density lipoprotein (LDL) cholesterol of >130 to <300 mg/dl (after exclusion of secondary forms of hyper- lipidemia) with an acute myocardial infarction (defined by new Q waves and increase of enzymes of >3-fold the normal value) and/or who underwent emergency percutaneous transluminal coronary balloon angioplasty due to severe or unstable angina pectoris (de- fined by clinical symptoms and electrocardiographic [ECG] alterations </inclusion>
<exclusion> >75 years old, diabetics (fasting blood glucose >125 mg/dl), patients with postcoronary artery bypass graft, known malignant disease, serious kidney or liver dysfunction (creatimine >1.5 mg/dl, alanine aminotransferase and aspartate aminotrans- ferase >2 times normal value), or women of child-bearing age not using a reliable con- traception</exclusion>
</doc>
<doc>
<label>LAMIL 1997</label>
<inclusion> Definite cases of AMI using EKG and Enzymatic criteria </inclusion>
<exclusion> Unspecified</exclusion>
</doc>
<doc>
<label>LIPS 2002</label>
<inclusion> Patients with unstable angina, who had successfully undergone their first PCI of 1 or more lesions in the native coronary arteries. Successful PCI was defined as a reduction of the stenosis diameter to less than 50% in the target lesion without evidence of myocardial necrosis, need for repeat PCI or CABG, or death before hospital discharge. Any type of PCI was allowed and included balloon angioplasty with or without stent placement, rotational or directional atherectomy, laser ablation, transluminal extraction catheter, or cutting balloon. Patients further needed to have a total cholesterol level between 135 and 270 mg/dL (3.5-7.0 mmol/L), with fasting triglyceride levels of less than 400 mg/dL (4.5 mmol/L) before the index procedure. The upper total cholesterol limit for eligibility was 212 mg/dL (5.5 mmol/L) for patients whose baseline lipids were measured from blood drawn 24 hours to 4 weeks following MI and 232 mg/dL (6.0 mmol/L) for patients with type 1 or 2 diabetes mellitus </inclusion>
<exclusion> Sustained systolic blood pressure of more than 180 mmHg and diastolic blood pressure of more than 100 mmHg despite medical therapy, left ventricular ejection fraction of less than 30%, a history of previous PCI or CABG, severe valvular disease, idiopathic cardiomyopathy or congenital heart disease, severe renal dysfunction (defined as serum creatinine level >1.8 mg/dL, obesity (defined as a body mass index >35 kg/m2 ), and the presence of malignant or other disease with a life expectancy of less than 4 years</exclusion>
</doc>
<doc>
<label>Macin 2005</label>
<inclusion> >21 years old who fulfilled both of the following criteria: ACS within 48 hours of onset and CRP levels ≥1.4 mg/dL within 24 hours. Acute coronary syn- drome was diagnosed in the presence of ischemic chest pain at rest lasting ≥20 minutes and at least one of the following: new or presumably new ST-segment deviations on elec- trocardiogram (electrocardiographic evidence of ST-segment elevation or depression), enzyme abnormalities (creatine kinase-MB above upper limit of reference in ≥2 samples obtained with an interval of >6 hours), and/or troponin T ≥0.02 ng/mL </inclusion>
<exclusion> (1) use of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase in- hibitor or another lipidlowering agent at any time during the preceding 1 month; (2) history of active liver disease; (3) untreated endocrine disorder; (4) history of systemic inflammatory disease or cancer; (5) known hypersensitivity to statins; (6) patients judged to be unlikely to comply with the study drug regimen or study process; (7) known in- fectious disease in the last 30 days; (8) unwilling to provide written informed consent; and (9) cardiogenic shock or acute pulmonary edema</exclusion>
</doc>
<doc>
<label>MIRACL 2001</label>
<inclusion> 18 years or older with chest pain or discomfort of at least 15 minutes’ duration that occurred at rest or with minimal exertion within the 24-hour period preceding hospitalization and represented a change from their usual anginal pattern </inclusion>
<exclusion> Serum total cholesterol level at screening exceeded 270 mg/dL (7 mmol/L) (sites in Poland and South Africa used levels of 310 mg/dL [8 mmol/L]), coronary revascularization was planned or anticipated at the time of screening, evidence of Q-wave acute MI within the preceding 4 weeks; coronary artery bypass surgery within the preceding 3 months; percutaneous coronary intervention within the preceding 6 months; left bundle-branch block or paced ventricular rhythm; severe congestive heart failure (New York Heart Association class IIIb or IV); concurrent treatment with other lipid-regulating agents (except niacin at doses of 500 mg/d), vitamin E (except at doses # 400 IU/d), or drugs associated with rhabdomyolysis in combination with statins; severe anemia; renal failure requiring dialysis; hepatic dysfunction (alanine aminotransferase greater than 2 times ULN); insulin-dependent diabetes; pregnancy or lactation</exclusion>
</doc>
<doc>
<label>OACIS-LIPID 2008</label>
<inclusion> (1) clinical history of central chest pressure, pain, or tightness lasting for 30 min or more, (2) typical electrocardiographic changes (i.e., ST-segment elevation >0.1 mV in at least 1 standard or 2 precordial leads, ST-segment depression >0.1 mV in at least 2 leads, abnormal Q wave, or T wave inversion in at least 2 leads), and (3) an increase in the serum creatine kinase activity more than twice the normal laboratory value. All patients presenting within 1 week after the onset of AMI were registered prospectively </inclusion>
<exclusion>concurrent therapy with any statins or had a history of side effects associated with any statin. Evidence of life-threatening arrhythmia, severe chronic con- gestive heart failure (New York Heart Association class III-IV), hepatic dysfunction, renal failure, cerebrovascular disease, poorly controlled diabetes, pregnancy, lactation, age <20 years, and unable to take medication or absence of written informed consent. Patients whom the doctors consider inappropriate for any other reason were also not included</exclusion>
</doc>
<doc>
<label>PACT 2004</label>
<inclusion> 24 hours of the onset of symptoms if they had electrocardiographic changes suggestive of an AMI or UAP </inclusion>
<exclusion> taking statin therapy before their event (other lipid-lowering ther- apies were permitted), participation in any other clinical trial or the taking of an in- vestigational drug within the previous 30 days, planned coronary revascularization or cardiac transplantation, severe renal or hepatic disease or other severe disease, drug- or alcohol-related problems, gastrointestinal disease or a history of gastrointestinal surgery that might affect drug absorption, and known hypersensitivity or previous serious ad- verse reactions to statin therapy. Women of child-bearing potential</exclusion>
</doc>
<doc>
<label>PAIS 2001</label>
<inclusion> men aged 18-80 or postmenopausal women with serum total choles- terol levels >5.2mmol/l and LDL cholesterol levels >3.5mmol/l; signs of either UA or acute MI (defined as ST segment elevations ≥1mm in 2 leads or T-wave inversion) </inclusion>
<exclusion> History of hypersensitivity to statins, severe Congestive heart failure, cardiomyopathy, significant liver disease, significant gastrointestinal disease or abdominal surgery that might adversely influence drug absorption, substance or alcohol abuse, history or present use of any other lipid-lowering or investigational agent, uncontrolled diabetes, thyroid disease, severe renal impairment, dysproteinaemia, primary muscle disease</exclusion>
</doc>
<doc>
<label>PRINCESS 2004</label>
<inclusion> Patients with ACS (myocardial infarction or unstable angina), no lower LDL-cholesterol limit</inclusion>
</doc>
<doc>
<label>PTT 2002</label>
<inclusion> Patients receiving Fibrinolysis therapy within 6 hours of ST-segment elevated acute MI </inclusion>
<exclusion> Contraindications for thrombolytic therapy, age >75 years, history of myocardial infarction, previous percutaneous transluminal coronary angioplasty, coro- nary artery bypass graft surgery, congestive heart failure, secondary hyperlipidemia, un- controlled hypertension or diabetes mellitus, liver disease, thyroid dysfunction, use of anticoagulant drugs other than aspirin, use of steroids or hormone replacement therapy, women of childbearing potential and patients with physical or psychosocial disorders that could interfere with protocol adherence</exclusion>
</doc>
<doc>
<label>RECIFE 1999</label>
<inclusion> diagnosis of acute myocardial infarction or unstable angina and admission total serum cholesterol ?5.2 mmol/L or LDL cholesterol ?3.4 mmol/L and serum triglycerides ?4.5 mmol/L </inclusion>
<exclusion> presence of heart failure with an ejection fraction of <40%, admin- istration of lipid lowering agents in the preceding 8 weeks, renal failure with serum creatinine level >200 mmol/L, and patients requiring coronary artery bypass surgery, premenopausal women, postmenopausal women on hormone replacement therapy</exclusion>
</doc>
<doc>
<label>Ren 2009</label>
<inclusion> Newly diagnosed unstable angina, age >18 years, ischemic symptoms <72 h, absence of cardiogenic shock, and not previously treated with statin </inclusion>
<exclusion> Severe renal dysfunction, primary cardiomyopathy or COPD, taking inflammatory drugs other than aspirin, elevated cardiac markers</exclusion>
</doc>
<doc>
<label>Sakamoto 2005</label>
<inclusion> Qualifying AMI (increased creatinine phosphokinase-MB and/or total creatinine phosphokinase level ≥2 times the upper limit of normal) and prolonged chest pain (>30 minutes), objective evidence of myocardial ischemia based on dynamic or interval ST- or T-wave changes in ≥2 contiguous electrocardiographic leads (≥0.1- mV ST elevation, ≥0.05-mV flat or downsloping ST depression at the J point and 80 ms after the J point, or ≥0.3-mV T-wave inversion), or new left bundle branch block; serum total cholesterol levels were required to be 180 to 240 mg/dl on admission </inclusion>
<exclusion> <18 years of age, use of lipid-lowering agents within the previous 3 months,known familial dyslipidemia, severe renal failure, known hepatic disease, signs and symptoms of severe heart failure (Killip’s class III or IV), a scheduled PCI or coronary artery bypass grafting (CABG), previous PCI (within 6 months) or CABG (within 3 months), and the presence of malignant disease or allergy to statins</exclusion>
</doc>
<doc>
<label>Shalnev VI 2007</label>
<inclusion> Patients with acute coronary syndrome (myocardial infarction or unstable angina)</inclusion>
</doc>
<doc>
<label>Adam 1982</label>
</doc>
<doc>
<label>Bauer 1994</label>
</doc>
<doc>
<label>Benson 1978</label>
</doc>
<doc>
<label>Butland 1983</label>
</doc>
<doc>
<label>Chatterjee 1986</label>
</doc>
<doc>
<label>Chodosh 1988</label>
</doc>
<doc>
<label>Dorow 1986c</label>
</doc>
<doc>
<label>Doshan 1986a</label>
</doc>
<doc>
<label>Doshan 1986b</label>
</doc>
<doc>
<label>Ellis 1981</label>
</doc>
<doc>
<label>Falliers 1986</label>
</doc>
<doc>
<label>Fenster 1983</label>
</doc>
<doc>
<label>Fogari 1990</label>
</doc>
<doc>
<label>Greefhorst 1984</label>
</doc>
<doc>
<label>Johnsson 1975</label>
</doc>
<doc>
<label>Lammers 1984</label>
</doc>
<doc>
<label>Lammers 1985a</label>
</doc>
<doc>
<label>Lammers 1986a</label>
</doc>
<doc>
<label>Lammers 1988</label>
</doc>
<doc>
<label>Lawrence 1982</label>
</doc>
<doc>
<label>Lofdahl 1981</label>
</doc>
<doc>
<label>Nicolaescu 1973</label>
</doc>
<doc>
<label>Nicolescu 1972</label>
</doc>
<doc>
<label>Ruffin 1979</label>
</doc>
<doc>
<label>Skinner 1975b</label>
</doc>
<doc>
<label>Tantucci 1990</label>
</doc>
<doc>
<label>van den Bergh 1981</label>
</doc>
<doc>
<label>van Zyl 1989</label>
</doc>
<doc>
<label>Beltrame 1998</label>
</doc>
<doc>
<label>Nelson 1983</label>
</doc>
<doc>
<label>Verma 1987</label>
</doc>
<doc>
<label>VMAC 2002</label>
</doc>
<doc>
<label>Anderson 1950</label>
</doc>
<doc>
<label>Griffith 1952</label>
</doc>
<doc>
<label>Harvey 1950</label>
</doc>
<doc>
<label>HELAS 2006</label>
</doc>
<doc>
<label>WASH 2004</label>
</doc>
<doc>
<label>Ashe 1993</label>
</doc>
<doc>
<label>Daltroy 1985</label>
</doc>
<doc>
<label>Duncan 2002</label>
</doc>
<doc>
<label>Hillebrand 1995</label>
</doc>
<doc>
<label>Izawa 2005</label>
</doc>
<doc>
<label>Jolly 1999</label>
</doc>
<doc>
<label>Moore 2006</label>
</doc>
<doc>
<label>Oldridge 1983</label>
</doc>
<doc>
<label>Sniehotta 2006</label>
</doc>
<doc>
<label>Wyer 2001</label>
</doc>
<doc>
<label>McConnell 1998</label>
</doc>
<doc>
<label>Sampaio 2002</label>
</doc>
<doc>
<label>Weiner 2000</label>
<exclusion> participants with recorded PEFR less than 80% of their best value were excluded from the study after the four week run-in period Eighty-two participants (46 male and 36 female) were recruited for the study. Six partic- ipants were excluded from the study and the remaining 76 subjects were separated into two groups according to beta2 -agonist consumption. High consumers (mean beta2 -agonist consumption of > 1 puff/d): mean ± SEM M/F = 15/8 Mean Age = 34.0 ± 2.8 yrs Normal consumers (mean beta2 -agonist consumption of ≤ 1 puff/d): mean ± SEM M/F = 27/26 Mean Age = 37.3 ± 3.1 yrs In the second stage of the study, the 23 high consumers were randomised into two groups: Group A (intervention) N = 12 Group B (control) N = 11</exclusion>
</doc>
<doc>
<label>Weiner 2002</label>
</doc>
<doc>
<label>Weiner 2002a</label>
</doc>
<doc>
<label>ARIES-1</label>
</doc>
<doc>
<label>ARIES-2</label>
</doc>
<doc>
<label>ASSET-1</label>
</doc>
<doc>
<label>BREATHE-1</label>
</doc>
<doc>
<label>BREATHE-2</label>
</doc>
<doc>
<label>BREATHE-5</label>
</doc>
<doc>
<label>Channick 2001</label>
</doc>
<doc>
<label>EARLY</label>
</doc>
<doc>
<label>Galiè 2003</label>
</doc>
<doc>
<label>SERAPH</label>
</doc>
<doc>
<label>STRIDE-1</label>
</doc>
<doc>
<label>STRIDE-1 (100mg)</label>
</doc>
<doc>
<label>STRIDE-1 (300mg)</label>
</doc>
<doc>
<label>STRIDE-2</label>
</doc>
<doc>
<label>STRIDE-2 (100mg)</label>
</doc>
<doc>
<label>STRIDE-2 (50mg)</label>
</doc>
<doc>
<label>STRIDE-4</label>
</doc>
<doc>
<label>STRIDE-4 (100mg)</label>
</doc>
<doc>
<label>STRIDE-4 (50mg)</label>
</doc>
<doc>
<label>Austin 2005</label>
</doc>
<doc>
<label>Belardinelli 1999</label>
<exclusion> Inclusion: heart failure, LVEF <40%, and sinus rhythm, diagnosis of chronic heart failure based on clinical symptoms & signs and/or radiological evidence of pulmonary congestion Exclusion: unstable angina, recent acute myocardial infarction, decompensated congestive heart failure, hemodynamically significant valvular heart disease, significant chronic pulmonary ill- ness, uncontrolled hypertension, renal insufficiency (serum creatinine >2.5 mg/dl), and ortho- pedic or neurological limitations)</exclusion>
</doc>
<doc>
<label>Dracup 2007</label>
</doc>
<doc>
<label>Giannuzzi 2003</label>
<exclusion> Inclusion: (1) heart failure secondary to idiopathic dilated cardiomyopathy, ischemic heart disease, or valvular disease; (2) echocardiographic ejection fraction <35%; (3) clinical stability for at least 3 months under optimized therapy; (4) New York Heart Association functional class II to III; (5) peak oxygen uptake (VO2 ) < 20 ml/kg/min; and (6) echocardiographic images of adequate quality for quantitative analysis Exclusion: any systemic disease limiting exercise, hypertrophic cardiomyopathy, valvular dis- ease requiring surgery, angina pectoris, sustained ventricular arrhythmias, severe hypertension, excess variability (>10%) at baseline cardiopulmonary exercise test, and inability to participate in a prospective study for any logistic reason.</exclusion>
</doc>
<doc>
<label>Gielen 2003</label>
</doc>
<doc>
<label>Gottlieb 1999</label>
<exclusion> Inclusion: NYHA 2-3 for at least three months and were on stable meds for the past one month. All patients were on maximal medical therapy with ACEi, diuretic and digoxin. All patients had EF<40% by nuclear ventriculography. No patient had obstructive valvular disease, myocardial infarction within three months, or limitation of exercise secondary to angina or new arrhythmias Exclusion: Not reported.</exclusion>
</doc>
<doc>
<label>Hambrecht 1995</label>
<exclusion> Inclusion: EF<40% as assessed by radionucleotide scintigraphy, and a reduced fractional short- ening <30% assessed by echocardiography; willingness to participate in the study for the next 6 months; and a permanent residence within 25km of the training facility. Physical work ca- pacity at baseline >25Watts without signs of myocardial ischaemia (i.e. angina or ST segment depression). Clinically stable >3 months. Exclusion: Exercise induced myocardial ischaemia or ventricular tachyarrhythmias (higher then Lown class IVa), valvular heart disease, uncontrolled hypertension, peripheral vascular disease, COPD and orthopaedic or other conditions precluding regular participation in exercise sessions</exclusion>
</doc>
<doc>
<label>Hambrecht 1998</label>
<exclusion> Inclusion: <70 years old, with CHF as a result of DCM or IHD. Exclusion: DM, hypertension, overt atherosclerotic peripheral vascular disease, hypercholes- terolaemia, ventricular tachycardia, COPD and primary valvular disease</exclusion>
</doc>
<doc>
<label>Hambrecht 2000</label>
</doc>
<doc>
<label>HF ACTION 2009</label>
<exclusion> Inclusion: LVEF <35%, NYHA class II-IV heart failure for the previous three months despite a six week period of treatment, optimal heart failure therapy at stable doses for six weeks be- fore, enrollment or documented rationale for variation, including intolerance, contraindica- tion, patient preference, and personal physicians judgment, sufficient stability, by investigator judgment, to begin an exercise program Exclusion: (selected) Age <18 yr, comorbid disease or behavioral or other limitations that inter- fere with performing exercise training or prevent the completion of one yr of exercise training, major cardiovascular event or cardiovascular procedure, including implantable cardioverter defibrillator (ICD) use and cardiac resynchronization, within the previous six wks</exclusion>
</doc>
<doc>
<label>Keteyian 1996</label>
<exclusion> Inclusion: NYHA class II or III, a resting EF ?35% measured by echocardiography or gated equilibrium radionuclide angiography, and no change in medical therapy ?30 days before randomisation Exclusion: atrial fibrillation, acute myocardial infarction ?3 months, angina pectoris at rest or induced by exercise, current enrolment in another clinical trial, and current participation in a regular exercise program (at least twice weekly).’</exclusion>
</doc>
<doc>
<label>Klecha 2007</label>
<exclusion> Inclusion: Ischaemic heart failure in NYHA groups II-III of > six months, clinically stable > six weeks & LVEF <35% Exclusion: Uncontrolled arterial hypertension, history of major ventricular arrhythmias, ACS, PCI or brain event 3 months prior to the study, AF or other arrhythmia making it impossible to perform MRI, previous coronary artery bypass grafting, implantable cardiodefibrillator , permanent pacemaker, or the presence of metal parts in the body, signs of osteoarticular dysfunction excluding participation in physical training, diabetes mellitus, COPD and anaemia</exclusion>
</doc>
<doc>
<label>Klocek 2005 (High)</label>
<exclusion> Inclusion: Stable chromic heart failure, LVEF < 40% on echocardiography ? one month before inclusion, age <65 years.” Exclusion: Moderate or severe pulmonary disease, orthostatic blood pressure fall (>20mmHg), or with myocardial infarction, unstable angina, heart surgery or coronary angioplasty within 3 months prior to inclusion as well as inability to perform bicycle training.</exclusion>
</doc>
<doc>
<label>Klocek 2005 (Low)</label>
</doc>
<doc>
<label>Koukouvou 2004</label>
<exclusion> Inclusion: Stable chromic heart failure, LVEF < 40% on echocardiography ? one month before inclusion, age <65 years.” Exclusion: Moderate or severe pulmonary disease, orthostatic blood pressure fall (>20mmHg), or with myocardial infarction, unstable angina, heart surgery or coronary angioplasty within 3 months prior to inclusion as well as inability to perform bicycle training.</exclusion>
</doc>
<doc>
<label>McKelvie 2002</label>
<exclusion> Inclusion: Aetiology of CHF was either ischaemic heart disease or dilated cardiomyopathy. Diagnosis of CHF was mainly based on clinical signs (NYHA II and III), radiological findings, and echocardiographically determined ejection fraction < 40% and shortening fraction < 30% Exclusion: recent myocardial infarction or unstable angina, aortic stenosis, diabetes mellitus, uncontrolled hypertension, musculoskeletal limitations or other contraindications for partici- pating in an exercise training program, documented exercise-induced severe ischaemia and/or serious arrhythmias</exclusion>
</doc>
<doc>
<label>Mueller 2007</label>
<exclusion> Inclusion: Chronic heart failure was documented by clinical, angiographic or echocardiographic criteria, and a resting ejection fraction <40% Exclusion: Not reported.</exclusion>
</doc>
<doc>
<label>Passino 2006</label>
</doc>
<doc>
<label>Pozehl 2008</label>
<exclusion> Inclusion: impaired left ventricular systolic function (EF<45%) and exercise capacity (peak VO2 <25 ml/min/kg). Exclusion NYHA class IV, myocardial infarction or unstable angina <6 months before the examination, exercise-limiting diseases, and severe pulmonary or renal disease * baseline data only available in 85 patients.</exclusion>
</doc>
<doc>
<label>Willenheimer 2000</label>
<exclusion> Inclusion: able to speak and read English; stable NYHA class II-IV no change in medical therapy ?30 days; resting LVEF <40% measured by echocardiography or gated equilibrium radionuclide angiography; medical diagnosis of heart failure either ischemic or non-ischaemic; and standard pharmacologic therapy for heart failure (diuretics, ACE inhibitors, and beta- blockers) Exclusion: participation in a formal exercise program <30 days prior to this study; clinical evidence decompensated heart failure; and any of the following medical conditions: atrial fibrillation, acute myocardial infarction <3 months, unstable angina pectoris, end-stage renal disease, or orthopedic impediments to exercise</exclusion>
</doc>
<doc>
<label>Galetta 2005</label>
</doc>
<doc>
<label>Iarussi 1994</label>
</doc>
<doc>
<label>Kalay 2006</label>
</doc>
<doc>
<label>Kraft 1990</label>
</doc>
<doc>
<label>Lipshultz 2004</label>
</doc>
<doc>
<label>Lopez 1998</label>
</doc>
<doc>
<label>Marty 2006</label>
</doc>
<doc>
<label>Milei 1987</label>
</doc>
<doc>
<label>Myers 1983</label>
</doc>
<doc>
<label>Speyer 1992</label>
</doc>
<doc>
<label>Swain 1997a(088001)</label>
</doc>
<doc>
<label>Swain 1997a(088006)</label>
</doc>
<doc>
<label>Venturini 1996</label>
</doc>
<doc>
<label>Wagdi 1995</label>
</doc>
<doc>
<label>Waldner 2006</label>
</doc>
<doc>
<label>Wexler 1996</label>
</doc>
<doc>
<label>Cleland 2005</label>
</doc>
<doc>
<label>Cosyns 2008</label>
</doc>
<doc>
<label>Ghali 2008</label>
</doc>
<doc>
<label>Kourea 2008a</label>
</doc>
<doc>
<label>Mancini 2003</label>
</doc>
<doc>
<label>Palazzuoli 2006</label>
</doc>
<doc>
<label>Palazzuoli 2007</label>
</doc>
<doc>
<label>Parissis 2008</label>
</doc>
<doc>
<label>Ponikowski 2007</label>
</doc>
<doc>
<label>Silverberg 2001</label>
</doc>
<doc>
<label>van Veldhuisen 2007</label>
</doc>
<doc>
<label>Colivicchi 2002</label>
<inclusion> (1) angiographic evidence of severe and diffuse coronary artery dis- ease, that was not amenable to direct revascularization by coronary artery bypass grafting or percutaneous transluminal coronary angioplasty, as determined by a cardiac surgeon and an interventional cardiologist during the index admission; (2) objective evidence of symptomatic reversible myocardial ischemia (0.1 mV ST-segment depression on the electrocardiogram) at a low exercise workload while receiving medical treatment (2 an- tianginal medications at maximal tolerated doses), as assessed by treadmill ergometry (Bruce’s protocol) before discharge; and (3) left ventricular ejection fraction 35% </inclusion>
<exclusion> presence of congestive heart failure, the need for continuous use of intravenous antianginal medications, and the presence of any major concurrent illness</exclusion>
</doc>
<doc>
<label>de Lemos 2004</label>
<inclusion> patients with ACS, between the ages of 21 and 80 years with either non-ST-elevation ACS; total cholesterol of 250 mg/dL (6.48 mmol/L) or lower; stabilized for at least 12 consecutive hours within 5 days after symptom onset, and meeting at least one of the following high-risk characteristics: age older than 70 years, diabetes mellitus, prior history of coronary artery disease, peripheral arterial disease, or stroke; elevation of serum creatine kinase-MB or troponin levels; recurrent angina with ST-segment changes; electrocardiographic evidence of ischemia on a pre-discharge stress test; or multivessel coronary artery disease determined by coronary angiography </inclusion>
<exclusion> on statins at time of randomization, coronary artery bypass graft surgery planned, or PCI planned within the following 2 weeks; ALT level higher than 20% above the upper limit of normal; an increased risk of myopathy due to renal impairment (serum creatinine level > 2.0 mg/dL) or concomitant therapy with agents known to enhance myopathy risk, such as fibrates, cyclosporine, macrolide antibiotics, azole antifungals, amiodarone, or verapamil; or a prior history of non exercise-related elevations in creatine kinase level or nontraumatic rhabdomyolysis</exclusion>
</doc>
<doc>
<label>ESTABLISH 2004</label>
<inclusion> ACS with significant stenosis on initial coronary angiography and received PCI. ACS was defined as high-risk unstable angina, non-ST-elevated myocardial infarction (MI) or ST-elevated MI. MI was diagnosed by the rise (2 times) in serum creatine phosphokinase and positivity for troponin T </inclusion>
<exclusion> failed PCI, diseased bypass graft, recommended CABG, cardiogenic shock, and administration of lipid-lowering drugs (statin, clofibrate, probucol or analog, nicotinic acid, or other prohibited drug) before enrollment</exclusion>
</doc>
<doc>
<label>FACS 2010</label>
<inclusion> ST elevation ACS must have resting chest pain less than 12 hours before admission and either ≥ 1 mm ST-segment elevation in 2 or more continuous leads or new left bundle branch block on ECG. Those with non-ST elevation ACS must have resting chest pain during the previous 48 hours and either ≥ 1 mm ST segment depression or negative T waves in 2 or more continuous leads </inclusion>
<exclusion> < 18 years of age or if they have concomitant active liver disease or persistent elevation of transaminases (> 3 times the upper limit of normal), a history of lipid-lowering therapy less than 30 days before the index event or a known allergy to fluvastatin or to any additives present in the drug. Other exclusions include inability to ingest oral medication, unwillingness to be followed for the duration of the study, muscle disease (e.g. myositis), and creatine kinase ≥ 5 times the upper limit of normal due to conditions other than myocardial infarction. Women of childbearing potential who are pregnant, nursing or who are not using effective contraception</exclusion>
</doc>
<doc>
<label>FLORIDA 2002</label>
<inclusion> new or markedly increased chest pain lasting longer than 30 minutes, or a new pathological Q wave of 0.04 s duration, or 25% of the corresponding R wave amplitude, both in at least 2 contiguous leads </inclusion>
<exclusion> age < 18 years, use of lipid-lowering agents within the previous 3 months, a high triglyceride level of > 4.5 mmol/l, known familial dyslipidemia, severe re- nal failure, known hepatic disease, signs and symptoms of severe heart failure (New York Heart Association class IV), a scheduled percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and co-medication that influences the ST-seg- ment (digoxin, quinidine or tricyclic antidepressants), atrial fibrillation, Wolff-Parkin- son-White syndrome, complete left bundle-branch block, known pre-existent ST-seg- ment deviations before the qualifying MI, left ventricular hypertrophy with a pattern of strain or presence of a permanent pacemaker</exclusion>
</doc>
<doc>
<label>L-CAD 2000</label>
<inclusion> total cholesterol of > 200 to < 400 mg/dL and low-density lipoprotein (LDL) cholesterol of > 130 to < 300 mg/dL (after exclusion of secondary forms of hyperlipidemia) with an acute myocardial infarction (defined by new Q waves and increase of enzymes of > 3-fold the normal value) and/or who underwent emergency percutaneous transluminal coronary balloon angioplasty due to severe or unstable angina pectoris (defined by clinical symptoms and electrocardiographic (ECG) alterations </inclusion>
<exclusion> > 75 years old, diabetics (fasting blood glucose > 125 mg/dL), pa- tients with post-coronary artery bypass graft, known malignant disease, serious kidney or liver dysfunction (creatinine > 1.5 mg/dL, alanine aminotransferase and aspartate aminotransferase > 2 times normal value), or women of child-bearing age not using a reliable contraception</exclusion>
</doc>
<doc>
<label>LAMIL 1997</label>
<inclusion> definite cases of acute MI using ECG and enzymatic criteria </inclusion>
<exclusion> unspecified</exclusion>
</doc>
<doc>
<label>LIPS 2002</label>
<inclusion> patients with unstable angina, who had successfully undergone their first PCI of 1 or more lesions in the native coronary arteries. Successful PCI was defined as a reduction of the stenosis diameter to less than 50% in the target lesion without evidence of myocardial necrosis, need for repeat PCI or CABG, or death before hospital discharge. Any type of PCI was allowed and included balloon angioplasty with or without stent placement, rotational or directional atherectomy, laser ablation, transluminal extraction catheter, or cutting balloon. Patients further needed to have a total cholesterol level between 135 and 270 mg/dL (3.5 to 7.0 mmol/L), with fasting triglyceride levels of less than 400 mg/dL (4.5 mmol/L) before the index procedure. The upper total cholesterol limit for eligibility was 212 mg/dL (5.5 mmol/L) for patients whose baseline lipids were measured from blood drawn 24 hours to 4 weeks following MI and 232 mg/dL (6.0 mmol/L) for patients with type 1 or 2 diabetes mellitus </inclusion>
<exclusion> sustained systolic blood pressure of more than 180 mmHg and diastolic blood pressure of more than 100 mmHg despite medical therapy, left ventricular ejection fraction of less than 30%, a history of previous PCI or CABG, severe valvular disease, idiopathic cardiomyopathy or congenital heart disease, severe renal dysfunction (defined as serum creatinine level > 1.8 mg/dL, obesity (defined as a body mass index > 35 kg/m2 ), and the presence of malignant or other disease with a life expectancy of less than 4 years</exclusion>
</doc>
<doc>
<label>Macin 2005</label>
<inclusion> > 21 years old who fulfilled both of the following criteria: ACS within 48 hours of onset and CRP levels ≥ 1.4 mg/dl within 24 hours. Acute coronary syndrome was diagnosed in the presence of ischemic chest pain at rest lasting ≥ 20 minutes and at least 1 of the following: new or presumably new ST-segment deviations on electrocardiogram (electrocardiographic evidence of ST-segment elevation or depression) , enzyme abnormalities (creatine kinase-MB above upper limit of reference in ≥ 2 samples obtained with an interval of > 6 hours), and/or troponin T ≥ 0.02 ng/mL </inclusion>
<exclusion> (1) use of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase in- hibitor or another lipid-lowering agent at any time during the preceding 1 month; (2) history of active liver disease; (3) untreated endocrine disorder; (4) history of systemic inflammatory disease or cancer; (5) known hypersensitivity to statins; (6) patients judged to be unlikely to comply with the study drug regimen or study process; (7) known in- fectious disease in the last 30 days; (8) unwilling to provide written informed consent; and (9) cardiogenic shock or acute pulmonary edema</exclusion>
</doc>
<doc>
<label>MIRACL 2001</label>
<inclusion> 18 years or older with chest pain or discomfort of at least 15 minutes’ duration that occurred at rest or with minimal exertion within the 24-hour period preceding hospitalization and represented a change from their usual anginal pattern </inclusion>
<exclusion> serum total cholesterol level at screening exceeded 270 mg/dL (7 mmol/L) (sites in Poland and South Africa used levels of 310 mg/dL (8 mmol/L)), coronary revascularization was planned or anticipated at the time of screening, evidence of Q-wave acute MI within the preceding 4 weeks; coronary artery bypass surgery within the preceding 3 months; percutaneous coronary intervention within the preceding 6 months; left bundle-branch block or paced ventricular rhythm; severe congestive heart failure (New York Heart Association class IIIb or IV); concurrent treatment with other lipid-regulating agents (except niacin at doses of 500 mg/d), vitamin E (except at doses # 400 IU/d), or drugs associated with rhabdomyolysis in combination with statins; severe anemia; renal failure requiring dialysis; hepatic dysfunction (alanine aminotransferase greater than 2 times ULN); insulin-dependent diabetes; pregnancy or lactation</exclusion>
</doc>
<doc>
<label>OACIS-LIPID 2008</label>
<inclusion> (1) clinical history of central chest pressure, pain, or tightness last- ing for 30 minutes or more, (2) typical electrocardiographic changes (i.e. ST-segment elevation > 0.1 mV in at least 1 standard or 2 precordial leads, ST-segment depression > 0.1 mV in at least 2 leads, abnormal Q wave, or T wave inversion in at least 2 leads) , and (3) an increase in the serum creatine kinase activity more than twice the normal laboratory value. All patients presenting within 1 week after the onset of acute MI were registered prospectively </inclusion>
<exclusion> concurrent therapy with any statins or had a history of side effects associated with any statin. Evidence of life-threatening arrhythmia, severe chronic con- gestive heart failure (New York Heart Association class III-IV), hepatic dysfunction, renal failure, cerebrovascular disease, poorly controlled diabetes, pregnancy, lactation, age < 20 years, and unable to take medication or absence of written informed consent. Patients whom the doctors consider inappropriate for any other reason were also not included</exclusion>
</doc>
<doc>
<label>PACT 2004</label>
<inclusion> 24 hours of the onset of symptoms if they had electrocardiographic changes suggestive of an acute MI or unstable angina </inclusion>
<exclusion> taking statin therapy before their event (other lipid-lowering ther- apies were permitted), participation in any other clinical trial or the taking of an in- vestigational drug within the previous 30 days, planned coronary revascularization or cardiac transplantation, severe renal or hepatic disease or other severe disease, drug- or alcohol-related problems, gastrointestinal disease or a history of gastrointestinal surgery that might affect drug absorption, and known hypersensitivity or previous serious ad- verse reactions to statin therapy Women of child-bearing potential</exclusion>
</doc>
<doc>
<label>PAIS 2001</label>
<inclusion> men aged 18 to 80 or postmenopausal women with serum total cholesterol levels > 5.2 mmol/l and LDL cholesterol levels > 3.5 mmol/l; signs of either UA or acute MI (defined as ST segment elevations ≥ 1 mm in 2 leads or T-wave inversion) </inclusion>
<exclusion> history of hypersensitivity to statins, severe congestive heart failure, cardiomyopathy, significant liver disease, significant gastrointestinal disease or abdomi- nal surgery that might adversely influence drug absorption, substance or alcohol abuse, history or present use of any other lipid-lowering or investigational agent, uncontrolled diabetes, thyroid disease, severe renal impairment, dysproteinemia, primary muscle dis- ease</exclusion>
</doc>
<doc>
<label>PRINCESS 2004</label>
<inclusion> patients with ACS (myocardial infarction or unstable angina), no lower LDL cholesterol limit</inclusion>
</doc>
<doc>
<label>PTT 2002</label>
<inclusion> patients receiving fibrinolysis therapy within 6 hours of ST-segment elevated acute MI </inclusion>
<exclusion> contraindications for thrombolytic therapy, age > 75 years, history of myocardial infarction, previous percutaneous transluminal coronary angioplasty, coro- nary artery bypass graft surgery, congestive heart failure, secondary hyperlipidemia, un- controlled hypertension or diabetes mellitus, liver disease, thyroid dysfunction, use of anticoagulant drugs other than aspirin, use of steroids or hormone replacement therapy, women of childbearing potential and patients with physical or psychosocial disorders that could interfere with protocol adherence</exclusion>
</doc>
<doc>
<label>RECIFE 1999</label>
<inclusion> diagnosis of acute myocardial infarction or unstable angina and admission total serum cholesterol ?5.2 mmol/L or LDL cholesterol ?3.4 mmol/L and serum triglycerides ?4.5 mmol/L </inclusion>
<exclusion> presence of heart failure with an ejection fraction of < 40%, ad- ministration of lipid-lowering agents in the preceding 8 weeks, renal failure with serum creatinine level > 200 mmol/L, and patients requiring coronary artery bypass surgery, premenopausal women, postmenopausal women on hormone replacement therapy</exclusion>
</doc>
<doc>
<label>Ren 2009</label>
<inclusion> newly diagnosed unstable angina, age > 18 years, ischemic symptoms < 72 h, absence of cardiogenic shock, and not previously treated with statin </inclusion>
<exclusion> severe renal dysfunction, primary cardiomyopathy or COPD, taking inflammatory drugs other than aspirin, elevated cardiac markers</exclusion>
</doc>
<doc>
<label>Sakamoto 2005</label>
<inclusion> qualifying AMI (increased creatinine phosphokinase-MB and/or total creatinine phosphokinase level ≥ 2 times the upper limit of normal) and prolonged chest pain (> 30 minutes), objective evidence of myocardial ischemia based on dynamic or interval ST- or T-wave changes in ≥ 2 contiguous electrocardiographic leads (≥ 0.1 mV ST elevation, ≥ 0.05 mV flat or downsloping ST depression at the J point and 80 ms after the J point, or ≥ 0.3 mV T-wave inversion), or new left bundle branch block; serum total cholesterol levels were required to be 180 to 240 mg/dL on admission </inclusion>
<exclusion> < 18 years of age, use of lipid-lowering agents within the previous 3 months,known familial dyslipidemia, severe renal failure, known hepatic disease, signs and symptoms of severe heart failure (Killip’s class III or IV), a scheduled PCI or coronary artery bypass grafting (CABG), previous PCI (within 6 months) or CABG (within 3 months), and the presence of malignant disease or allergy to statins</exclusion>
</doc>
<doc>
<label>Shal’nev 2007</label>
<inclusion> patients with acute coronary syndrome (myocardial infarction or unstable angina)</inclusion>
</doc>
<doc>
<label>B31</label>
<inclusion> complete resection of the primary tumour and axillary-node dissection. Adequate hematopoietic, hepatic and renal function, LVEF that met or exceeded the lower limit of normal. Tumours had to be strongly HER2-positive (immunohistochemistry score of 3+, or positive by FISH); positivity must have been confirmed at central or reference laboratories . </inclusion>
<exclusion> clinical or radiological evidence of metastatic disease, angina pectoris requiring antianginal medication, arrhythmia requiring medication, severe conduction abnormality, clinically significant valvular disease, cardiomegaly on chest radiography, left ventricular hypertrophy on echocardiography, poorly controlled hypertension, history of myocardial infarction, CHF, cardiomyopathy Note: 15% of patients had a tumour diameter larger than 4 cm; 14% had more than 10 nodes affected by the disease HER2-positive: 100%</exclusion>
</doc>
<doc>
<label>BCIRG006</label>
<inclusion> definitive surgery of the breast cancer (either mastectomy with axillary lymph node involvement assessment, or breast conserving surgery with axillary lymph node involvement assessment); Karnofsky Performance status index > 80%; normal cardiac, hepatic and renal function, normal values of the haemochrome; negative pregnancy test; normal audiology assessment . </inclusion>
<exclusion> prior systemic anti-cancer therapy or radiation therapy for breast cancer or prior anthracycline therapy, for any malignancy; bilateral invasive breast cancer; pregnancy; pre-existing motor or sensory neurotoxicity; any T4 or N2 or known N3 or M1 breast cancer; cardiac diseases; other serious illness or medical condition (neurologic or psychiatric disorders, dementia or seizures, uncontrolled infection, active peptic ulcer, unstable diabetes mellitus, impaired hearing); past or current history of neoplasm other than breast carcinoma (except for: curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix, other cancer curatively treated and with no evidence of disease for at least 10 years); current therapy with any hormonal agent such as Raloxifene, Tamoxifen, or other selective ER modulators, with corticosteroids, with ovarian hormonal replacement therapy; definite contraindications for the use of corticosteroids; and concurrent treatment with other experimental drugs or with any other anti-cancer therapy Note: 6% of patients had a tumour diameter larger than 5 cm; 9% had more than 10 nodes affected by the disease HER2-positive: 100%</exclusion>
</doc>
<doc>
<label>Buzdar</label>
<inclusion> adequate bone marrow, liver and renal function. Each patient was reviewed in a multidisciplinary conference with designation of whether breast conservation was a reasonable surgical option before treatment was initiated. HER2- positivity had to be proven by an immunohistochemistry score 3 or FISH . </inclusion>
<exclusion> history of uncompensated CHF or a cardiac ejection fraction less than 45% Note: 93% (one patient had a IIIb stage disease; two patients had a bilateral breast cancer) HER2-positive: all tumours were HER2-positive by FISH or showed 3+ overexpression by immunohistochemistry</exclusion>
</doc>
<doc>
<label>FinHer</label>
<inclusion> less than 66 years of age, WHO performance status of 0 or 1, prior breast surgery with axillary-node dissection or sentinel-node biopsy for invasive breast cancer, and a negative test for PRs. HER2-positive for randomisation to receive or not receive trastuzumab . </inclusion>
<exclusion> distant metastases, pregnancy, severe hypertension, cardiac diseases, abnormal laboratory values for hepatic function, abnormal haemochrome values Note: 55% had a tumour diameter larger than two cms; 26% had more than three nodes affected by the disease HER2-positive: 100% among the patients randomised to receive or not receive trastuzumab</exclusion>
</doc>
<doc>
<label>HERA</label>
<inclusion> complete excision of the cancer and HER2 over expression or HER2 amplification (immunohistochemistry score 3 or FISH positive) assessed in the participating institution and verified in the central laboratory of the trial. Patient must have received at least four cycles of an approved (neo-) adjuvant chemotherapy regimen. In all cases, the maximum cumulative allowable dose of Doxorubicin was 360 mg/m2 and of Epirubicin was 720 mg/m2. Adequate baseline hepatic, renal, and bone marrow function and use of adequate nonhormone-based contraceptive measures, if indicated, were required . </inclusion>
<exclusion> distant metastases; previous invasive breast carcinoma; neoplasm not involving the breast (except for curatively treated basal-cell or squamous- cell carcinoma of the skin or in situ of the cervix); clinical stage T4 tumours including inflammatory breast cancer or involvement of supraclavicular nodes; suspicious internal mammary nodes (unless subjected to radiotherapy); prior mediastinal irradiation (except for internal mammary node irradiation for the present breast cancer); stem-cell support for chemotherapy; LVEF of less than 55% after completion of all chemotherapy and radiotherapy; history of documented CHF; coronary artery disease with previous Q-wave myocardial infarction, angina pectoris requiring medication, uncontrolled hypertension, clinically significant valvular disease, unstable arrhythmias Note: 5% of patients had a tumour diameter larger than 5 cm; 28% had more than four nodes affected by the disease HER2-positive: 100%</exclusion>
</doc>
<doc>
<label>N9831</label>
<inclusion> complete resection of the primary tumour and axillary-node dissection; adequate hematopoietic, hepatic and renal function. LVEF that met or exceeded the lower limit of normal. Tumours had to be strongly HER2-positive; HER2-positivity had to be confirmed at central or reference laboratories . </inclusion>
<exclusion> clinical or radiological evidence of metastatic disease, angina pectoris requiring anti-anginal medication, arrhythmia requiring medication, severe conduction abnormality, clinically significant valvular disease, cardiomegaly on chest radiography, poorly controlled hypertension, clinically significant pericardial effusion, history of myocardial infarction, CHF, cardiomyopathy Note: 13% of patients had a tumour diameter larger than 4 cm; 13% had more than ten nodes affected by the disease HER2-positive: 100%</exclusion>
</doc>
<doc>
<label>NOAH</label>
<inclusion> all patients had to have tumour hormone-receptors assessed and to have at least one measurable lesion according to response evaluation criteria in solid tumours (with a minimum indicator lesion size of 20 mm when measured by palpation) or inflammatory carcinoma, adequate hematopoietic, hepatic and renal function, an Eastern Cooperative Oncology Group performance status 1 or lower, and a LVEF of 55% or higher; women of childbearing potential had to use contraception. Tumours had to be HER2-positive (defined as 3+ over expression by immunohistochemical testing or HER2 amplification by fluorescent in-situ hybridisation according to a central laboratory . </inclusion>
<exclusion> bilateral breast cancer; metastases (other than in ipsilateral supraclavicular nodes); previous treatment for invasive malignant disease; previous or concurrent malignant disease other than basal-cell carcinoma of the skin or in-situ cervical cancer; pregnancy or lactation; use of other investigational drugs within the past 30 days; other serious illness or medical disorders including cardiac failure (New York Heart Association class II or higher) Note: all included patients with locally advanced breast cancer HER2-positive: 100%</exclusion>
</doc>
<doc>
<label>PACS-04</label>
<inclusion> age between 18 and 65 years, breast cancer completely surgically removed, at least four weeks since prior chemotherapy, normally blood tests, normal lung functions, LVEF above 55% or between 50% and 55% if approved by cardiologists, normal blood tests . </inclusion>
<exclusion> women with T4 or greater disease, clinically or radiologically suspected metastases, deeply adherent or inflammatory disease, clinically or radiologically suspected contralateral lesion, prior breast cancer, LVEF of less than 50%, clinical signs of CHF Note: 54% had a tumour diameter larger than 2 cm; 42% had more than four nodes affected by the disease HER2-positive: 100%</exclusion>
</doc>
<doc>
<label>ANHMRC 1989 (P)</label>
</doc>
<doc>
<label>ANHMRC 1989 (X)</label>
</doc>
<doc>
<label>Benetos 1992</label>
</doc>
<doc>
<label>Cappuccio 1997 (H)</label>
</doc>
<doc>
<label>Cappuccio 1997 (N)</label>
</doc>
<doc>
<label>Chalmers 1986</label>
</doc>
<doc>
<label>Cobiac 1992</label>
</doc>
<doc>
<label>Erwteman 1984</label>
</doc>
<doc>
<label>Fotherby 1993</label>
</doc>
<doc>
<label>Gates 2004</label>
</doc>
<doc>
<label>Grobbee 1987</label>
</doc>
<doc>
<label>MacGregor 1982</label>
</doc>
<doc>
<label>MacGregor 1989</label>
</doc>
<doc>
<label>Mascioli 1991</label>
</doc>
<doc>
<label>Meland 1997</label>
</doc>
<doc>
<label>Morgan 1981 (F)</label>
</doc>
<doc>
<label>Morgan 1981 (M)</label>
</doc>
<doc>
<label>Nestel 1993 (F)</label>
</doc>
<doc>
<label>Nestel 1993 (M)</label>
</doc>
<doc>
<label>Parijs 1973</label>
</doc>
<doc>
<label>Puska 1983 (H)</label>
</doc>
<doc>
<label>Puska 1983 (N)</label>
</doc>
<doc>
<label>Richards 1984</label>
</doc>
<doc>
<label>Ruppert 1993</label>
</doc>
<doc>
<label>Sacks 2001 (H)</label>
</doc>
<doc>
<label>Sacks 2001 (N)</label>
</doc>
<doc>
<label>Schorr 1996</label>
</doc>
<doc>
<label>Silman 1983</label>
</doc>
<doc>
<label>Swift 2005</label>
</doc>
<doc>
<label>TOHPRG 1992</label>
</doc>
<doc>
<label>TOHPRG 1997</label>
</doc>
<doc>
<label>Watt 1983</label>
</doc>
<doc>
<label>Watt 1985 (HH)</label>
</doc>
<doc>
<label>Watt 1985 (LL)</label>
</doc>
<doc>
<label>AFFIRM Substudy 2003</label>
</doc>
<doc>
<label>AFIB 1997</label>
</doc>
<doc>
<label>Aliot 1996</label>
</doc>
<doc>
<label>ASAP 2003</label>
</doc>
<doc>
<label>Bellandi 2001</label>
</doc>
<doc>
<label>Benditt 1999</label>
</doc>
<doc>
<label>Byrne-Quinn 1970</label>
</doc>
<doc>
<label>Carunchio 1995</label>
</doc>
<doc>
<label>Channer 2004</label>
</doc>
<doc>
<label>DAFNE 2003</label>
</doc>
<doc>
<label>DIAMOND 2001</label>
</doc>
<doc>
<label>Dogan 2004</label>
</doc>
<doc>
<label>EURIDIS ADONIS 2004</label>
</doc>
<doc>
<label>FAPIS 1996</label>
</doc>
<doc>
<label>GEFACA 2001</label>
</doc>
<doc>
<label>Hillestad 1971</label>
</doc>
<doc>
<label>Hohnloser 1995</label>
</doc>
<doc>
<label>Juul-Moller 1990</label>
</doc>
<doc>
<label>Kalusche 1994</label>
</doc>
<doc>
<label>Karlson 1998</label>
</doc>
<doc>
<label>Kochiadakis 2000</label>
</doc>
<doc>
<label>Kochiadakis 2004a</label>
</doc>
<doc>
<label>Kochiadakis 2004b</label>
</doc>
<doc>
<label>Kuhlkamp 2000</label>
</doc>
<doc>
<label>Lloyd 1984</label>
</doc>
<doc>
<label>Naccarelli 1996</label>
</doc>
<doc>
<label>Okishige 2000</label>
</doc>
<doc>
<label>PAFAC 2004</label>
</doc>
<doc>
<label>Plewan 2001</label>
</doc>
<doc>
<label>PRODIS 1996</label>
</doc>
<doc>
<label>RAFT 2003</label>
</doc>
<doc>
<label>Reimold 1993</label>
</doc>
<doc>
<label>Richiardi 1992</label>
</doc>
<doc>
<label>SAFE-T 2005</label>
</doc>
<doc>
<label>SAFIRE-D 2000</label>
</doc>
<doc>
<label>Singh 1991</label>
</doc>
<doc>
<label>SMART 2002</label>
</doc>
<doc>
<label>SOCESP 1999</label>
</doc>
<doc>
<label>Sodermark 1975</label>
</doc>
<doc>
<label>SOPAT 2004</label>
</doc>
<doc>
<label>Steinbeck 1988</label>
</doc>
<doc>
<label>Stroobandt 1997</label>
</doc>
<doc>
<label>Van Gelder 1989</label>
</doc>
<doc>
<label>Villani 1992</label>
</doc>
<doc>
<label>Vitolo 1981</label>
</doc>
<doc>
<label>Baltzan 2000</label>
<inclusion> not mentioned </inclusion>
<exclusion> not mentioned</exclusion>
</doc>
<doc>
<label>Bauldoff 2000</label>
<inclusion> not mentioned </inclusion>
<exclusion> not mentioned</exclusion>
</doc>
<doc>
<label>Bauldoff 2002</label>
<inclusion> COPD diagnosis, FEV1 < 50% predicted; 40 to 85 years; speak, read, write English; ability to hear music; completion of pulmonary rehabilitation programmes; time since completion PRP: less or 6 months prior to study entry </inclusion>
<exclusion> unstable cardiac disease; musculoskeletal disability; inability to walk indepen- dently due to disease advancement; diagnosis of deafness</exclusion>
</doc>
<doc>
<label>Bauldoff 2005</label>
<inclusion> diagnosis of COPD and FEV1/FVC < 70%; prior enrollment in pulmonary rehabilitation programme, ability to read, write, speak English; willingness/ability to perform arm exercise </inclusion>
<exclusion> unstable cardiac disease; musculoskeletal disability preventing arm exercise; cognitive impairment limiting completion of questionnaires; untreated deafness precluding use of walk- man-type devices</exclusion>
</doc>
<doc>
<label>Bourjeily-Habr 2002</label>
<inclusion> forced expiratory volume in 1 second (FEV1) <65% of predicted value with an FEV1 to forced vital capacity (FVC) ratio of < 70%, hyperinflation based on residual volume/total lung capacity (RV/TLC) ratio > 40%, and reduced lung transfer factor; age < 70 years; self-reported exercise limitation despite pharmacological treatment; were otherwise medically stable </inclusion>
<exclusion> history of cardiovascular and neuromuscular disease, active or debilitating joint disease; formal pulmonary rehabilitation within 2 years of the date of inclusion into the study</exclusion>
</doc>
<doc>
<label>Bredin 1999</label>
<inclusion> Patients diagnosed with SCLC, NSCLC or mesothelioma who had completed treatment and reported breathlessness; shortness of breath defined as a reported change in breathing or degree of breathlessness as perceived by the patient and reported as a problem</inclusion>
</doc>
<doc>
<label>Brooks 2003</label>
<inclusion> diagnosis of COPD; can speak and read English; can ambulate independently; reported experiencing dyspnea once a week; showed an increase in the level of perceived dyspnea after a 6 minute walk</inclusion>
</doc>
<doc>
<label>Corner 1996</label>
<inclusion> Patients with small cell and non-small cell lung cancer who had completed chemotherapy or radiotherapy and were suffering from breathlessness</inclusion>
</doc>
<doc>
<label>Crisafulli 2007</label>
<inclusion> LTOT for at least 6 months before enrollment; stable condition with no evidence of acute exacerbation or change in medication in the previous 4 months; diagnosis of COPD according to GOLD criteria</inclusion>
</doc>
<doc>
<label>Cristiano 1997</label>
<exclusion> evidence of restrictive lung disease by history or pulmonary function testing; history of heart disease; signs of active pulmonary infection</exclusion>
</doc>
<doc>
<label>Dalton 1995</label>
</doc>
<doc>
<label>Egan 2002</label>
<inclusion> aged 18 years or older; history of chronic bronchitis (with infection), emphy- sema, chronic airway obstruction, chronic asthma, or a combination of these; forced Expiratory Volume (FEV1) on admission prior to initializing intravenous medications to determine severity of disease; cog- nitive function at time of entry to the study was adequate to understand and complete a questionnaire; admission to a respiratory unit bed within 72 hours of admission to hospital, informed consent was ob- tained in writing</inclusion>
</doc>
<doc>
<label>Eiser 1997</label>
<inclusion> severe but stable COPD; HADS anxiety scores > = 8 </inclusion>
<exclusion> chest infection within 1 month of the start of the study</exclusion>
</doc>
<doc>
<label>Fujie 2002</label>
<inclusion> COPD; stable disease </inclusion>
<exclusion> not explicitly stated as exclusion criteria but as “patients did not have”: history of heart disease; symptoms of active pulmonary infection; involvement in pulmonary rehabilitation programme</exclusion>
</doc>
<doc>
<label>Galbraith 2007</label>
<inclusion> stable chronic breathlessness from any cause; dyspnoea > 2 on dyspnoea exertion scale </inclusion>
<exclusion> oxygen dependant; anaemia; fever; unable to use VAS or fan; treatment changes in previous 48 h</exclusion>
</doc>
<doc>
<label>Garrod 2005</label>
</doc>
<doc>
<label>Gift 1992</label>
<inclusion> COPD; not confounded with other medical diagnoses; patients having dys- pnea; ability to read and understand English; willing to participate and signing a consent form</inclusion>
</doc>
<doc>
<label>Goodyer 1995</label>
<inclusion> age over 70 years, chronic stable heart failure; no alteration of medication; responsible for administering their own medication; not regularly supervised by friends; relatives or a district nurse </inclusion>
<exclusion> Folstein’s Mental test less than 21; severe mobility disorder due to Parkinson’s disease; arthritis or hemiparesis; heart condition not primary cause of shortness of breath or exercise tolerance</exclusion>
</doc>
<doc>
<label>Gupta 2006a</label>
<inclusion> clinical stability; moderate to severe COPD; no previously prescribed walking aid; unaided 6MW < 375 m; completed pulmonary rehabilitation programme</inclusion>
</doc>
<doc>
<label>Gupta 2006b</label>
<inclusion> clinically stable, diagnosis of moderate-to-severe COPD according to Amer- ican Thoracic Society criteria, completed pulmonary rehabilitation in the last year, not had previous rol- lator use, unassisted 6MW distance <375 m </inclusion>
<exclusion> associated medical conditions that limited exercise tolerance, inability to communicate</exclusion>
</doc>
<doc>
<label>Hermiz 2002</label>
<inclusion> COPD; age 30 - 80; attendance of hospital emergency department or were admitted to hospital with COPD </inclusion>
<exclusion> residence outside the region; insufficient English speaking skills; resident in nursing home; confused or demented</exclusion>
</doc>
<doc>
<label>Hochstetter 2005</label>
</doc>
<doc>
<label>Honeyman 1996</label>
<inclusion> 6- minute walking distance less than 300 metres </inclusion>
<exclusion> ambulation limited by angina; claudication or arthritis rather than breath- lessness</exclusion>
</doc>
<doc>
<label>Jobst 1986</label>
<inclusion> COPD with disabling breathlessness for at least 5 years; severely limiting exercise tolerance and compromising performance of activities of normal living (washing, shaving, dressing) </inclusion>
<exclusion> one patient excluded as medication was changed during intervention period</exclusion>
</doc>
<doc>
<label>Ketelaars 1998</label>
<inclusion> diagnosis of COPD according to American Thoracic Society (ATS) guidelines; being 40 to 80 years of age; not receiving help with activities of daily living from health care professionals- </inclusion>
<exclusion> other severely disabling illnesses unrelated to respiratory illness, such as car- diovascular, neurologic, and locomotor diseases; patients not discharged to their home</exclusion>
</doc>
<doc>
<label>Lange 2006</label>
<inclusion> ALS with respiratory symptoms (ALSFRS-RS score = < 11); not participating in any other trial </inclusion>
<exclusion> ALSFRS-RS score = < 5; previous use of HFCWO; FVC < 40% expected; prior or present tracheostomy; use of a cough assist device; congestive heart failure or other contraindications for HFCWO (unstable neck injury, hemodynamic instability)</exclusion>
</doc>
<doc>
<label>Lewith 2004</label>
<inclusion> COPD; cystic fibrosis; pulmonary fibrosis; breathlessness > 60 mm VAS </inclusion>
<exclusion> known clotting disorder; on anticoagulants; pregnancy WITHDRAWAL CRITERIA: if they desired; interference with routine medical management; acute respiratory infection; commenced treatment with steroids</exclusion>
</doc>
<doc>
<label>Louie 2004</label>
<inclusion> symptoms of dyspnoea, no prior experience of guided imagery relaxation training</inclusion>
</doc>
<doc>
<label>Maa 1997</label>
<inclusion> 19 years or older, COPD, beginning a 12-week pulmonary rehabilitation programme, able to speak English, learn to self-administer acupressure or have a caretaker willing to learn to administer acupressure</inclusion>
</doc>
<doc>
<label>McMillan 2007</label>
<inclusion> diagnosis of cancer, identified family caregiver, both had to consent, patients and caregivers at least sixth-grade education and be able to read and understand English, minimum score of 7 on Short Portable Mental Status Questionnaire, Palliative Performance Scale min. 40 </inclusion>
<exclusion> if not two of the symptoms pain, dyspnoea, constipation as documented by baseline data collection</exclusion>
</doc>
<doc>
<label>Moore 2002</label>
<inclusion> Patients with lung cancer who had completed their initial anticancer treatment and were expected to survive for at least three months were invited to participate </inclusion>
<exclusion> ineligible, if they were receiving cancer treatment, were having close medical supervision or had a poor prognosis or performance status</exclusion>
</doc>
<doc>
<label>Nakayama 1998</label>
<inclusion> not mentioned </inclusion>
<exclusion> not mentioned</exclusion>
</doc>
<doc>
<label>Neder 2002</label>
<inclusion> absence of associated locomotor or neurological conditions; disease stability as indicated by no change in medication dosage or exacerbation of symptoms in the preceding 4 weeks</inclusion>
</doc>
<doc>
<label>Pfister 1998</label>
<inclusion> clinical diagnosis of mild to severe COPD, confirmed by history, physical examination and spirometry (emphysema, chronic bronchitis, asthmatic bronchitis); attending pulmonary rehabilitation at least 1 month and exercising regularly on the treadmill </inclusion>
<exclusion> restrictive lung disease</exclusion>
</doc>
<doc>
<label>Probst 2004</label>
<inclusion> no locomotory, neurologic condition or disability limiting the ability to walk; no need for oxygen supplementation during the 6 MWT; familiarity with the 6 MWT; naivety to the use of walking aids</inclusion>
</doc>
<doc>
<label>Rabow 2004</label>
<inclusion> diagnosis of advanced cancer, advanced COPD or advanced CHF; believed life expectancy of 1 to 5 years not yet ready for hospice care </inclusion>
<exclusion> nonmelanoma skin cancer, dementia, psychosis, enrolled in hospice care, unable to complete a written survey in English or Spanish</exclusion>
</doc>
<doc>
<label>Rea 2004</label>
<inclusion> COPD by ICD-9-CM codes and GP records for clinical diagnoses of moderate to severe COPD EXCLUSION CRITERIA: Chronic asthma; bronchiectasis; comorbidity more significant than COPD; unable to give informed consent; prognosis < 12 months; LTOT or too unwell; GP practice </inclusion>
<exclusion> no longer enrolled with participating GP practice or moved out of area; unable to contact patient, insufficient PN resource</exclusion>
</doc>
<doc>
<label>Renfroe 1988</label>
<inclusion> diagnosis of bronchial asthma, chronic bronchitis, emphysema or all of these; dyspnoea on exertion; absence of serious medical problems other than COPD; absence of acute disorders at this time (such as pneumonia or urinary tract infection)</inclusion>
</doc>
<doc>
<label>Rosser 1983</label>
<inclusion> dyspnoea due to COPD </inclusion>
<exclusion> presence of another severe illness or a cause of dyspnoea other than COAD; living too far away to take part in the study; inability to understand English; dementia detected clinically or by screening questionnaire; other conditions which were a contradiction to psychotherapy</exclusion>
</doc>
<doc>
<label>Sibuya 1994</label>
<inclusion> not mentioned </inclusion>
<exclusion> not mentioned</exclusion>
</doc>
<doc>
<label>Sidani 2004</label>
<inclusion> confirmed medical diagnosis of COPD, speak and read English, reported experiencing dyspnoea at least once a week, demonstrated an increase in the level of perceived dyspnoea of at last 2 points on the Borg scale following a 6 minutes walk test</inclusion>
</doc>
<doc>
<label>Solway 2002</label>
<inclusion> COPD; clinically stable; between 55 and 85 y; unaccustomed of a walking aid </inclusion>
<exclusion> presence of associated medical conditions that limited exercise tolerance; inability to communicate English</exclusion>
</doc>
<doc>
<label>Vickers 2005</label>
<inclusion> age > 18; subjective complaint of shortness of breath and ATS Breathlessness Scale > 2; steroid medication min. 48 h pursued </inclusion>
<exclusion> shortness of breath predated cancer diagnosis; recent onset of symptoms (< 7 d); anemia; recent acupuncture; contraindications to acupuncture; planned initiation or change in oncologic therapy or symptomatic management of breathlessness; likelihood of patients death during trial period; primary cause of dyspnoea: CHF, sarcoid disease, hypersensitivity pneumonitis, pneumothorax, chest wall deformity, obesity, neuromuscular disorder, pulmonary vascular disease, hepatomegaly, phrenic nerve paralysis. If primary cause of dyspnoea was ascites, effusion, pneumonia, large airways obstruction, supra vena cava obstruction or pulmonary embolism, patients only eligible, if shortness of breath despite conventional therapy</exclusion>
</doc>
<doc>
<label>Vivodtzev 2006</label>
<inclusion> severe bronchial obstruction (i.e., COPD and/or bronchiectasis) but no ev- idence of cardiovascular, renal, or hepatic diseases; FEV1 < 50% pred. with an FEV1/FVC ratio of < 70%; disability and malnutrition as established by a BMI of < 22 kg/m2; quadriceps muscle atrophy (i. e., isometric maximal voluntary contraction of < 50% predicted); inability to perform cycle exercise or extremely limited (i.e., <3 to 5 min) exercise tolerance at the lowest workloads (i.e., < 20 W); the ability to perform experimental maneuvers; all patients were recruited after a sojourn in an ICU and/or after an acute exacerbation that required hospitalization, while they were subsequently admitted for 1 month as inpatients in the pulmonary rehabilitation center; no acute respiratory failure at the time of the study; a signed informed consent form</inclusion>
</doc>
<doc>
<label>Wu 2004</label>
<inclusion> COPD; steroids < 10 mg daily; able to walk unassisted; no health problems affecting the progress of COPD; no hospitalisation within last 2 months; no pulmonary rehab within last 6 months; speak Taiwanese or Chinese</inclusion>
</doc>
<doc>
<label>Wu 2006</label>
<inclusion> diagnoses of COPD, stable disease, no acute exacerbation</inclusion>
</doc>
<doc>
<label>Yu 2007</label>
<inclusion> to be aged 60 years or older; to be able to communicate; intact cognitive function as indicated by an Abbreviated Mental Test score of 6/10 or higher; to be discharged home </inclusion>
<exclusion> preexisting psychiatric diagnosis; current use of psychotic medications; prior training or current use of relaxation therapy; pre scheduled cardiac surgery within 6 months of hospital discharge</exclusion>
</doc>
<doc>
<label>Batist 2001</label>
</doc>
<doc>
<label>Brambilla 1986</label>
</doc>
<doc>
<label>Chan 2004</label>
</doc>
<doc>
<label>FESG 1988</label>
</doc>
<doc>
<label>Gasparini 1991</label>
</doc>
<doc>
<label>Harris 2002</label>
</doc>
<doc>
<label>IMBSWE 1988</label>
</doc>
<doc>
<label>Mouridsen 1984</label>
</doc>
<doc>
<label>Adam 1982</label>
</doc>
<doc>
<label>Bauer 1994</label>
</doc>
<doc>
<label>Benson 1978</label>
</doc>
<doc>
<label>Butland 1983</label>
</doc>
<doc>
<label>Chatterjee 1986</label>
</doc>
<doc>
<label>Chodosh 1988</label>
</doc>
<doc>
<label>Dorow 1986c</label>
</doc>
<doc>
<label>Doshan 1986a</label>
</doc>
<doc>
<label>Doshan 1986b</label>
</doc>
<doc>
<label>Ellis 1981</label>
</doc>
<doc>
<label>Falliers 1986</label>
</doc>
<doc>
<label>Fenster 1983</label>
</doc>
<doc>
<label>Fogari 1990</label>
</doc>
<doc>
<label>Greefhorst 1984</label>
</doc>
<doc>
<label>Johnsson 1975</label>
</doc>
<doc>
<label>Lammers 1984</label>
</doc>
<doc>
<label>Lammers 1985a</label>
</doc>
<doc>
<label>Lammers 1986a</label>
</doc>
<doc>
<label>Lammers 1988</label>
</doc>
<doc>
<label>Lawrence 1982</label>
</doc>
<doc>
<label>Lofdahl 1981</label>
</doc>
<doc>
<label>Nicolaescu 1973</label>
</doc>
<doc>
<label>Nicolescu 1972</label>
</doc>
<doc>
<label>Ruffin 1979</label>
</doc>
<doc>
<label>Skinner 1975b</label>
</doc>
<doc>
<label>Tantucci 1990</label>
</doc>
<doc>
<label>van den Bergh 1981</label>
</doc>
<doc>
<label>van Zyl 1989</label>
</doc>
<doc>
<label>A-COMET-I 2006</label>
</doc>
<doc>
<label>A-COMET-II 2006</label>
</doc>
<doc>
<label>A-STAR 2006</label>
</doc>
<doc>
<label>AFFIRM Substudy 2003</label>
</doc>
<doc>
<label>AFIB 1997</label>
</doc>
<doc>
<label>Aliot 1996</label>
</doc>
<doc>
<label>ASAP 2003</label>
</doc>
<doc>
<label>ATHENA 2009</label>
</doc>
<doc>
<label>Bellandi 2001</label>
</doc>
<doc>
<label>Benditt 1999</label>
</doc>
<doc>
<label>Byrne-Quinn 1970</label>
</doc>
<doc>
<label>Carunchio 1995</label>
</doc>
<doc>
<label>Channer 2004</label>
</doc>
<doc>
<label>DAFNE 2003</label>
</doc>
<doc>
<label>DAPHNE 2008</label>
</doc>
<doc>
<label>DIAMOND 2001</label>
</doc>
<doc>
<label>Dogan 2004</label>
</doc>
<doc>
<label>DYONISOS 2010</label>
</doc>
<doc>
<label>EMERALD 2000</label>
</doc>
<doc>
<label>EURIDIS ADONIS 2007</label>
</doc>
<doc>
<label>FAPIS 1996</label>
</doc>
<doc>
<label>Flec-SL 2012</label>
</doc>
<doc>
<label>GEFACA 2001</label>
</doc>
<doc>
<label>Hillestad 1971</label>
</doc>
<doc>
<label>Hohnloser 1995</label>
</doc>
<doc>
<label>Juul-Moller 1990</label>
</doc>
<doc>
<label>Kalusche 1994</label>
</doc>
<doc>
<label>Karlson 1998</label>
</doc>
<doc>
<label>Kochiadakis 2000</label>
</doc>
<doc>
<label>Kochiadakis 2004a</label>
</doc>
<doc>
<label>Kochiadakis 2004b</label>
</doc>
<doc>
<label>Kuhlkamp 2000</label>
</doc>
<doc>
<label>Lloyd 1984</label>
</doc>
<doc>
<label>Naccarelli 1996</label>
</doc>
<doc>
<label>Nergardh 2007</label>
</doc>
<doc>
<label>Niu 2006</label>
</doc>
<doc>
<label>Okishige 2000</label>
</doc>
<doc>
<label>PAFAC 2004</label>
</doc>
<doc>
<label>PITAGORA 2008</label>
</doc>
<doc>
<label>Plewan 2001</label>
</doc>
<doc>
<label>PRODIS 1996</label>
</doc>
<doc>
<label>RAFT 2003</label>
</doc>
<doc>
<label>Reimold 1993</label>
</doc>
<doc>
<label>Richiardi 1992</label>
</doc>
<doc>
<label>SAFE-T 2005</label>
</doc>
<doc>
<label>SAFIRE-D 2000</label>
</doc>
<doc>
<label>Santas 2012</label>
</doc>
<doc>
<label>Singh 1991</label>
</doc>
<doc>
<label>SMART 2002</label>
</doc>
<doc>
<label>SOCESP 1999</label>
</doc>
<doc>
<label>Sodermark 1975</label>
</doc>
<doc>
<label>SOPAT 2004</label>
</doc>
<doc>
<label>Steinbeck 1988</label>
</doc>
<doc>
<label>Stroobandt 1997</label>
</doc>
<doc>
<label>SVA-4 2008</label>
</doc>
<doc>
<label>Van Gelder 1989</label>
</doc>
<doc>
<label>Vijayalaskshmi 2006</label>
</doc>
<doc>
<label>Villani 1992</label>
</doc>
<doc>
<label>Vitolo 1981</label>
</doc>
<doc>
<label>Aaser 1997</label>
</doc>
<doc>
<label>Bagatin 1993</label>
</doc>
<doc>
<label>Dormans 1996</label>
</doc>
<doc>
<label>Kramer 1996</label>
</doc>
<doc>
<label>Lahav 1992</label>
</doc>
<doc>
<label>Licata 2003</label>
</doc>
<doc>
<label>Pivac 1998</label>
</doc>
<doc>
<label>Schuller 1997</label>
</doc>
<doc>
<label>Anderson 1950</label>
</doc>
<doc>
<label>Griffith 1952</label>
</doc>
<doc>
<label>Harvey 1950</label>
</doc>
<doc>
<label>HELAS 2006</label>
</doc>
<doc>
<label>WASH 2004</label>
</doc>
<doc>
<label>Ding 2004</label>
</doc>
<doc>
<label>Wang 2006</label>
</doc>
<doc>
<label>ABCD-2V 2006</label>
</doc>
<doc>
<label>ABCD-H 1998</label>
</doc>
<doc>
<label>ABCD-N 2002</label>
</doc>
<doc>
<label>ACCORD BP 2010</label>
</doc>
<doc>
<label>HOT 1998</label>
</doc>
<doc>
<label>HELAS 2006</label>
</doc>
<doc>
<label>WASH 2004</label>
</doc>
<doc>
<label>WATCH 2009</label>
</doc>
<doc>
<label>Arbane 2011</label>
</doc>
<doc>
<label>Brocki 2010</label>
</doc>
<doc>
<label>Stigt 2013</label>
</doc>
<doc>
<label>CHAOS 2002</label>
</doc>
<doc>
<label>FOLARDA 2004</label>
</doc>
<doc>
<label>GOES 2003</label>
<inclusion> Myocardial infarction, Coronary artery lesions (>60%) on coronary angiography, Percutaneous coronary intervention (PCI), Coronary artery bypass graft surgery (CABG), Patients had to be stable, with no invasive vascular procedures scheduled, Statin therapy for at least three months, Taking any form of vitamin B-containing medication, regularly or sporadic </inclusion>
<exclusion> Age < 18 years, History of low vitamin B12 levels, Therapy for hyperhomocysteinemia, Severe renal failure, or any other treatment for renal disease, Hepatic disease, Severe heart failure (New York Heart Association functional class IV), Serious illness that would exclude follow-up time of at least three years</exclusion>
</doc>
<doc>
<label>HOPE-2 2006</label>
<inclusion> Men and women aged >55 years, Hstory of vascular disease (coronary, cerebrovascular, or peripheral vascular) or diabetes and additional risk factors for atherosclerosis, Irrespective of their homocysteine levels, from countries with mandatory folate fortifi- cation of food (Canada and the United States) and countries without mandatory folate fortification (Brazil, western Europe, and Slovakia) </inclusion>
<exclusion> Patients taking vitamin supplements containing more than 0.2 mg of folic acid per day</exclusion>
</doc>
<doc>
<label>NORVIT 2006</label>
<inclusion> Men and women aged 30 to 85 years, History of acute myocardial infarction within seven days before randomisation </inclusion>
<exclusion> Coexisting disease associated with a life expectancy < 4 years, Prescribed treatment with B vitamins or untreated vitamin B deficiency, Inability to follow the protocol, as judged by the investigator</exclusion>
</doc>
<doc>
<label>VISP 2004</label>
<inclusion> Nondisabling ischemic stroke(Modified Rankin Stroke Scale 3): Onset 120 days before randomization. Focal neurological deficit of likely atherothrombotic origin, classified as ischemic stroke by questionnaire/algorithm or confirmed as new cerebral infarction consistent with symptoms by cranial computed tomography or brain magnetic resonance imaging, Total homocysteine level 25th percentile for North American stroke population, Age: ≥ 35 years, Accessibility for follow-up, Agreement to take study medication and not take other multivitamins or pills containing folic acid or vitamin B6, Written informed consent. </inclusion>
<exclusion> Potential sources of emboli (atrial fibrillation within 30 days of stroke, prosthetic cardiac valve, intracardiac thrombus or neoplasm, or valvular vegetation), Other major neurological illness that would obscure evaluation of recurrent stroke, Life expectancy 2 years, Renal failure requiring dialysis, Untreated anemia or untreated vitamin B12 deficiency, Systolic blood pressure 185 mm Hg or diastolic blood pressure 105 mm Hg on 2 readings 5 minutes apart at time of eligibility determination, Refractory depression, severe cognitive impairment, or alcoholism or other substance abuse, Use within the last 30 days of medications that affect total homocysteine level (methotrex- ate, tamoxifen, levodopa, niacin, or phenytoin) or bile acid sequestrants that can decrease folate levels, Childbearing potential, Participation in another trial with active intervention, General anesthesia or hospital stay of 3 days, any type of invasive cardiac instrumentation, or endarterectomy, stent placement, thrombectomy, or any other endovascular treatment of carotid artery within 30 days prior to randomization or scheduled to be performed within 30 days after randomization</exclusion>
</doc>
<doc>
<label>WAFACS 2008</label>
</doc>
<doc>
<label>WENBIT 2008</label>
<inclusion> Age: 18 years or older, Undergoing coronary angiography for suspected CAD and/or aortic valve stenosis at the 2 university hospitals in western Norway </inclusion>
<exclusion> Unavailability for follow-up, Participation in other trials, Hisytory of alcohol abuse, serious mental illness, or cancer</exclusion>
</doc>
<doc>
<label>Batist 2001</label>
</doc>
<doc>
<label>Brambilla 1986</label>
</doc>
<doc>
<label>Chan 2004</label>
</doc>
<doc>
<label>FESG 1988</label>
</doc>
<doc>
<label>Gasparini 1991</label>
</doc>
<doc>
<label>Harris 2002</label>
</doc>
<doc>
<label>IMBSWE 1988</label>
</doc>
<doc>
<label>Mouridsen 1984</label>
</doc>
<doc>
<label>Christenson 1997a</label>
</doc>
<doc>
<label>Christenson 1997b</label>
</doc>
<doc>
<label>Christenson 1997c</label>
</doc>
<doc>
<label>Christenson 1999</label>
</doc>
<doc>
<label>Christenson 2003</label>
</doc>
<doc>
<label>Oberhoffer 2006</label>
</doc>
<doc>
<label>BVAIT 2009</label>
<inclusion> 1. Men and postmenopausal women 40 years old 2. Fasting tHcy 8.5 mol/L 3. No clinical signs/symptoms of cardiovascular disease (CVD) . </inclusion>
<exclusion> 1. Fasting triglycerides > 5.64 mmol/L (500 mg/dL) 2. Diabetes mellitus or fasting serum glucose > 6.99 mmol/L (126 mg/dL) 3. Systolic blood pressure ≥ 160 mm Hg and/or diastolic blood pressure ≥ 100 mm Hg 4. Untreated thyroid disease 5. Creatinine clearance < 70 mL/min 6. Life-threatening illness with prognosis 5 years 7. 5 alcoholic drinks daily</exclusion>
</doc>
<doc>
<label>CHAOS 2002</label>
</doc>
<doc>
<label>FOLARDA 2004</label>
</doc>
<doc>
<label>GOES 2003</label>
<inclusion> 1. Myocardial infarction 2. Coronary artery lesions (> 60%) on coronary angiography 3. Percutaneous coronary intervention 4. Coronary artery bypass graft surgery 5. Patients had to be stable, with no invasive vascular procedures scheduled 6. Statin therapy for at least 3 months 7. Taking any form of vitamin B-containing medication, regularly or sporadically . </inclusion>
<exclusion> 1. Age < 18 years 2. History of low vitamin B12 levels 3. Therapy for hyperhomocysteinaemia 4. Severe renal failure, or any other treatment for renal disease 5. Hepatic disease 6. Severe heart failure (New York Heart Association functional class IV) 7. Serious illness that would exclude follow-up time of at least 3 years</exclusion>
</doc>
<doc>
<label>HOPE-2 2006</label>
<inclusion> 1. Men and women aged > 55 years 2. History of vascular disease (coronary, cerebrovascular or peripheral vascular) or diabetes and additional risk factors for atherosclerosis, irrespective of their homocysteine levels, from countries with mandatory folate fortification of food (Canada and the United States) and countries without mandatory folate fortification (Brazil, western Europe and Slovakia) . </inclusion>
<exclusion> 1. Patients taking vitamin supplements containing more than 0.2 mg of folic acid per day</exclusion>
</doc>
<doc>
<label>NORVIT 2006</label>
<inclusion> 1. Men and women aged 30 to 85 years, 2. History of acute MI within 7 days before randomisation (Continued) . </inclusion>
<exclusion> 1. Coexisting disease associated with a life expectancy < 4 years 2. Prescribed treatment with B vitamins or untreated vitamin B deficiency 3. Inability to follow the protocol, as judged by the investigator</exclusion>
</doc>
<doc>
<label>SEARCH 2010</label>
<inclusion> 1. Men and women 2. Aged 18 to 80 years 3. History of myocardial infarction 4. Had no clear indication for folic acid 5. Blood cholesterol levels of at least 135 mg/dL if already taking a statin medication or 174 mg/dL if not (to convert cholesterol to mmol/L, multiply by 0.0259) . </inclusion>
<exclusion> 1. Chronic liver, renal or muscle disease 2. History of any cancer (except non-melanoma skin cancer) 3. Use of potentially interacting medications</exclusion>
</doc>
<doc>
<label>SU.FOL.OM3 2010</label>
<inclusion> 1. Men and women 2. Aged 45 to 80 years 3. History of acute coronary or cerebral ischaemic event within the 12 months before randomisation . </inclusion>
<exclusion> 1. Age (< 45 years or > 80 years) 2. Ill-defined diagnosis of cardiovascular disease 3. Inability or unwillingness to comply with study treatment 4. Disease or treatment that might interfere with metabolism of homocysteine or omega 3 fatty acids, in particular methotrexate for treating cancer or rheumatoid arthritis and chronic renal failure (plasma creatinine concentration > 200 mol/L or creatinine clearance < 40 mL/min) 5. Individuals with transient ischaemic attacks</exclusion>
</doc>
<doc>
<label>VISP 2004</label>
<inclusion> 1. Non-disabling ischaemic stroke (Modified Rankin Stroke Scale 3): onset 120 days before randomisation. Focal neurological deficit of likely atherothrombotic origin, classified as ischaemic stroke by questionnaire/algorithm or confirmed as new cerebral infarction consistent with symptoms by cranial computed tomography or brain magnetic resonance imaging (Continued) 2. Total homocysteine level 25th percentile for North American stroke population 3. Age: ≥ 35 years 4. Accessibility for follow-up 5. Agreement to take study medication and not take other multivitamins or pills containing folic acid or vitamin B6 6. Written informed consent . </inclusion>
<exclusion> 1. Potential sources of emboli (atrial fibrillation within 30 days of stroke, prosthetic cardiac valve, intracardiac thrombus or neoplasm, or valvular vegetation) 2. Other major neurological illness that would obscure evaluation of recurrent stroke 3. Life expectancy 2 years 4. Renal failure requiring dialysis 5. Untreated anaemia or untreated vitamin B12 deficiency 6. Systolic blood pressure 185 mm Hg or diastolic blood pressure 105 mm Hg on 2 readings 5 minutes apart at time of eligibility determination 7. Refractory depression, severe cognitive impairment, or alcoholism or other substance abuse 8. Use within the last 30 days of medications that affect total homocysteine level (methotrexate, tamoxifen, levodopa, niacin or phenytoin) or bile acid sequestrants that can decrease folate levels 9. Childbearing potential 10. Participation in another trial with active intervention 11. General anaesthesia or hospital stay of 3 days, any type of invasive cardiac instrumentation or endarterectomy, stent placement, thrombectomy or any other endovascular treatment of carotid artery within 30 days prior to randomisation or scheduled to be performed within 30 days after randomisation</exclusion>
</doc>
<doc>
<label>VITATOPS 2010</label>
<inclusion> 1. Stroke (ischaemic or haemorrhagic) or transient ischaemic attack (eye or brain), as defined by standard criteria, within the past 7 months 2. Patients with haemorrhagic stroke . </inclusion>
<exclusion> 1. Taking folic acid, vitamin B6, vitamin B12 or a folate antagonist (e.g. methotrexate) 2. Pregnant or women of childbearing potential 3. Patients with limited life expectancy (e.g. because of ill health)</exclusion>
</doc>
<doc>
<label>WAFACS 2008</label>
</doc>
<doc>
<label>WENBIT 2008</label>
<inclusion> 1. Age: 18 years or older 2. Undergoing coronary angiography for suspected coronary artery disease and/or aortic valve stenosis at the 2 university hospitals in western Norway . </inclusion>
<exclusion> 1. Unavailability for follow-up 2. Participation in other trials 3. History of alcohol abuse, serious mental illness or cancer</exclusion>
</doc>
<doc>
<label>Azeka 2002</label>
</doc>
<doc>
<label>Buchhorn 2001</label>
<inclusion> idiopathic DC; EF < 30%; listed for transplantation; 2 months of standard treatment insufficient </inclusion>
<exclusion> active myocarditis; sustained ventricular tachycardia or heart block not controlled by antiarrhythmic intervention or pacemaker; systemic arterial hypertension; progressive systemic diseases causing cardiomyopathy; clinically important hepatic or renal disease; hemodynamic instability with adrenergic agonist or antagonist treatment or ventilatory mechanical support Baseline severity of HF: NYHA Class IV (all patients) Co-diagnoses (extracardial): not specified</exclusion>
</doc>
<doc>
<label>Shaddy 2007</label>
<inclusion> congenital heart disease and severe heart failure due to left-to-right shunts; modified Ross score > 6 points despite digitalis and diuretic therapy </inclusion>
<exclusion> not specified Baseline severity of HF: modified Ross score (mean +/- SD): treatment arm: 8.3 +/- 1.9; control arm: 7.2 +/- 2.4 (after 1 week run-in on standard therapy) Co-diagnoses (extracardial): trisomy 21 (6 cases), duodenal stenosis (2) cheilog- nathopalatoschisis (1), tuberous sclerosis (1)</exclusion>
</doc>
<doc>
<label>AASK</label>
</doc>
<doc>
<label>ABCD (H)</label>
</doc>
<doc>
<label>ABCD (N)</label>
</doc>
<doc>
<label>HOT</label>
</doc>
<doc>
<label>MDRD</label>
</doc>
<doc>
<label>REIN-2</label>
</doc>
<doc>
<label>Toto</label>
</doc>
<doc>
<label>Arthur 2002</label>
</doc>
<doc>
<label>Bell 1998</label>
</doc>
<doc>
<label>Carlson 2000</label>
</doc>
<doc>
<label>Dalal 2007</label>
</doc>
<doc>
<label>Daskapan 2005</label>
</doc>
<doc>
<label>Gordon 2002 Community</label>
</doc>
<doc>
<label>Gordon 2002 Supervised</label>
</doc>
<doc>
<label>Jolly 2007</label>
</doc>
<doc>
<label>Kassaian 2000</label>
</doc>
<doc>
<label>Marchionni 2003</label>
</doc>
<doc>
<label>Miller 1984 Brief</label>
</doc>
<doc>
<label>Miller 1984 Expanded</label>
</doc>
<doc>
<label>Sparks 1993</label>
</doc>
<doc>
<label>Wu 2006</label>
</doc>
<doc>
<label>Blackwood 1990</label>
</doc>
<doc>
<label>Dig captopril 1988</label>
</doc>
<doc>
<label>Dig milrinone 1989</label>
</doc>
<doc>
<label>DIG study 1997</label>
</doc>
<doc>
<label>Dig xamoterol 1988</label>
</doc>
<doc>
<label>DIMT 1993</label>
</doc>
<doc>
<label>Fleg 1982</label>
</doc>
<doc>
<label>Guyatt 1988</label>
</doc>
<doc>
<label>Lee 1982</label>
</doc>
<doc>
<label>PROVED 1993</label>
</doc>
<doc>
<label>Pugh 1989</label>
</doc>
<doc>
<label>RADIANCE 1993</label>
</doc>
<doc>
<label>Taggart 1983</label>
</doc>
<doc>
<label>CAPRIE 1996</label>
</doc>
<doc>
<label>HOT 1998</label>
</doc>
<doc>
<label>Huynh 2001</label>
</doc>
<doc>
<label>TPT 1998</label>
</doc>
<doc>
<label>Cen 1999</label>
<exclusion> electrolyte disturbance,acute myocardial infarction,recently use the drugs which influ- ence cardiac ventricle (not include digitalis)</exclusion>
</doc>
<doc>
<label>Cheng 2001</label>
<exclusion> none</exclusion>
</doc>
<doc>
<label>Gao 2001</label>
<exclusion> none</exclusion>
</doc>
<doc>
<label>He 2001</label>
<exclusion> none</exclusion>
</doc>
<doc>
<label>He 2004</label>
<exclusion> none</exclusion>
</doc>
<doc>
<label>Hu 1998</label>
<exclusion> none</exclusion>
</doc>
<doc>
<label>Li 1998a</label>
<exclusion> none</exclusion>
</doc>
<doc>
<label>Li 1998b</label>
<exclusion> none</exclusion>
</doc>
<doc>
<label>Li 2003a</label>
<exclusion> not state</exclusion>
</doc>
<doc>
<label>Li 2004</label>
<exclusion> acute inflammation, acute myocardial infarction, chronic bronchitis, chronic liver disease, renal inadequacy</exclusion>
</doc>
<doc>
<label>Liao 1996</label>
<exclusion> not state</exclusion>
</doc>
<doc>
<label>Ma 2003</label>
<exclusion> atrial fibrillation, liver and renal diseases, infection, diabetes, malignant tumor, respi- ratory system diseases</exclusion>
</doc>
<doc>
<label>Mao 1998</label>
<exclusion> not state</exclusion>
</doc>
<doc>
<label>Mao 2003</label>
<inclusion> heart failure; age 41-70 years; heart failure class 2-3; not taking digitalis or drugs affecting the metabolisation of digoxin within 1 week; liver and kidney fuction were normal, normal electrolyte </inclusion>
<exclusion> acute myocardial infarction, or acute respiratory insufficiency of PHD, or serious mitral stenosis in sinus rhythm, or HCM with obstruction, diabetes, hyperthyoidism</exclusion>
</doc>
<doc>
<label>Sun 1998</label>
<exclusion> not stated</exclusion>
</doc>
<doc>
<label>Tang 2001</label>
<exclusion> not state</exclusion>
</doc>
<doc>
<label>Wang 1997a</label>
<exclusion> hypertension</exclusion>
</doc>
<doc>
<label>Wang 2004a</label>
<exclusion> not stated</exclusion>
</doc>
<doc>
<label>Zhang 2002</label>
<exclusion> not stated</exclusion>
</doc>